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1. Abstract 
 
 
Objectives  
To examine the relationship between particular traditional risk factors and their effect on the 
development of gestational diabetes mellitus (GDM) and birthweight (Part 1) as well as to 
assess first trimester maternal biochemical predictors of development of GDM (Part 2). 
 
 
Methods  
Part 1. A retrospective study of prospectively collected data from fifteen maternity units in 
North West London between 1988-2000- the St Mary‘s Maternity Information System 
(SMMIS) dataset. The dataset was modified to include only those who were nulliparous 
(thus ensuring that only one pregnancy per woman was included) and excluding women with 
pre-existing diabetes (thus studying only women who either did or didn‘t develop gestational 
diabetes). Birthweight z-scores were calculated.  
 
Part 2. A nested case-control study using first-trimester (11+0 to 13+6 weeks of gestation) 
samples.  that were obtained as part of a large prospective observational on-going study 
aimed at identifying first-trimester predictors of adverse pregnancy outcomes.  Maternal 
levels of lipids (cholesterol, low density lipoprotein cholesterol (LDL), high density lipoprotein 
cholesterol (HDL), non-fasting triglycerides, C- reactive protein (CRP), γ-glutamyl 
transferase (γ - GT), adiponectin, E-selectin, tissue plasminogen activator (t-PA) and vitamin 
D (25(OH)D) were measured.  Statistical Package for the Social Sciences (SPSS) Version 
17.0 and R (version 2.11.0) was used for statistical analysis. 
 
Results  
Part 1. There was a strong association between advancing maternal age and increasing 
body mass index (BMI) on the development of GDM (p<0.01 for both). This varied within 
each racial group and was more pronounced in Black African and South Asian groups. 
Using White European women with a BMI of 18.5-24.9 as a reference group, Black African 
and South Asian pregnant women had higher Odds Ratios (ORs) for GDM development 
within all BMI categories compared to the reference group.  
 
Maternal BMI was positively associated with birthweight z-scores within all racial groups 
(p<0.001 for all) irrespective of glycaemic status but its effect was much greater in women 
with GDM. The difference in birthweight z-scores between GDM and non-GDM women 
varied according to racial group and was much higher in non-white racial groups and at high 
rather than at low BMIs.  
 
Part 2. Simple maternal demographic and clinical characteristics obtained at the first 
antenatal visit provide a good prediction of GDM. Low levels of HDL and high levels of t-PA 
are independent predictors of GDM. (p=0.001 and p<0.001 respectively). First trimester 
maternal serum 25(OH)D levels are not associated with the development of GDM. 
 
Conclusions  
Maternal age and BMI interact with racial group in relation to the development of GDM. Both 
factors are important in the development of GDM, particularly so in Black African and South 
Asian women. GDM strongly accentuates the effect of BMI on birthweight, especially within 
non-white populations. First trimester prediction of GDM can be enhanced by the 
measurement of specific maternal biomarkers. 
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2.1 Diabetes Mellitus 
 
Diabetes Mellitus (DM) was first described as long ago as1550 BC, in ancient Egypt, as a 
polyuric state. But it was only in the 2nd century AD that the term ‗diabetes‘ was used by 
Aretaeus of Cappadocia, coming from the Greek meaning ‗siphon‘ or ‗pass through‘.1  
Today, DM is defined as a disorder of carbohydrate metabolism, characterised by chronic 
hyperglycaemia resulting from defects in insulin secretion, insulin action or both. Diabetes is 
usually irreversible and although most patients can have a reasonably normal lifestyle, it is 
considered to be a major public health problem due to its associated long-term micro- and 
macro-vascular complications, premature mortality, increasing prevalence and considerable 
use of health resources.2 
 
The prevalence of DM in the UK was estimated in the year 2000 among adults ≥ 20 years 
old as approximately 1.7 million, and the prevalence of DM is continuing to increase 
worldwide due to population growth, aging, urbanisation, increasing prevalence of obesity 
and physical inactivity. Although the prevalence varies within regions worldwide, the World 
Health Organisation (WHO) has provided estimates worldwide and predicted that if obesity 
levels remain constant, the prevalence of DM will rise from 170 million in 2000 to 366 million 
in 2030, producing a ‗Diabetes Epidemic‘.3 (Fig 2.1) If obesity levels rise, then the numbers 
affected will be even greater. 
 
The prevalence of DM worldwide has also been shown to vary in different populations. Race 
and ethnicity, which are not the same, are two useful concepts when attempting to 
understand differential health risks and disparities,4 particularly within the context of 
diabetes. Race is defined as a division of humankind that has distinct physiological 
characteristics and suggests a biological component.5 Ethnicity is defined as belonging to a 
social group that has a common national or cultural tradition.5  
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Fig 2.1 Prevalence of Diabetes Worldwide in 2000 and the estimated prevalence in 2030.3 
 
2.2 Physiology of Diabetes Mellitus 
2.2.1 Insulin and glucose metabolism 
Insulin is a 51 amino acid peptide hormone comprising two polypeptide chains, A and B, 
which are linked by disulphide bridges. Insulin is the principle anabolic hormone of the body 
and exerts several metabolic actions, such as the regulation of the storage and release of 
glucose, fat and amino acids. Insulin is synthesised and secreted by the β-cells of the 
pancreatic islets principally in response to glucose, though other hormonal, neuronal and 
macronutrients may alter this response.  
 
A large function of insulin is to promote storage of ingested nutrients. The three major 
tissues specialised for energy storage are the liver, muscles and adipose tissue. 
 
2.2.2 Insulin and the Liver 
Insulin enters into the portal circulation, which carries it to the liver, its primary target organ. 
The liver is the principle organ of glucose metabolism. Insulin exerts its action in two ways: 
1. Promotes anabolism  
Insulin promotes glycogen synthesis and storage at the same time and inhibits 
glycogen breakdown. It also increases both protein and triglyceride formation by the 
liver and promotes glycolysis.  
2. Inhibits catabolism 
The Americas 
2000: 33 million 
2030: 66.8 million  
 
 
 
 
 
 
Africa 
2000: 7 million 
2030: 18.2 million 
Middle East 
2000: 15.2 million 
2030: 42.6 million 
Europe 
2000: 33.3million 
2030: 48 million 
Asia and Australasia 
2000: 82.7 million 
2030: 190.5 million 
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Insulin acts to reverse the catabolic events of the post-absorptive state by inhibiting 
hepatic glycogenolysis, ketogenesis and gluconeogenesis.6 
 
Other tissues such as muscle and fat are facultative glucose consumers (Fig 2.2).2 
 
2.2.3 Insulin and other major tissues 
1. Muscle  
Insulin promotes protein synthesis in muscle by increasing amino acid transport. In 
addition, insulin promotes glycogen synthesis to replace glycogen stores that are 
expended by muscle activity.  
2. Adipose tissue  
Adipose tissue in the form of triglyceride is the most efficient means of storing 
energy. Insulin acts to promote triglyceride storage in adipocytes by a number of 
mechanisms.
 
 
 
 
   
Liver          
 
 
            ↑Hepatic glucose production            ↑Glucose disposal 
 
Fig 2.2 Regulation of glucose metabolism by insulin. 
 
 
 
Secretion of insulin is tightly matched to circulating glucose concentrations. Between meals, 
insulin is secreted at a low basal level, accounting for approximately 50% of insulin 
secretion. Concentrations rise rapidly following meals. In healthy individuals, venous plasma 
glucose concentrations are maintained in the range of 5-7mmol/L. 
 
↑ Glycogen synthesis 
↓ Glycogenolysis 
↓ Gluconeogenesis 
↑ Glucose uptake 
↑ Glucose oxidation 
↑ Glycogen synthesis 
Muscle 
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Insulin has major anabolic actions on intermediate metabolism affecting glucose, lipid and 
protein metabolism. In the majority of people, a balance is achieved between the rate of the 
appearance of glucose in the circulation and the rate of disappearance from the circulation.2  
 
In diabetic women, disturbances not only in glucose metabolism but also lipid metabolism 
have an influence on fetal growth and may influence the metabolic profile of their offspring. 
Diabetic mothers tend to exhibit abnormal lipid profiles, and it is the resulting increase in 
fatty acids and triglycerides as well as alterations in the delivery of amino acids, which 
contribute to the intrauterine environment and fetal growth. 
 
2.3 Classifications of Diabetes  
There are two main types of diabetes, Type 1 and Type 2. This classification reflects 
differences in the underlying cause/defect. 
 
 Type 1 DM is caused by an absolute deficiency of insulin, usually as the result of a T-
cell mediated destruction of the β-cells of the pancreatic islets. 
 Type 2 DM is a heterogeneous disorder that results from an interaction between a 
genetic predisposition and environmental factors and leads to a combination of 
deficiency in insulin production and decreased insulin effectiveness due to insulin 
resistance. 
Other specific types of diabetes include7: 
 
 Genetic defects of β-cell function 
o Associated with monogenic defects in β-cell function and frequently 
characterised by onset of mild hyperglycaemia at an early age and usually 
autosomal dominant pattern. Referred to as maturity-onset of the young 
(MODY) and characterised by impaired insulin secretion with minimal or 
no defects in insulin action.  
 
 Genetic defects in insulin action 
o Genetically determined abnormalities of insulin action associated with 
mutations of the insulin receptor.  
 
 Diseases of the exocrine pancreas  
o Any process that diffusely injures the pancreas eg pancreatitis, trauma, 
infection, cystic fibrosis 
 
 Drug or chemical induced  
o May impair insulin secretion or may precipitate diabetes in individuals with 
insulin resistance.  
2. Background 
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2.4 Epidemiology of DM 
The epidemiology and clinical features of Type 1 and 2 DM are different (Table 1). The UK 
currently has an overall prevalence of approximately 4%.8 
 
Table 1 Incidence, epidemiology and clinical features of pre-existing DM.1 
 
 Type 1 DM Type 2 DM 
 
 
Prevalence  
(Adults and Children) 
Accounts for 15% of DM 
 
 
Accounts for 85% of DM  
 
 
Epidemiology Patients are: 
 
 Younger-usually 
present in children or 
young adults  
 
 
 Most commonly 
affects Europeans 
who are not usually 
overweight 
 
Patients are: 
 
 Older  
 
 Often overweight 
 
 
 Affects all racial 
groups but in the UK 
is more common in 
women of Asian, 
Afro-Caribbean and 
Middle Eastern origin 
 
Clinical features Absolute insulin deficiency 
and if untreated can cause: 
 
- thirst 
- polyuria 
- blurred vision 
- weight loss 
- ketoacidosis 
 
May have hyperglycaemia for 
a long period of time without 
clinical symptoms 
 
- Do not tend to 
become ketotic  
 
The rapidly rising global prevalence of DM, as well as changing trends in the development of 
Type 2 DM as more adolescents and young children receive the diagnosis, has resulted in 
the need to identify those individuals at risk. This would allow preventative measures to be 
targeted towards these groups.  
 
Risk factors for Type 2 DM can be split into two groups, those that are modifiable and those 
that are not, which reflects the combination of predisposing and environmental factors that 
result in the disease (Table 2).9  
2. Background 
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Table 2 Modifiable and non-modifiable risk factors for Type 2 DM.9 
 
Modifiable risk factors 
 Overweight/Obesity 
 Physical inactivity 
 Dietary factors 
 Smoking 
 Abnormal lipids 
 Hypertension 
 Inflammation 
 Intrauterine environment 
 
Non-Modifiable risk factors 
 Age 
 Gender 
 Ethnicity/Race 
 Family history of Type 2 DM 
 History of GDM 
 Polycystic ovarian syndrome  
 
 
2.5 Physiology of pregnancy 
2.5.1 Glucose metabolism and insulin resistance 
Pregnancy is associated with profound changes in maternal metabolism to ensure a 
continuous supply of nutrients to the developing fetus, despite intermittent maternal food 
intake.9 Glucose handling is significantly altered in pregnancy as in normal pregnancy fasting 
levels of glucose are decreased with advancing gestation10 and serum levels following a 
meal are increased compared to the non-pregnant state.10,11 
 
The following explanations for the above have been suggested: 
 haemodilutional effects of early pregnancy (increasing plasma volume) 
 increased utilisation of glucose- either by the feto-placental unit or increased 
maternal uptake of glucose secondary to increased β-cell function 
 inadequate production of glucose12-13 
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The response to the decrease in fasting glucose is an increase in hepatic glucose 
production. During pregnancy, there is also a change in insulin sensitivity. In early 
pregnancy, insulin secretion increases, while insulin sensitivity is unchanged, decreases, or 
may even increase14,15 but with advancing gestation there is a marked fall in insulin 
sensitivity.12  Parallel patterns of increasing concentrations of placental hormones such as 
human placental lactogen, prolactin, cortisol and progesterone, which have been suggested 
to  antagonise the actions of insulin, lead to a state of relative insulin resistance and reduced 
insulin sensitivity as pregnancy progresses, which has the effect of facilitating the provision 
of fuel substrate to the fetus.14 
 
In women with normal β- cell function, insulin resistance associated with pregnancy is 
compensated for by an increase in insulin secretion.16 Therefore, in the majority of 
pregnancies the balance between progressive insulin resistance and the supply of insulin is 
readily met.17 However, in some women insulin resistance becomes dominant, the women 
become hyperglycaemic during pregnancy and GDM ensues. This is not usually present 
until the second or third trimester of pregnancy as the levels of diabetogenic placental 
hormones increase with placental size. In women with GDM, hyperglycaemia is progressive 
until delivery. However, in most cases, insulin resistance resolves in the postpartum period18 
and glucose control returns to a more normal pattern. 
 
2.5.2 Intrauterine environment 
The intrauterine environment is critical for fetal development. Several factors influence 
transfer across the placenta such as uteroplacental and umbilical blood flows, area available 
for exchange, placental metabolism, and activity/expression of specific transporter proteins 
in the placental barrier. Fetal growth is dependent on the availability of a constantly 
adequate supply of glucose, lipids and amino acids from the mother for energy, production 
of new tissues and protein synthesis.19 
 
Glucose is the main energy substrate for the fetus. Fetal production of glucose is minimal 
and the fetus is therefore almost entirely dependent on the placental supply of glucose from 
the maternal circulation. Net glucose transfer is highly dependent on maternal-fetal 
concentration gradients. Glucose crosses the placenta by carrier mediated facilitated 
diffusion via specific glucose transport proteins (GLUTs).6 
 
It has been shown that the fetus can produce insulin as early as 11 weeks gestation. The 
production of insulin enhances glucose utilisation among the insulin sensitive tissues such 
as skeletal muscle, liver, heart and adipose tissue. GLUT transporters increase or decrease 
2. Background 
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glucose transport in response to changes in fetal glucose. Insulin also increases amino acid 
uptake and protein synthesis in the fetus.20 Alterations in maternal metabolic processes that 
reduce or increase the availability of these substrates put the mother and fetus at risk. 
 
2.6 Gestational Diabetes Mellitus  
Gestational diabetes is defined as carbohydrate intolerance of varying severity, with onset or 
first recognition during pregnancy, irrespective of glycaemic status post pregnancy.21 
Gestational diabetes was originally defined due its association with an increased risk of Type 
DM in this group of women after pregnancy.  Its prevalence in England and Wales is thought 
to be approximately 3-5%. 22 
 
2.6.1 Pathophysiology 
Gestational diabetes is accompanied by alterations in glucose metabolism that deviate from 
the normal metabolic changes that occur in pregnancy. Most cases of GDM have been 
suggested to result from inadequate insulin secretion as a result of β- cell dysfunction. 23-24 
This has been supported by the majority of studies investigating maternal β- cell function in 
pregnancy, which consistently find decreased β-cell function in GDM in comparison to 
women who maintain normal glucose tolerance throughout pregnancy.13,24-28 The underlying 
mechanisms of β- cell dysfunction has been suggested to result from circulating immune 
markers as well as from genetic variants (particularly those found within individuals who are 
obese and have a metabolic state of chronic insulin resistance).2,29   
 
It has also been suggested that GDM may develop not only as a result of imbalance 
between insulin secretion and demand but also due to the fact that insulin secretion begins 
at a lower starting point in these women compared to those that remain normoglycaemic 
during pregnancy. This would suggest that β-cell dysfunction in women with GDM is chronic 
rather than just acquired during pregnancy but it only becomes apparent in pregnancy, when 
glucose metabolism is physiologically challenged, and continues to deteriorate over time, 
resulting in the long-term maternal complications of Type 2 DM.30, 31 Consequently, GDM 
appears to represent the presence of chronic metabolic abnormalities that predate 
pregnancy but are first detected during pregnancy. 
 
2.6.2 Risk factors for GDM 
Gestational diabetes mellitus results from inadequate insulin secretion for the degree of 
insulin resistance. Therefore, risk factors must either relate to impaired insulin secretion or 
contribute directly to the insulin resistant state, or both. Established risk factors for GDM 
development are given in Table 3. 
2. Background 
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Table 3 Summary of reported risk factors for GDM.32 
 
 
 
GDM and Type 2 DM share common aetiologies and pathogenesis. The two are thought to 
be aetiologically indistinct from each other, with GDM preceding the onset of Type 2 DM.32 
 
 
2.6.3 Complications of GDM 
2.6.3.1 Fetal outcomes – short term  
In 1952, Pedersen hypothesised that maternal hyperglycaemia was transmitted to the fetus, 
causing the fetus to produce and release large amounts of insulin, resulting in fetal 
hyperinsulinaemia.33 
 
 
Maternal factors 
*Older age 
*High parity 
*Increased pre-pregnancy weight 
*Increased pregnancy weight gain 
*Raised BMI  
*Short stature 
*Low birth weight 
*-Thalassaemia trait 
*Polycystic ovarian syndrome 
*High intake of saturated fat 
 
Family history 
*Family history of DM 
*Family history of GDM 
 
Previous obstetric history 
*Congenital malformation 
*Stillbirth 
*Macrosomia 
*Caesarean section 
*Previous GDM 
 
Pregnancy factors 
*High blood pressure in pregnancy 
*Multiple pregnancy 
*Increased iron stores 
 
Protective factors 
*Young age 
*Alcohol use 
2. Background 
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The effects of fetal hyperinsulinaemia include: 
 
Macrosomia 
An overgrowth of insulin-sensitive tissues such as adipose tissues, especially around the 
chest, shoulders and abdomen,increasing the risk of shoulder dystocia, perinatal death, birth 
trauma and the need for caesarean section. Fetal complications in GDM are further 
highlighted in the Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study, which 
examined the frequency of adverse outcomes in women with carbohydrate intolerance that 
was less severe than overt diabetes. The study noted strong associations (although less 
than those in overt diabetes) between maternal glucose levels and adverse pregnancy 
outcomes such as increased birthweight (birthweight >90th percentile), increased rate of 
caesarean section, neonatal hypoglycaemia and increased cord serum c-peptide levels 
(>90th percentile), suggestive of fetal hyperinsulinaemia.34 
 
Congenital abnormalities 
The incidence of congenital abnormalities is increased in GDM, but not as much as in 
pregnancies complicated by pre-existing DM. This is because major hyperglycaemia occurs 
later in pregnancy and therefore does not usually reach teratogenic levels in the first 
trimester.35 
 
2.6.3.2 Fetal outcomes – long term  
In the long term, intrauterine exposure to diabetes can place the offspring at risk of obesity, 
metabolic syndrome and in later life, DM.34 Various studies have been conducted 
investigating the long term effects of GDM on offspring, some with conflicting results.  
 
Vohr et al36 investigated the long term effects of GDM on the adiposity of offspring at 4-7 
years of age. Comparisons were made between the offspring of mothers with GDM who 
were large for gestational age (birthweight >90th centile), and appropriate for gestational age 
(birthweight > 10th centile but < 90th centile) with GDM, large for gestational age in women 
without GDM and appropriate for gestational age in women without GDM. Offspring who 
were large for gestational age in pregnancies complicated by GDM were likely to be heavier, 
have a higher BMI and other anthropometric measurements, and a higher blood pressure in 
comparison to other groups. By the age of 7, 35.2% of offspring large for gestational age at 
delivery in pregnancies complicated by GDM had a BMI>90th percentile. However, they 
reported no difference in blood pressure or glucose values between the babies whose 
mother had GDM and control babies.  
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These findings were supported by the data of Wright et al37, who found that at the age of 3, 
children of mothers with GDM had greater adiposity when assessed by the sum of skin folds 
in comparison to children of mothers who did not develop diabetes during pregnancy. 
Although in contrast to Vohr et al36, they found in addition higher systolic blood pressures. 
These findings contrast to those of Whitaker et al38, who found that at the age of 8-10 years 
there was no change in childhood adiposity, BMI or glucose tolerance test values between 
offspring of mothers with and those without GDM. However, in this study, the main 
comparison of interest was between the offspring of mothers with GDM that were treated 
with diet alone and the offspring of mothers with no diabetes. No comparisons were made 
between women with more severe forms of GDM requiring pharmacological treatment, such 
as insulin, which may result in an increased risk of childhood obesity.  
 
Plagemann et al39, noted an increase in the frequency of impaired glucose tolerance in the 
offspring of pregnancies complicated by diabetes. There were higher frequencies of 
impaired glucose tolerance noted in the GDM group compared to the pre-existing DM group. 
(11.1% vs 9.4% between ages 1-4 and 20% vs 17.4% between the ages of 5-9). This is 
markedly elevated in comparison to the usually quoted 5% frequency of impaired glucose 
tolerance in a normal population. 
  
Clausen et al40, found that the risk of the offspring being overweight doubled in pregnancies 
complicated by GDM (diet controlled) or Type 1 DM in comparison to offspring from the 
background population with pregnancies not complicated with DM. The risk of metabolic 
syndrome increased 4-fold in offspring of mothers with GDM and 2.5-fold in those with Type 
1 DM. 
 
2.6.3.3 Maternal Outcomes 
There are increased rates of induction of labour, operative deliveries and shoulder dystocia 
associated with GDM.41 Increased risks of pre-eclampsia and gestational hypertension have 
also been documented.34 
 
In the long-term, women with GDM have an increased risk of developing diabetes later on in 
life, the rate of which varies between studies. Women with GDM have an18-50% risk of 
developing diabetes within 5 years following the index pregnancy and an increased risk of 
other cardiovascular risk factors such as obesity, hypertension, dyslipidaemia and 
subclinical atherosclerosis.42-44 
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Lee at al45 performed a large cohort study examining the long term risk of developing Type 2 
DM and potential predictors of this risk. The risk of DM was found to increase in both GDM 
and control groups over time. The risk of women with previous GDM developing diabetes 
was 1.7% at first year postpartum, 17% at 10 years and 25% at 15 years postpartum. This is 
in comparison to the controls where none developed DM within the first 5 years postpartum. 
The risk of DM within the control group was 2% at 10 years and 3.9% at 15 years 
postpartum. The use of insulin during pregnancy was suggested to be the biggest predictor 
in the long term of developing Type 2 DM in the GDM group.  
 
2.7 Traditional risk factors and GDM  
Gestational diabetes mellitus is an important disease and early recognition and treatment 
during pregnancy may reduce the incidence of complications. Screening for GDM remains 
controversial. Despite extensive research into GDM, there remains no general consensus 
regarding screening and different screening policies have been employed worldwide. In the 
UK, the National Institute for Clinical Excellence (NICE)22 recommended selective screening 
for  GDM, using risk factors associated with a higher rate of GDM.  
 
2.7.1 Maternal age and GDM 
In the past few decades, changes in social attitudes have resulted in women delaying their 
first pregnancy. The mean age of mothers at childbirth in the UK has been increasing since 
the mid-1970s, from 26.5 years in 1975 to 29.6 in 2010. This reflects the worldwide tendency 
of women to delay their childbearing to older ages.46 Advanced maternal age has long been 
considered to be an obstetric risk factor with an increased risk of chromosomal 
abnormalities, spontaneous miscarriages, stillbirths, hypertensive disorders and GDM.47-62 
However, it is unclear whether it is maternal age itself or maternal age related co-morbidity 
that contributes to poor pregnancy outcomes, in older women.  
2.7.2 Race and GDM  
The prevalence of GDM varies in direct proportion to the prevalence of Type 2 DM in any 
particular population or racial/ethnic group. The prevalence of GDM is highly variable and 
different racial/ethnic groups in the same environment experience widely variable risk.31 The 
average prevalence of GDM in England and Wales is thought to be approximately 3-5% but 
with some racial groups such South Asian and Black Caribbean women being at increased 
risk.22 
 
Racial origin is thought to be important because it reflects a particular grouping of genetic 
factors. Genetic factors are known to be important in the development of many diseases; for 
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example sickle cell disease in West Africans, thalassaemia in East Europeans, cystic fibrosis 
in white Europeans and haemochromatosis in people of Celtic origin.  Many diseases of 
genetic origin are not exclusive to one racial group, but there are often major differences in 
prevalence between racial groups, reflecting their geographical origin and differing 
evolutionary pressures during the progress of human colonisation around the globe.  
 
‗Ethnicity‘ is often used instead of racial origin, but in fact the term describes a cultural rather 
than genetic grouping. A good example, related to the aetiology of GDM, is diet. It is thought 
that some racial genetic differences have evolved in parallel with local diets, which are often 
environmentally determined. ―Syndrome X‖ describes a cluster of various interrelated 
cardiometabolic factors that promote the development of atherosclerotic cardiovascular 
disease and Type 2 DM. It is thought that the common occurrence of ―syndrome X‖ in South 
Asians has evolved to suit the intermittent nature of the food supply in the Indian 
subcontinent, linked to the Monsoon weather patterns. The incidence is noted to be 
increasing rapidly in India and other South Asian countries. Relative fasting is often 
obligatory when food supplies fail and the need to rationalise this may have resulted in 
fasting being incorporated into some religious practices. Intermittent fasting can normalise 
carbohydrate metabolism in people with ―syndrome X‖ and in polycystic ovarian syndrome 
(which is common in the subcontinent), and provide a reservoir of women who become 
fertile during food shortage whereas their ―non-syndrome X‖ cousins become underweight 
and infertile.63 
 
Race is commonly contiguous with ethnicity for evolutionary reasons but when it becomes 
disconnected, a change in ethnicity can cause particular problems. Thus translating people 
from the rural subcontinent to urban centres both in that area and as immigrants to 
developed countries, exposes them to an ad-lib continuous diet high in carbohydrates and 
unsaturated fats. This probably accounts for the very high rates of diabetes, hypertension, 
renal disease and vascular disorders, including coronary atherosclerosis, in people of South 
Asian origin living in urban centres and developed countries.64-7 
 
India has a higher number of diabetic patients than any other country.3 This increase has 
been attributed to the so-called epidemiologic, nutritional and economic transition. The 
increase in food production and consumption, rural to urban immigration with the associated 
increase in ‗junk food‘ consumption and decline in physical activity, result in a rise in obesity, 
and are contributor factors to the rise in the prevalence of DM.  This does not exclude an 
underlying genetic susceptibility in the Asian group compared with other racial groups. 
Scholfield et al68 conducted a prospective cohort study comparing indices of glucose 
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homeostasis between non-diabetic vegetarians living in Washington DC, 29 of whom were 
of South Asian (Indian) origin and 33 ‗Americans‘ (presumably of white European origin, 
although this was not explicitly stated in the paper). There were 14 males and 15 females in 
the South Asian group, and 16 males and 17 females in the ‗American‘ group. During a 3hr 
glucose tolerance test, the South Asians had significantly higher insulin levels at all times 
except for the 3hr sample. Asian Indian men also had significantly higher plasma glucose at 
1hr and 2 hrs of the glucose tolerance test. Insulinogenic scores, calculated from insulin 
responses to the glucose challenge measured over a 3hr period, showed significantly higher 
values within the Asian Indian group in comparison to the American one.  The results 
suggest an underlying racial predisposition to glucose intolerance in the Asian population, 
although the differences were mainly observed within males, rather than females. 
 
Several cohort studies have investigated the relationship between race and rates or risk of 
GDM. High rates of GDM are consistently reported in non-white populations, with the highest 
rates in Asian, Black and Hispanic/ Latino American populations.69-76 
 
Thorpe et al73 conducted a retrospective cohort study that investigated birth trends and 
maternal characteristics in women diagnosed with GDM who delivered in New York City 
between 1990 and 2001. The study showed a continuing increase in GDM over the time 
period from 2.6% in 1990 to 3.8% in 2001, despite a 12% decline in the number of births. 
The prevalence of GDM increased significantly within all racial groups except non-Hispanic 
white women. The highest increase was noted in South Asians, with an increase of 90% 
over the study period. 
 
Berkowitz et al74 examined the epidemiological characteristics of GDM in an ethnically 
diverse cohort of 10,187 women who had undergone standardised screening for glucose 
intolerance. The rates of GDM were lowest in white Europeans, followed by black people, 
Hispanics and Orientals and those who were classified as belonging to an ‗other‘ racial/ 
ethnic group. Non-white racial groups were found to have an independent association with 
the development of GDM. 
 
Similar ethnic variation was shown more recently by Savitz et al75 who aimed to characterise 
the pattern of the occurrence of GDM among a wide range of ethnic groups in New York 
City. They looked at 951,920 singleton live births. This study found that, compared to the 
non-Hispanic white population, the adjusted relative risk (aRR) for African Americans (aRR 
=1.2, 95% CI (confidence intervals) 1.2- 1.3) and Sub Saharan Africans (aRR = 1.2, 95% CI 
1.2-1.4) were slightly elevated, and even more elevated for non-Hispanic Caribbeans (aRR= 
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1.6, 95%CI 1.6-1.7), Central Americans (aRR= 1.5, 95%CI 1.4-1.5) and South Americans 
(aRR=2.0, 95%CI 1.9-2.1). The aRR was highest for women from South Central Asia (4.7, 
95%CI 4.6-4.9) suggesting an almost 5 fold increase in the prevalence of GDM within this 
group.  
 
The increased prevalence of GDM in Asian women was further highlighted by Gunton et al76, 
who investigated the relationship between BMI, insulin resistance and beta-cell function in 
pregnant women. A comparison in outcomes was made between white and Asian women. 
Compared to white women, Asians were more likely to have GDM  (31.7% vs 14%) and 
lower BMI, resulting in the suggestion that Asians develop GDM at lower BMI than their 
white counterparts.  
 
The influence of race on maternal and fetal outcomes is also highlighted by Nystrom et al77 
who conducted a retrospective study of Asian, White and Asian-White couples and 
compared the differences in perinatal outcomes (adjusted odd ratios: aOR) between the 
groups. In comparison to White couples, Asian–White couples had an increased incidence 
of GDM (aOR 2.4 for White mother/Asian father and aOR=2.6 for Asian mother/White father) 
though not as high as Asian couples (aOR=4.7). 
 
2.7.3 BMI and GDM 
Obesity and being overweight are defined as abnormal or excessive fat accumulation that 
may impair health (Table 4). The prevalence of maternal obesity has slowly increased over 
the last few decades and is a growing concern due to the associated maternal morbidity and 
mortality.  
 
Table 4 WHO BMI classification and categories.78 
Classification BMI (kg/m2) 
Underweight <18.5 
Normal 18.5- 24.9 
Overweight ≥25.0 
Obese ≥30.0 
 Class I 
 Class II 
 Class III 
≥30.0- 34.9 
≥35.0- 39.9 
≥40.0 
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There is an increasing number of women of reproductive age who are overweight and 
obese; In England in 2010 32% of women between the ages of 35-64 were overweight and 
21% were obese.79 Therefore obese women are becoming increasingly more common in 
antenatal clinics. In the UK, the prevalence of women with a BMI ≥ 35 at any point in 
pregnancy who reach 24+0 weeks gestation and above is approximately 5% with 8% 
developing GDM. 80 
 
It has long been acknowledged that increased maternal weight and obesity are also linked to 
other adverse pregnancy outcomes, such as infection, morbidity, postpartum haemorrhage, 
macrosomia and stillbirth. Obesity is as an independent risk factor for developing GDM.   
 
Several studies have looked at the relationship between pre-pregnancy BMI, weight gain 
during pregnancy and GDM.71,81-89  The relationship between BMI and GDM is also unique in 
that BMI is the only modifiable risk factor that, if acted upon by successful dieting, could 
reduce the risk and rates of GDM. 
 
Kabiru et al 88conducted a prospective cohort study investigating the effect of increased BMI 
category between the first and last visits on pregnancy outcomes. 5131 women were 
included in the study. Women with an initially normal BMI, who increased in BMI category 
during the pregnancy, had an increased rate of complications such as GDM compared to 
those that remained in their pre-pregnancy BMI category (GDM rate: 3.7% vs 0.5 %; p 
=0.005, lacerations at delivery 31.7% vs 24.0%; p<0.001, failed induction of labour: 15.9% 
vs 4.7%: p<0.001, and caesarean section delivery: 21.0% vs 8.2%: p<0.001). Women who 
were overweight at the initial visit and then increased by one BMI category during the 
pregnancy also displayed increased complications in comparison to those whose BMI did 
not change category during their pregnancy. Complications included GDM (3.3% vs 1.0%, 
p=0.005), pre-eclampsia (3.7% vs 2.8%, p=0.002), failed induction of labour (10.3% vs 
7.9%, p<0.001), operative vaginal delivery (11.4% vs 8.4%, p<0.001) and caesarean section 
for failure to progress (6.9% vs 3.5%, p=0.002).  
 
A systematic review examined the effect of pre-pregnancy BMI on the risk of GDM, also 
aiming to quantify the change in the risk of GDM as the BMI increased.86 For each study that 
was pooled into the systematic review, the unadjusted odds ratio (OR) was calculated. The 
review indicated that pre-pregnancy BMI is directly associated with the incidence of 
developing GDM. The unadjusted ORs for overweight, moderately and morbidly obese 
women were 1.97 (95% CI 1.77 to 2.19), 3.01 (95% CI 2.34 to 3.87) and 5.55 (95% CI 4.27 
to 7.21) respectively compared to normal weight women. Torloni et al86 calculated that with 
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every 1kg/m² increase in BMI, the prevalence of GDM would increase by 0.97%. The 
findings of the above are supported by a meta-analysis of 20 studies that examined the risk 
of GDM with increasing BMI.87 The unadjusted ORs of developing GDM were 2.14 (95% CI 
1.82–2.53), 3.56 (95%CI 3.05–4.21), and 8.56 (95% CI 5.07–16.04) among overweight, 
obese and severely obese women respectively compared with normal weight pregnant 
women. This illustrates the marked increase in the risk of GDM with increasing BMI. 
 
Although the above studies highlight the association between weight gain, raised BMI and 
an increased rate of GDM, Glazer et al89 explored the effect of modifying weight pre-
pregnancy and risk of GDM. Their study included 4102 women, all of whom weighed over 
200Ibs; 32% lost weight but 61% gained weight. Women who lost at least 10Ibs between 
pregnancies had a decreased risk of GDM in comparison to those who lost less than 10Ibs 
(RR=0.63). Women who gained at least 10Ibs had an increased risk of GDM (RR=1.47). 
This emphasises the importance of reducing obesity in women of reproductive age. Obesity 
is a modifiable risk factor associated with GDM and indeed Type 2 DM. 
 
2.8 Screening for GDM 
The goal for any screening test is to detect a disease reliably to allow cure or amelioration of 
the disease or minimise morbidity/ mortality either in the short or long term. To assess the 
value of screening, the prevalence of the disease in the general population, incidence in the 
study population and the sensitivity, positive and negative predictive values of the screening 
tests should be known.90 Screening is also dependent on the efficiency of the local health 
care system and the economic condition of the country.  In order that the cost effectiveness 
of the screening programmes can be determined, short and long term complications of the 
detected disease should be well established. Early treatment or intervention for the disease 
must be known to decrease mortality and morbidity. Quality of the life for the individual 
should be improved.91 
 
Screening for GDM was originally established to identify a group of pregnant women who 
are at risk of developing Type 2 DM in the future and GDM is therefore a surrogate outcome. 
31 The issue of screening is important due to the increasing prevalence of GDM and Type 2 
DM. The potential benefits of treating GDM were demonstrated by the ACHOIS randomised 
control trial where 92 intervention and treatment of GDM led to a significant reduction in 
serious perinatal complications (1% vs 4%; p=0.01), defined as death, shoulder dystocia, 
bone fracture and nerve palsy, in comparison to routine antenatal led care.  
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2.8.1. Methods of screening (Universal vs Selective) 
Several different methods are used for screening for GDM and which is the best screening 
method remains controversial.  Some advocate universal biochemical screening, others 
advocate selective screening. Many women who are screen positive may not meet the 
diagnostic criteria for GDM and therefore represent a group of false positive women.  
 
Traditionally, women have been screened on the basis of clinical risk factors. Risk based 
selective screening has the potential to be hampered by inadequate patient history, failure of 
appropriate referral and the possibility that a significant proportion of women with GDM may 
be missed.  Although in theory universal screening should result in earlier diagnosis of GDM, 
the value of universal screening programmes is made less certain by the lack of data on the 
benefit of intervention in women that would have been screened negative based on clinical 
risk factors.  
 
In the UK in 2002, The Health Technology Assessment group conducted a systematic 
review of screening for GDM and found that screening by risk factors such as BMI, 
advanced maternal age, family history of diabetes, minority ethnic background, increased 
weight gain in early adulthood and smoking resulted in low sensitivities (50-69%) and 
specificities (58-68%).93 
 
Griffin et al94, conducted a prospective randomised study where patients were randomised to 
universal or selective screening. The universal screening group underwent a 50-g glucose 
challenge test performed and if their plasma glucose at 1 h was above or equal to 7.8 mmol/l 
they had a formal 3-h 100-g oral glucose tolerance test (GTT). The selective screening 
group had a 3-h 100-g OGTT at 32 weeks if any risk factor for GDM was present. Universal 
screening was associated with a higher prevalence of diagnosed GDM (2.7% vs 1.45%: 
p<0.03), as expected. Universal screening facilitated earlier diagnosis, intervention and 
lower rates of obstetric complications such as macrosomia, caesarean section rates, pre-
eclampsia and admissions to neonatal units. 
 
A large observational multi ethnic cohort study by Cosson et al91 compared the effectiveness 
of screening for GDM with universal or selective screening methods. The cohorts consisted 
of 159 women with GDM with risk-based screening, 265 women with GDM who underwent 
universal screening and 1255 women with no GDM who were the controls. This study also 
looked at whether either screening method could improve prognosis. Universal screening 
increased the prevalence of detected GDM from 8.3% to 12.6% and consequently selective 
screening potentially missed about 30% of all women with GDM. There was evidence of 
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health benefits for children when using universal rather than selective screening for GDM, 
especially for outcomes such as large for gestational age (7.5 % vs 17.6%; p<0.05), preterm 
delivery (6.0% vs 10.1%; p<0.05), neonatal jaundice (3% vs 7.5%; p<0.05) and the need for 
hospitalisation (12.5 % vs 23.3%; p<0.05). 
 
However, there are potential harms of screening on women, which can be both physical and 
psychological.95 A false positive screening result can result in women being inconvenienced, 
and/or experiencing a significant decline in the perception of their own health. There is the 
additional time, cost, physical discomfort and psychological burden of screening and 
diagnostic testing if a woman screens positive.96 Rumbold et al96 looked at women‘s 
experiences of being screened for GDM. This involved 158 women who were reviewed prior 
to screening and again after screening. More women who screened negative (i.e normal) 
related their experience as positive compared to women who screened positive (77% vs 
57%, p<0.01). Women, who screened positive for GDM, had lower perceptions of their 
health. 
 
2.8.2 Current screening guidelines in the UK 
During the time of this study (1988-2000), there was no national policy on screening for 
GDM. An HTA93 set up on behalf of NICE revealed that there was still considerable variation 
in practice across the UK. A survey of UK obstetric units in 199997 revealed that the majority 
screened for GDM but there was little consensus on the most appropriate method. The 
inconsistencies of screening practices provided evidence of the need for guidelines.  
 
NICE guidelines in 2003 stated that there was not enough evidence for routine screening of 
GDM and it was therefore not recommended.98 However, since then new NICE guidelines 
addressed the issue of screening for GDM, with the aim of improving quality of care based 
on the best available evidence of clinical and cost effectiveness at the time.   
 
Since 2008, the NICE in the UK has put in place recommendations for screening for GDM.22 
 
In a mainly healthy population, the current recommendation is screening based on risk 
factors. At booking, women should be investigated for the following risk factors: 
 
 BMI above 30 kg/m2 
 Previous macrosomic baby (weighing 4.5kg or above) 
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 Previous GDM 
 Family history of DM (first degree relative with DM) 
 Racial origin with a high prevalence of DM (e.g. South Asian) 
Women with any one of these risk factors should be offered diagnostic testing for GDM 
between 24-28 weeks gestation or earlier (between 16-18 weeks) if they have a previous 
history of GDM. Women with previous GDM should also have a repeat diagnostic test at 28 
weeks if the early one at 16-18 weeks was normal. A 2-hour 75 g OGTT should be used to 
test for GDM and the diagnosis made using the criteria defined by the WHO.  
Screening for GDM using fasting plasma glucose, random blood glucose, glucose challenge 
test and urinalysis for glucose should be considered with caution, as screening by these 
methods has produced varied results.22 
 
The later in pregnancy biochemical screening such as glucose tolerance tests are 
performed, the higher the detection rate of GDM. This is because as pregnancy advances 
insulin resistance progressively increases. However, the earlier in pregnancy GDM is 
diagnosed, the greater is the potential to reduce adverse outcomes. 
 
Although currently risk factor screening methods are widely used to identify women at risk of 
GDM, none of the variables such as BMI, ethnicity or family history have a high enough 
predictive value to allow truly efficient targeting and earlier intervention. Screening on the 
basis of risk factors alone has been shown to result in low sensitivities and specificities with 
sensitivities ranging from 50-68%, specificities from 58-68% and positive predictive values 
between 3-5%. Current UK guidelines recognise the benefits of treating GDM, as shown in 
the ACHOIS trial, but despite this, screening by the use of risk factors is considered to be 
more practical, more cost effective and less disruptive to women than universal screening.  
 
Risk factor based screening is the current practice in most of Europe and outside of the US. 
However, in the US, the American Diabetes Association (ADA), recommend biochemical 
screening for undiagnosed Type 2 DM at the time of initial antenatal visit, in those with risk 
factors.99 (Table 5). Women with an abnormal GTT in early pregnancy will receive a 
diagnosis of overt diabetes and not gestational diabetes.  
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Table 5: ADA recommended risk factors for Type 2 DM requiring OGTT 
Overweight (BMI ≥ 25 kg/m2 and have additional risk factors: 
 
Physical inactivity 
 
First-degree relative with diabetes 
High-risk race/ethnicity (e.g., African American, Latino, Native American, 
Asian American, Paciﬁc Islander) 
 
Women who delivered a baby weighing >=9 lb or were diagnosed with 
GDM 
 
Hypertension (≥140/90 mmHg or on therapy for hypertension) 
 
HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level 
>250 mg/dL (2.82 mmol/L) 
 
Women with polycystic ovarian syndrome 
Hb A1C ≥5.7%, IGT, or IFG on previous testing 
Other clinical conditions associated with insulin resistance (e.g., severe 
obesity, acanthosis nigricans) 
History of cardiovascular disease 
 
All women not known to have pre-existing diabetes should be screened for GDM between 
24-28 weeks.  
 
The American College of Obstetricians and Gynaecologists (ACOG)100 also recommend 
universal screening for GDM, where all pregnant women between 24-28 weeks gestation 
undergo a 50g, 1hour glucose tolerance test.  
 
There are substantial differences between UK and US guidelines for screening for GDM. 
Other than the use of universal screening recommended in the US in comparison to the 
recommended selective screening in the UK, there is also the difference in the attempt at an 
early identification of those women with undiagnosed type 2 DM. NICE guidelines take into 
consideration the cost-effectiveness of the screening programme to direct the guideline 
recommendations. 
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2.9 Prediction of GDM 
 
The identification of individuals at high risk of developing GDM who would benefit from 
targeted preventative measures, has resulted in the investigation of novel biomarkers and 
potential use of them as predictors, due to their associations in the pathogenesis of Type 2 
DM. Biomarkers are defined as a characteristic that is objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes or pharmacologic 
responses to a therapeutic intervention.  
 
Previous studies investigating the value of biomarkers in the prediction of Type 2 DM have 
reported conflicting and inconsistent results. This may be due to many of the factors being 
interlinked and sharing similar metabolic pathways and the lack of consistency in the 
diagnostic criteria of DM between studies.101 
 
However, the close relationship between the epidemiology, risk factors and pathogenesis 
between Type 2 DM and GDM has stimulated the examination of screening biomarkers for 
the development of GDM. The association between these markers and the development of 
GDM has predominantly been studied within the second and third trimesters. 
 
Most of the biomarkers that have been identified and suggested to play a role in the patho-
physiology of DM can be separated into four groups: adipose derived, liver derived, 
inflammatory derived and endothelial derived factors. The roles of these markers as 
potential predictors of GDM will be discussed individually.  
 
 
 
2.10 Adipose derived factors 
2.10.1 Adiponectin 
Adiponectin is a protein that is secreted exclusively by adipocytes with insulin sensitising, 
anti-inflammatory and anti-atherogenic properties.102-3 It is abundantly present in the 
peripheral circulation and considered to be an important mediator of insulin resistance, 
where hypoadipenctinaemia has been found to be characteristic of obesity, Type 2 DM and 
atherosclerotic disease.104-107 This is further highlighted by studies that have involved the 
Pima Indians, a population located in Arizona who have the highest reported prevalence of 
obesity, DM and insulin resistance in the world, where low levels of adiponectin were 
associated with DM and obesity, and the degree of hypoadiponectinaemia increased this 
association.108 
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Low adiponectin levels have been shown to be significantly correlated with endothelial 
dysfunction, increased intima media thickness and coronary artery calcification progression, 
independent of other cardiovascular risk factors.109-15 Low adiponectin levels have also been 
found in diseases associated with obesity such as Type 2 DM, hypertension, metabolic 
syndrome and coronary artery disease.112 This is further highlighted by the association of 
smoking, a risk factor for cardiovascular disease and low adiponectin levels. Adiponectin 
levels have been reported to be lower in current smokers in comparison to never smokers 
and ex-smokers.113 Adiponectin levels have also been found to vary among racial groups 
with lower levels found in non-white racial groups, even after adjusting for BMI.114 
 
Adiponectin levels have been measured during pregnancy and postpartum.115-117 Ritterah et 
al117 measured maternal adiponectin levels at 16, 22, 30 and 36 week of gestation. They 
found a general trend towards declining adiponectin levels as pregnancy advanced with a 
sharper decline from 30 weeks gestation onwards. However, the cause of this sharp decline 
remained unidentified as there was no significant correlation between adiponectin and other 
factors measured during pregnancy such as changes in BMI, weight or carbohydrate 
metabolism. 
 
A summary of studies investigating the role of adiponectin as a predictor of GDM is given in 
Table 6. Only a few studies have explored the association between first trimester levels of 
maternal adiponectin and the development of GDM.  These studies have found significantly 
lower levels of adiponectin in women who subsequently developed GDM in comparison to 
those who remained normoglycaemic during pregnancy.  
 
Williams et al115 compared maternal plasma adiponectin concentrations in 41 cases and 70 
controls in early pregnancy and found that adiponectin concentrations were significantly 
lower in women who subsequently developed GDM than in controls. Furthermore, they 
found that women with adiponectin concentrations less than 6.4 mg/ml (lower tertile of 
distribution of control values) experienced a 4.6-fold increased risk of GDM, as compared 
with those with higher concentrations. The risk of developing GDM increased by 20% for 
each 1 g/ml decrease in plasma adiponectin and this was independent of confounding 
factors such as maternal age, family history of diabetes and adiposity in early pregnancy. 
This significant difference in adiponectin prior to the development of the disease encourages 
its potential use as a predictive biomarker of GDM. 
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Lain et al116 also investigated adiponectin levels in the first trimester of pregnancy (mean 
gestational age 9.3 +/-2.6 weeks). Mean adiponectin concentrations were lower in women 
who developed GDM in comparison to those who did not (p<0.001). Categorising women in 
quartiles of adiponectin levels revealed that women in the lowest quartile (≤2.5µg/ml) were 
11 times more likely to develop GDM in comparison to controls (OR: 11·0, 95% CI 2·0, 
60·6). This finding persisted after adjustment for confounding factors (e.g. maternal age and 
BMI). 
 
Georgiou et al118 also confirmed hypoadiponectinaemia in the first trimester in women who 
subsequently went on to develop GDM and were able to evaluate its predictive value for 
GDM. Although the predictive model had a high sensitivity and specificity, it did not assess 
adiponectin in isolation but also took into account insulin levels, which are predictive in 
themselves.  
 
A recent longitudinal study had findings, which contradict previous conclusions. Paradisi et 
al119 investigated 50 women at high risk of developing GDM; 12 of whom went on to develop 
GDM. Although the study revealed that adiponectin levels decreased as pregnancy 
continued (consistent with other studies), Paradisi et al did not find a significant association 
between first trimester adiponectin levels and subsequent development of GDM.  
 
Inconsistency in results may be influenced by small numbers (<50) of subjects studied as 
well as a consistent lack in information regarding diabetic status pre-pregnancy. Recent 
conflicting results encourage doubt about the validity of adiponectin as a predictor of GDM, 
and therefore justify further investigations.  
 
Table 6 Summary of studies assessing the maternal adiponectin levels in GDM.  
 
Study Cohort  Gestation Results  Comments 
 
Ranheim 2004
120 
Controls=29 
GDM=22 
 
3
rd
 trimester 8.1 ± 1.2 μg/ml vs. 12.2 ± 1.1 
μg/ml; p = 0.04 
Lower in GDM with 
BMI<25 
Retnakaran 2004
121 
Asians=28 
White=116 
South 
Asians=31 
2
nd
 and 3
rd
 trimesters Median adiponectin levels in 
South Asian group (9.7μg/ml), 
White (15.8 μg/ml);  p < 0.01 
Lower in South 
Asians 
Williams 2004115 Controls =111 
GDM=41 
1
st
 trimester <6.4mcg/ml OR 4.6 (96%CI 1.8-
11.6) 
Lower in GDM 
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Tsai 2005
128 
Controls=219 
GDM=34 
3
rd
 trimester  8.3 μg +/- 3.8 vs 9. μg7+/- 3.9, 
p<0.05 
 
Lower in GDM  
Correlated negatively 
with BMI 
Fuglsang 2006
129 
N=11 1
st
, 2
nd
, 3
rd
 trimesters 
and  5-8 wks post 
partum 
From 18/40, significant inverse 
correlation between BMI and 
adiponectin (p<0.03). No 
correlation at week 8. 
Fall in levels from 
mid-late pregnancy.  
Negative correlation 
with BMI.  
Weerakiet 2006
124 
Controls =299 
GDM=60 
3
rd
 trimester For cut-off value of 10 mg/ml, 
the sensitivity, specificity, PPV 
and NPV were 91.7%, 30.8%, 
21.0% and 94.9%, respectively. 
 
Lower in GDM. 
Independent 
predictor for GDM. 
Cortelazzi 2007
130 
Controls =13 
GDM=18 
3
rd
 trimester 5·2±0·5mg/l vs. 8·2 ±0·8 mg/l; 
p< 0·01 
Lower in GDM. 
Retnakaran 2008
125 
Controls =80 
GDM=41 
3
rd
 trimester Adiponectin  (3.6 vs. 5.3μg/ml, 
p<0.01 
Lower in GDM. 
Adiponectin is  
positively associated 
with insulin 
sensitivity 
 
Ritterath 2008
117 
N=32 1
st
, 2
nd
, 3
rd
 trimesters 
and post partum (6 
wks) 
Relationship with triglycerides:  
16
th
 wk r = -0.41; p = 0.05, 22
nd
 
wk r = -0.41; p = 0.02, 30
th
 wk r 
= -0.53; p < 0.01,  
36
th
 wk r= -0.37; p < 0.05,  
6wks postnatal r= -0.37; p <0.05  
Negative correlation 
with BMI. 
No difference 
between NGT and 
GDM/IGT groups. 
Fall in levels during 
pregnancy. 
Gao 2008
126 
GDM=22, 
GIGT= 10 
Controls = 22 
1
st
, 2
nd
, 3
rd
 trimesters  14-20wks  
GDM 5.06 ±1.25 ng/ml,  
GIGT 6.88 ±1.15 ng/ml, 
Controls 9.18 ±1.95 ng/ml,  
24-30wks  
3.00 ±1.03 ng/ml,  
4.50 ±1.42 ng/ml,  
5.50 ± 1.60 ng/ml,  
All above p<0.01 
BMI negatively 
correlated with 
adiponectin levels.  
Fall in adiponectin 
during pregnancy.  
Lower in GDM. 
Vitoratos 2008
127 
Controls = 22,  
GDM =22 
 
3
rd
 trimester and 
postpartum 
GDM: 5381.2 ±552.09 ng/ml 
Controls: 8449.9 ±829.3 ng/ml 
Postnatal  
GDM=3278.5 ±841.61 ng/ml 
Controls 6958.1 ±694.0 ng/ml 
ROC curve (cut off 5253) 
sensitivity 86.4% and specificity 
59.1%  
Lower in GDM during 
pregnancy and 
postpartum 
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Lain 2008
116 
Controls =59 
GDM =30 
1
st
, trimester OR 0.69 (0.52-0.92) 
< 25th% OR 10.2 (1.3-78.7) 
Lower in GDM 
Georgiou 2008
118 
Controls =14 
GDM=14 
1
st
 trimester Threshold <35μ/ml, model for 
prediction: sensitivity 87.5%, 
NPV + PPV 85.7% 
Lower in GDM 
Potential for 
prediction 
Paradisi 2010
119 
Controls=38 
GDM=12 
1
st 
trimester 2.32±0.16 vs 1.98±0.22ng/ml: 
p>0.05 
No difference in 
every trimester but 
decline in levels with 
advancing gestation.  
Mrizak 2013
122 
Controls =24 
GDM=28 
3
rd
 trimester 10.02 ± 1.1 μg/ml vs 8.58 ± 1.7 
μg/ml, p=0.01 
Lower in GDM 
 
 
Lacroix 2013
123 
Controls=407 
GDM=38 
 
1
st
 and 
2
nd
 trimesters 
OR, 1.12 per 1 µg/mL decrease 
of adiponectin levels; p = 0.02, 
adjusted for BMI and HbA1c at 
1st trimester 
Lower in GDM 
N: Number overall in study, GIGT: Gestational Impaired Glucose Intolerance, NGT: Normal Glucose Tolerance, 
NPV: Negative Predictive value, PPV:Positive Predictive Value, OR: Odds Ratio, r= correlation coefficient.  
 
2.10.2 Leptin 
The role of leptin is very different to that of adiponectin. Leptin is a polypeptide produced in 
many tissues such as the stomach, intestines and placenta. Although mainly derived from 
adipocytes, leptin plays a key role in the regulation of food intake, energy balance and 
metabolism. Leptin has been suggested to also play a role in cardiovascular disease by 
stimulating vascular inflammation, oxidative stress and vascular smooth muscle 
hypertrophy.131 
 
Leptin levels are altered by periods of fasting and eating. They also display a circadian 
rhythm with levels being highest between midnight and early morning.132 Leptin levels have 
been positively correlated with the percentage of body fat and BMI. Levels are increased 
with overfeeding and decreased in periods of starvation with excessive levels noted in 
obesity and Type 2 DM.133 
 
In an uncomplicated pregnancy, leptin concentrations have been found to increase during 
pregnancy, peaking at approximately 28 weeks gestation, plateauing thereafter, declining 
slightly just before delivery and falling post-partum.  This was previously thought to be due to 
the increase in maternal weight and metabolic and hormonal changes that occur during 
pregnancy. However, the majority of the increase in circulating levels of leptin has been 
shown to occur in early pregnancy prior to any significant metabolic or weight changes and 
is thought to be predominantly hormonally influenced.134 
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The use of leptin as a predictor of GDM has been investigated. In the few studies that are 
reported, conflicting results have been found. Qui et al130 found an association between 
maternal leptin levels taken at 13 weeks of gestation and risk of GDM, independent of 
adiposity. Women with leptin concentrations of 31.0 ng/mL or higher experienced a 4.7-fold 
increased risk of GDM (95% CI 1.2- 18.0) as compared to women with concentrations of 
14.3 ng/mL or lower. Gao et al126 found a significant difference between leptin levels taken 
between 14-20 weeks of gestation in women who developed GDM, compared with those 
who did not. The levels of leptin were lower in GDM groups in comparison to non-GDM 
(p<0.01). Kirwan et al136 reported similar results. In contrast, Georgiou et al,118 did not find a 
significant difference in first trimester maternal leptin levels between women who later on 
developed GDM and those that remained normoglycaemic.  
 
The studies that assessed maternal leptin levels at later gestations also give conflicting 
results.137-40 Lopez-Tinoco et al139 found that leptin levels taken during the third trimester 
were significantly higher in the GDM group compared to women who remained 
normoglycaemic during pregnancy. There was also a positive correlation between leptin and 
insulin resistance. However, Saucedo et al140 found that leptin levels during the third 
trimester were not significantly different between GDM and non-GDM groups.  
 
Table 7 Summary of studies assessing the maternal leptin levels in GDM 
Study 
 
Cohort Gestation Results Comments 
Festa 1999
143 
Controls =166 
GDM=55 
22-29 wks 26.9 ng/ml vs. 19.4 ng/ml, p<0.01 Leptin levels lower 
in GDM (adjusted 
for BMI) 
Leptin higher 
during pregnancy 
Vitoratos 2001
144
 
 
Controls =17 
GDM=17 
3
rd
 trimester 16.52 ± 5.07 ng/ml vs 10.61 ± 1.47 
ng/ml, p<0.01 
Higher in GDM 
Qiu 2004
135 
Controls =776 
GDM=47 
<16 wks Levels ≥31.0 mg/ml lead to RR= 
4.7 (95% CI 1.2-18.0) vs levels 
<14.3mg/ml 
Higher in GDM 
Ranheim 2004
120 
Controls =29 
GDM=22 
 
3
rd
 trimester 23.3 ±1.7 ng/ml vs  22.7±1.3ng/ml, 
p= 0.6 
No significant 
difference  
Gao 2008
126 
Controls= 22 
GDM=22, 
GIGT= 10 
 
1
st
, 2
nd
, 3
rd
  
trimesters  
14-20 wks:  
GDM 12.79±2.31 ng/ml,  
NGT 4.98±1.41 ng/ml  
GIGT 9.61±0.96 ng/ml p<0.01 
Higher in GIGT 
and GDM 
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24-32 wks:  
GDM 22.64 ±5.8 ng/ml,  
NGT 8.88± 2.41 ng/ml,  
IGT 15.11±2.75 ng/ml:p<0.01 
 
Saucedo 2010
140 
Controls=60 
GDM=60 
3
rd
 trimester 22.7±4.9ng/ml vs 23.3±11.7ng/ml, 
p>0.05 
No difference  
Soheilykhah 2010
138 
Controls =27 
GDM=29 
GIGT=26 
3
rd
 trimester  GDM 30.60 (33.40), GIGT 24.10 
(17.07) NGT 21.60 (12.60), p= 
0.03 
Higher in GDM, 
correlates with 
insulin resistance 
Horosz E 2011
141 
Controls =86 
GDM=48 
3
rd
 trimester 24.14 ± 12.77 vs  21.34 
±11.67ng/ml 
No difference  
Roca-Rodriguez 2012
142 
Controls=21 
Prev GDM=41  
Post partum 32 025.5 ±19 917.3 ng/mL vs 
20 258.9±16 359.9 ng/mL, p=0.02 
(GDM vs controls) 
 
Leptin higher post 
partum in women 
with prev GDM  
 
 
N: Number overall in study, GIGT: Gestational Impaired Glucose Tolerance, NGT: Normal Glucose Tolerance, 
RR= Relative risk  
 
2.10.3 Resistin 
Resistin is a cysteine rich protein which forms part of the group of adipocyte derived proteins 
previously mentioned. Resistin has been suggested to cause insulin resistance and play a 
role in glucose homeostasis and glucose tolerance in mice.145 The role of resistin in humans 
remains controversial. It has been suggested that although it may affect glucose metabolism 
and its levels are elevated in obesity and Type 2 DM, resistin may also have an 
inflammatory role and influence the development of cardiovascular disease.146-7 Increased 
placental expression suggests a possible role in the insulin resistant state that typically 
characterises pregnancy.148 The role of resistin in GDM remains unclear (Table 8). 
 
First trimester maternal serum resistin levels have been found to be unchanged from pre-
pregnancy levels.149 Serum resistin samples taken pre-delivery and within the first five days 
post-delivery were found to be significantly higher in women with GDM in comparison to 
women with an uncomplicated pregnancy. There was a general downward trend of maternal 
serum levels post-delivery in both groups.149  These findings were consistent with those of 
Vitoratos et al150, and both highlight the significant contribution of resistin from the placenta. 
However, there have been conflicting findings in other studies. Cortelazzi et al130 found no 
difference in maternal plasma resistin levels between women with GDM and those with an 
uncomplicated pregnancy at 37-41 weeks of gestation. 
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The small number of studies assessing levels of resistin during pregnancy152 and particularly 
those studies assessing first trimester maternal levels of resistin and future development of 
GDM implies that further studies will be required but based on the above studies it is unlikely 
that resistin will be an important predictor of GDM development. 
 
 Table 8 Summary of studies assessing the maternal resistin levels in GDM. 
 
Study  Cohort Gestation Results Comments 
 
Cortelazzi 2007
130 
Controls=13 
GDM=18 
3
rd
 trimester 8·5 ± 2·3ng/ml vs 6·9 ± 0·7ng/ml,  
p>0.05 
No difference  
Nien 2007
153 
Normal BMI and 
pregnant= 261 
Overweight and 
pregnant =140 
Non pregnant and 
normal BMI=40 
 
1
st
, 2
nd
 and 3
rd
 
trimesters 
10.2 (5–16) ng/ml, range: vs 12.5 
(5-40)  ng/ml, p=0.04 
(non pregnant, normal BMI vs 
pregnant normal BMI) 
Resistin higher in 
pregnancy (1
st
 
trim) 
Chen 2007
151 
Controls=20 
GDM=20 
3
rd
 trimester 62·38 ± 13·6 ng/ml vs 22·21 ± 8·14 
ng/ml, p<0·01 
 
Higher in GDM 
 
Megia 2008
154 
Non pregnant 
(normal BMI) =40 
Pregnant (normal 
BMI)=261 
Pregnant with 
BMI>25=140 
3
rd
 trimester and 
post-partum (1-
6mths) 
3rd trim: 4.32 ± 1.56 ng/ml vs 9.30 
±1.32 ng/ml, p<0.01 
Post-partum: 4.24±1.56 ng/ml vs 
3.11±1.63 ng/ml, p<0.01 
Lower in GDM  
Lower post-
partum 
 
Lain 2008
116 
Controls=59 
GDM=30 
1
st
 trimester 17.2 ng/ml vs 15.8 ng/ml, p=0.45  
(GDM vs controls) 
 
No difference 
Kuzmicki 2009
155
 
 
Controls=81 
GDM=82 
3
rd
 trimester 21.9 (17.55–25.40) ng/ml  vs 
19.03(15.92–23.91) ng/ml, p<0.05 
 
Higher in GDM 
Vitoratos 2011
150 
Controls=30 
GDM=30 
3
rd
 trimester 0.28 ng/ml vs 0.21 ng/ml, p = 0.02 Higher in GDM  
Nanda 2012
149 
Controls =240 
GDM=60 
1
st
 trimester 8.32ng/ml vs 8.28ng/ml p = .549 No difference  
 
 
2.10.4 Visfastin 
Secreted by visceral adipose tissue, the role of visfastin in DM has remained controversial 
because of contradictory results from studies investigating the association with pre-existing 
2. Background 
 
The Epidemiology and Prediction of Gestational Diabetes Mellitus   38 
DM. Visfatin has been proposed as an insulin mimicking adipocytokine. Increased levels 
have been found in insulin resistant states including obesity and Type 2 DM156-8 
 
In relation to GDM, maternal visfastin levels have been found to be both lower 159-63 and 
higher in women with established GDM.163-67  However these studies involved maternal 
samples taken at time of diagnosis of GDM i.e. during the third trimester (Table 9). Limited 
data exist investigating the role of visfastin in early pregnancy. Ferreira et al166 measured 
first trimester maternal serum visfastin and found significantly higher levels in the GDM 
group in comparison to the non GDM group (Table 9). This finding supports the role of 
visfastin in insulin resistant states.  
 
Table 9 Summary of studies assessing the maternal visfatin levels in GDM. 
 
Study 
 
Cohort Gestation Results Comments 
Krzyzanowska 
2006
163 
Controls =30 
GDM=24 
3
rd
 trimester 
and post 
partum  
64.0 (50.9– 
74.8) ng/ml vs 46.0 (36.9–54.6) 
ng/ml, p<0.01 
Higher in GDM 
Chan, 2006
161 
Controls =20 
GDM=20 
3
rd
 trimester 9.4 ±3.8 ng/ml vs 12.6 ± 4.5 ng/ml;     
p=0.02 
 
Lower in GDM 
Haider 2007
160 
Controls =10 
GDM=10 
3
rd
 trimester 1.9±0.8 ng/ml vs 5.2±4.4 ng/ml,  
p=0.05 
Lower in GDM 
Lewandowski 
2007
164 
Controls =20 
GDM=16 
3
rd
 trimester 76.8 ng/ml (95% CI 70.2–83.4) vs 
93.1 ng/ml(95% CI 86.2–99.9); 
p<0.01 
Higher in GDM 
Szamatowicz 
2009
165 
Controls =63 
GDM=61 
3
rd
 trimester 14.8 (10.8-17.3) mg/l 15.3 (11.8-
19.4) mg/l, 
GDM vs NGT, p>0.05 
No difference  
Ferreira 2011
166 
Controls= 300 
GDM=100 
1
st
 trimester 1.34 (0.70-2.87) MoM, vs 1.00 (0.53-
1.92) MoM; p < 0.01 
Higher in GDM 
Rezvan 2012
162 
Controls =35 
GDM=35 
3
rd
 trimester 5.29 ± 0.47 ng/ml vs 7.76 ± 0.53 
ng/ml, p < 0.01 
Lower in GDM 
NGT: Normal Glucose Tolerance, MoM=multiple of the median 
 
2.10.5 Lipids 
Insulin resistance and Type 2 DM are associated with a dyslipidaemic profile, characterised 
by reduced high density lipoproteins, a predominance of low density lipoproteins and 
elevated triglycerides.168-71 This dyslipidaemic profile has also been found in pregnancies 
complicated by GDM. However, results have been inconsistent. There are very few studies 
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that have investigated lipid levels during the first trimester in order to examine any 
associated risk of GDM development. 
 
Enquobahrie et al172 in a cohort study compared lipid levels at approximately 13 weeks 
gestation between 47 women who developed GDM and 804 who did not. A positive 
association between triglyceride levels and risk of GDM was established. Women with a 
triglyceride level >137mg/dL experienced a 6-fold increase in risk of GDM compared to 
women with triglyceride levels in the lower tertile. (RR = 6.1; 95% CI: 2.1–17.4). There was 
no association found between risk of GDM and other lipids such as total cholesterol, high-
density lipoprotein, and low-density lipoprotein. 
 
Table 10 Summary of studies assessing the maternal lipids levels in GDM. 
 
Study 
 
Cohort Gestation Results Comments 
Nolan 1995
174 
N=388  1
st
 trimester TGs: p<0.01, r=0.60  Predictive of GDM 
 
Enquobahrie 
2005
172 
Controls= 851 
GDM=47 
1
st
 trimester TGs ≥137 mg/dL 
RR 3.45 (1.14-10.50), 
p<0.05 vs lowest tertile 
 
Elevated TGs associated 
with increased risk GDM 
No difference for total 
cholesterol, HDL and LDL 
Sánchez-Vera 
2007
173 
Controls =107 
GDM=62 
2
nd
 trimester TGs: 5.2 mmol/L vs 4.2 
mmol/L,  
Cholesterol: 1.14  mmol/L 
vs 0.8 mmol/L 
Glucose: 5.2mmol/L vs 
4.4mmol/L  
p<0.05 for all factors 
(GDM vs controls) 
 
GDM: increased 
triglycerides, cholesterol 
and glucose 
Paradisi 2010
119 
Controls =38 
GDM=12 
2
nd
 trimester TGs> 158 mg/dl 
(RR = 5.87) 
 
 
 
Increased risk of GDM 
with elevated TGs 
N: Number in study overall, HDL= High Density Lipoproteins, LDL= Low Density Lipoproteins, TGs= triglycerides, 
RR= relative risk. 
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2.11 Liver Derived factors  
2.11.1 Gamma- glutamyltransferase  
Gamma- glutamyltransferase (γ-GT) is an enzyme found in hepatocytes and biliary epithelial 
cells. Outside pregnancy it is widely used as a marker of liver disease and alcohol 
consumption and is strongly associated with excess fat deposition in the liver, termed non-
alcoholic fatty liver disease.175 It is also thought to contribute to anti-oxidant systems, where 
an increase in γ-GT may be a marker of oxidative stress.176 Oxidative stress may also play a 
role in the pathophysiology of DM. 
 
A large population study that investigated the distribution and population determinants of γ-
GT found an association between increasing BMI and γ-GT.  This was found particularly in 
the upper percentiles for BMI in women.177 
 
Few studies have examined the role of γ-GT as a predictor of GDM (Table 10). Tan et al178, 
measured levels of γ-GT in the late second trimester at the time of diagnosis. A cut off ≥ 24 
IU/L was associated with an increased risk of developing GDM (aOR 2.1 (95% CI 1.2–3.8)). 
 
2.11.2 Alanine transaminase  
The liver plays an important role in normal glucose homeostasis. Alanine transaminase 
(ALT) is primarily found in the liver and its levels are usually associated with non-alcoholic 
fatty liver disease. However, some studies have suggested an association between high 
ALT levels and later development of DM; elevated ALT is associated with a decline in 
hepatic insulin sensitivity which promotes the development of DM.180-2This association is 
independent of adiposity and ALT, along with other liver enzymes, has been found to be an 
independent predictor of Type 2 DM.182 
 
Table 11 Summary of studies assessing the maternal γ-GT and ALT levels in GDM. 
 
Study 
 
Cohort Biomarker Gestation Results Comments 
Tan 2008
178 
Controls =29 
GDM=27 
γ-GT 2
nd
 trimester aOR 2.3 (95% CI 
1.2–4.2), p < 0.01 
Higher in GDM. 
Independent 
risk factor for 
GDM 
Alanbay 
2012
179 
Controls =42 
GDM=37 
γ-GT 2
nd
 and 3
rd
 trimesters ROC analysis (γ-GT cut off 
16IU/L):  
sensitivity: 86%, specificity:  
γ-GT 
independent 
predictor of 
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37% GDM 
Tan 2012
180 
N =2610 
GDM=319 
 
γ-GT and 
ALT 
2
nd
 and 3
rd
 trimesters γ-GT: 18 ± 12 IU/L vs. 
16 ± 11 IU/L, p = 0.03 
RR 1.35 (95%CI 1.0–1.8); 
p = 0.04 (unadjusted), 
p>0.05 (adjusted) 
 
γ-GT Higher in 
GDM 
ALT - no 
difference 
between groups 
N: Number in study overall, aOR= Adjusted Odds Ratio, ROC: Receiver Operator Curve, RR: relative risk.  
 
The extent of the association between ALT and insulin resistance has not been extended to 
the context of pregnancy. Only one study has examined the association between second 
and third trimester maternal ALT levels and GDM development and found no correlation.180 
 
2.11.3 Sex hormone binding globulin  
Sex hormone binding globulin (SHBG) is a glycoprotein that is synthesised and secreted in 
the liver. Its principal function is to act as a transport protein and regulate circulating 
concentrations of free sex hormones. However, the concentration of SHBG is affected by 
various clinical conditions. Elevated concentrations have been found in conditions such as 
thyrotoxicosis and low SHBG levels have been found consistently within insulin resistant 
states such as obesity and DM.183 Ding et al conducted a large nested case control study of 
post-menopausal women and found that higher levels of SHBG were associated with a 
lower risk of DM.184 Other studies have supported the association of reduced SHBG 
concentrations as a potent marker of hyperinsulinaemia185 and insulin resistance.186 
 
However, the literature surrounding SHBG and prediction of GDM is limited (Table 12). 
Caglar et al187 found significantly lower levels of SHBG at 13-16 weeks gestation in women 
who later developed GDM in comparison to women who remained normoglycaemic. This 
has been confirmed in further studies149 and highlights the association of SHBG with insulin 
resistance. A further study by Spencer et al188 compared women with pre-existing DM and 
uncomplicated pregnancies. They found that during the first trimester of pregnancy, there 
were significant reduced levels of SHBG in women with pre-existing DM in comparison to 
women with uncomplicated pregnancies. 
 
Table 12 Summary of studies assessing maternal SHBG levels in GDM. 
Study 
 
Cohort Gestation Results Comments 
Bartha 2000
190 
Controls =32 
GDM=34 
3
rd
 trimester 309.54±112.22 nmol/l vs 460.54±144.54 
nmol/l, p<0.01  
Lower in GDM 
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Thadhani 
2003
189 
Controls =94 
GDM=44 
1st trimester OR 0.69 (0.48-0.99) Lower in GDM 
Smirnakis 
2005
191 
Controls =108 
GDM=35 
<20 weeks OR 4.5 (1.4-14.1) 
Lowest tertile as reference 
Lower in GDM 
Spencer 
2005
188 
Controls=400 
GDM/PED=64 
1st trimester Median MoM=0.81, p<0.01 Lower in GDM 
McElduff 
2007
184 
Controls =158 
GDM=62 
2
nd
 and 3
rd
 
trimester 
335±87nmol/l vs 339±101nmol/l; p=0.78 No difference  
Caglar 2012
187 
Controls=63 
GDM=30 
13-16 weeks Threshold 97.47nmol/L,  
sensitivity 80%,specificity 84.6%,  
PPV 50%, NPV 95.7% 
OR 12.3 (95%CI 1.7-83) 
Lower in GDM 
NPV= Negative Predictive value, PPV=Positive Predictive Value, MoM= Multiples of the Median, OR=Odds ratio. 
 
2.12 Endothelial derived factors 
2.12.1 Tissue plasminogen activator  
Tissue plasminogen activator (t-PA) is a haemostatic factor that converts plasmin to 
plasminogen and is therefore involved in fibrinolysis, tissue remodelling and cell 
migration.192Tissue plasminogen activator is a marker of endothelial dysfunction and has 
been shown to be a strong independent predictor of DM independent of insulin resistance.193 
 
Tissue plasminogen activator has been found to be positively correlated with waist 
circumference, visceral fat and glycosylated haemoglobin.194-6 Weight reduction has been 
shown to decrease the risk of cardiovascular morbidity resulting in a significant reduction in 
markers of endothelial dysfunction195-6, encouraging intervention and lifestyle modification 
towards these patients deemed to be at risk.  
 
The Framingham offspring study examined the association between insulin levels and 
haemostatic factors in a mixed population (men and women) with normal and impaired 
glucose tolerance. Tissue plasminogen activator levels were significantly higher in those with 
impaired compared to those with normal glucose tolerance, suggesting a mechanism for 
subsequent increased cardiovascular risk in this group.197 
 
Although elevated t-PA has been reported in insulin resistance, Type 2 DM and obesity, 
there are no previous studies that have investigated its role in GDM. 
 
2.12.2 E-selectin 
E-selectin is a cell adhesion molecule that is exclusively expressed in the endothelium. 
Outside pregnancy, E-selectin is associated with BMI, race and smoking.198-200 E- selectin is 
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thought to be positively correlated with BMI and weight reduction in non-diabetic obese 
women resulted in a significant decrease in E-selectin level compared to those who did not 
lose weight.198 Racial variation also exists between endothelial markers and significant 
differences between Hispanic vs white and black populations have been reported, with 
elevated levels in non-white racial groups.199 Measured levels of E -selectin in a healthy 
population were significantly higher in smokers vs non-smokers and displayed a significant 
positive trend with increasing levels of smoking.200 
 
Very few studies have examined the association of E-selectin with GDM (Table 13). Studies 
that have been performed have found variable results.201-3 One study found no difference in 
the third trimester maternal E-selectin levels between women with GDM, normoglycaemic 
controls and the non-pregnant.202 This contrasted with another study that found significantly 
higher E-selectin levels between women with GDM and those with normal glucose tolerance 
in comparison to non-pregnant controls.203 
 
Furthermore, a study assessing postnatal levels of E-selectin found that its levels remained 
elevated in women that had GDM compared to those that remained normoglycaemic in 
whom a significant drop in E-selectin levels was noticed.201 
 
In the postnatal period- between 2 and 24 months- another study found that women with a 
previous history of GDM and an abnormal oral glucose tolerance test postnatally had 
significantly elevated E-selectin levels compared to women with no previous history of 
GDM.204 
 
There are no previous studies that have examined first trimester maternal E-selectin levels 
and the subsequent development of GDM. 
 
Table 13 Summary of studies assessing maternal E-selectin levels in GDM. 
 
Study 
 
Cohort Gestation  Results Comments 
Kautzky-Willer 
1997
203 
Controls =8 
GDM=9 
3
rd
 trimester and  
3 weeks post- 
partum 
GDM vs 
controls, p<0.05  
Higher in GDM 
and remain 
raised post 
delivery 
Telejko 2009
201 
Controls =68 
GDM=56 
3
rd
 trimester  35.8 (25.0–46.4) 
ng/ml vs 34.2 
(25.8–46.2) 
No difference in 
GDM 
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ng/ml, p>0.05 
2.13 Inflammatory factors 
2.13.1 C-reactive protein  
Chronic subclinical inflammation has been proposed to play a key role in the 
pathophysiology of DM development and cardiovascular disease. C-reactive protein (CRP) 
is produced in the liver and is a sensitive marker of inflammation produced in the liver and 
has emerged as an independent predictor of cardiovascular disease in within previously 
healthy populations.205-16 
 
Circulating levels of CRP have been shown to correlate with measures of body fat, including 
BMI.209 Several studies have confirmed the strong association between obesity and raised 
CRP, suggesting that obesity is state of chronic inflammation and contributes to the 
pathology of subsequent cardiovascular disease in these groups.208-9 
 
C-reactive protein has been studied extensively during pregnancy but predominantly within 
the context of subclinical infection in preterm prelabour rupture of membranes. A rise in CRP 
levels has been noted as early as 4 weeks gestation. However, the study population was 
undergoing in vitro fertilisation treatment and therefore may have had underlying 
confounding factors accounting for subfertility that may also influence the results.211 An 
increase in CRP has been noted in other studies as well as in other stages of pregnancy.211  
 
Early pregnancy CRP levels have been shown to be significantly higher in women who went 
onto develop GDM in comparison to normoglycaemic pregnancies (Table 14)191, 211-2 
 
Table 14 Summary of studies assessing maternal CRP levels in GDM. 
 
Study 
 
Cohort Gestation Results Comments 
Wolf 2003
211 
Controls =94 
GDM=43 
1st 
trimester 
aOR 3.6 (1.2-11.4) vs the 
reference group* 
Higher in GDM 
Retnakaran 2003
213 
Controls =93 
GDM=48 
3rd 
trimester 
Correlation between BMI and CRP 
(r = 0.38, p<0.01)  
BMI important 
determinant of CRP 
and not glycaemic 
status during 
pregnancy 
Qiu 2004
212 
N=851 
GDM=38 
<16 weeks  OR 3.5  (1.2-9.8) vs the reference 
group* 
Higher in GDM 
Chen 2006
214 
N=172 
GDM=35 
15-16 wks ≥10.76 mg/L 
aOR 2.67 (1.16-6.17) 
CRP higher but not 
after adjustment for 
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BMI 
Smirnakis 2007
189 
Controls =73 
(GDM=35) 
1st 
trimester 
OR 2.2 (0.7-2.5) vs the reference 
group* 
Higher in GDM 
N: Number in study overall, aOR: Adjusted Odds Ratio, OR: odds ratio 
 
* Studies have made comparison with control groups using CRP tertiles. The lowest tertile served as the 
reference group. 
 
2.13.2 Tumour necrosis factor alpha  
Tumour necrosis factor alpha (TNF-) is a cytokine involved in systemic inflammation and 
has been found to play a role in insulin resistance. The placenta is a major source of TNF- 
and levels have been found to vary throughout pregnancy, depending on gestation, showing 
a downward trend from pre-pregnancy to early pregnancy and an increase in late 
pregnancy.126, 214-5 
 
The majority of studies conducted measured TNF- levels during the third trimester of 
pregnancy. Studies on TNF- during the first trimester of pregnancy have found varying 
results. Kirwan et al136 found that although there is a downward trend of TNF- levels from 
pre-pregnancy to early pregnancy, there is then an increase in levels as pregnancy 
advances to the third trimester. These changes were consistent, irrespective of glycaemic 
status during pregnancy.  During the third trimester, TNF- levels were also found to be 
significantly higher in those women who developed GDM in comparison to those who 
remained normoglyacemic. TNF- was shown to be a significant predictor of insulin 
sensitivity (Table 15).  
 
 
Table 15 Summary of studies assessing maternal TNF-α levels in GDM. 
 
Study 
 
Cohort Gestation Results Comments 
Winkler 
2002
218 
Controls =35 
GDM=30 
2nd and 3rd 
trimesters 
6.3 ± 0.6 ng/l vs 4.1±0.4 ng/l, 
 p<0.05 
 
Higher in GDM 
Kirwan 
2002
136 
Controls =15 
GDM=5 
Pre-preg,1st - 3rd 
trimesters 
2.84pg/ml vs 1.15pg/ml, p<0.01 
(late pregnancy vs pre-pregnancy) 
 
TNF-α significantly 
higher in late 
pregnancy vs pre 
pregnancy 
Kinalski 
2005
217 
Controls =30 
GDM=30 
3rd trimester 1.71 ± 0.92 pg/ml vs 1.27 ± 0.42 
pg/ml, p = 0.02 
Higher in GDM 
2. Background 
 
The Epidemiology and Prediction of Gestational Diabetes Mellitus   46 
 
Altinova 
2007
216 
Controls =31 
GDM=34 
3rd tirmester 20.5 ± 2.4 pg/ml vs 14.0 ± 1.5 
pg/ml, p = 0.04 
 
Higher in GDM 
Gao 2008
126 
Controls =10 
GDM=22 
2nd and 3
rd
 
trimesters  
14-20 wks: 165.37±33.60 pg/ml vs 
30.60±11.83 pg/ml, p<0.01  
24-32 wks: 290.61±60.05 pg/ml  vs 
8.37±2.41pg/ml, p<0.01 
Higher in GDM 
 
 
Other biomarkers associated with GDM 
2.14. Vitamin D 
2.14.1. Physiology of Vitamin D 
Vitamin D is a fat-soluble vitamin which is predominately made in skin exposed to sunlight. 
The two important forms of vitamin D are vitamin D2 (ergocalciferol), which is the dominant 
form in plants and invertebrates and vitamin D3 (cholecalciferol), which is the dominant form 
in vertebrates including humans. Vitamin D3 is present naturally in a small range of foods. 
The majority is then made endogenously in the skin and circulates bound to vitamin D3 
binding protein.  
 
In the liver, Vitamin D3 is metabolised to 25 hydroxyvitamin D (25 (OH) Vit D), which is the 
major circulating metabolite. In the kidneys 25-OH Vit D is further oxidised to its active form 
1, 25 dihydroxy-vitamin D (1, 25 (OH)2  D). The production of 1, 25 (OH)2 D is tightly 
regulated by parathyroid hormones and serum calcium and phosphorus levels. Fibroblast 
factor 23 also plays a role in vitamin D synthesis where it acts to suppress 1, 25 (OH)2 D 
synthesis (Fig 2.13). Vitamin D is critical for skeletal mineralisation, as 1, 25 (OH)2 D 
increases the efficiency of absorption of renal calcium and intestinal calcium and 
phosphorus.219 
 
Vitamin D plays a large role in calcium and phosphorus homeostasis and is responsible for 
bone mineralization, where a deficiency in vitamin D levels can predispose an individual to 
an increased risk of fractures. Vitamin D also has several non-skeletal functions. Vitamin D 
receptors have been found in organs such as the brain, breast, colon, immune cells and 
pancreas. Low levels of vitamin D have been associated with cardiovascular disease, DM, 
cancer and immune dysfunction. 220, 223 
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Fig 2.3 Vitamin D synthesis and functions 
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2.14.2 Vitamin D deficiency 
Measurement of blood 25 (OH) vitamin D is used to determine a patient‘s vitamin D status 
as it reflects the patient‘s total vitamin D stores from sunlight exposure, dietary intake and 
adipose stores in the liver.219 Factors that influence vitamin D levels include dietary intake, 
variations in skin synthesis secondary to differences in skin pigmentation and clothing use, 
age, and factors that cause malabsorption from the bowel such as inflammatory bowel 
disease and gastric surgery and drugs such as long term use of glucocorticoids and anti-
epileptic drugs.224 Racial differences and the influence of skin pigmentation on vitamin D 
levels indicate its evolutionary importance and may account for the increased rates of low 
vitamin D levels in non-white racial groups. Serum vitamin D and blood glucose levels vary 
between seasons and are lower in winter due to decreased sunlight exposure.225 
 
It is estimated that over a billion of the global population have Vitamin D insufficiency and 
this is a growing concern due to the association between low levels of 25 (OH) vitamin D 
and bone fractures and other conditions associated with the other non-skeletal functions of 
vitamin D.225-30 
 
There is controversy regarding the blood level of 25 (OH) Vitamin D needed for good bone 
health and also the use of vitamin D supplementation in an attempt to reduce the disease 
risks associated with vitamin D deficiency. There is a lack of randomised control trials and 
therefore insufficient evidence to support routine supplementation, particularly in population 
groups with a low incidence of deficiency.229 
 
2.14.3 Vitamin D and Type 2 DM   
The prevalence of both Vitamin D deficiency and Type 2 DM is continuing to increase and 
has potential public health implications. A link between vitamin D deficiency and Type 2 DM 
is supported by the two sharing similar risk factors such as obesity, increasing age and racial 
origin.230-6 There are also biological factors which support the link between Type 2 DM and 
vitamin D deficiency, such as the expression of the vitamin D receptor (VDR) in pancreatic 
beta cells that secrete insulin and peripheral target tissues that respond to insulin such as 
adipose tissue.  
 
An association between insulin resistance and vitamin D has been proposed due to the 
effects of vitamin D on pancreatic β-cells and insulin sensitivity and studies have shown an 
inverse relationship between insulin resistance and vitamin D230-41, 237-8 Although studies have 
largely shown a significant association between low levels of vitamin D and an increased risk 
of Type 2 DM some of the results are inconsistent.225-236, 241-53 
2. Background 
 
The Epidemiology and Prediction of Gestational Diabetes Mellitus   49 
Seasonal variation has been noted in the incidence of Type 1 and Type 2 DM. Peak 
incidence has been recorded during March and April with a trough during September and 
October. Glycosylated Haemoglobin (Hba1c) levels and plasma glucose have been 
measured to explore the relationship with the seasons. One hypothesis for the increase in 
incidence and diagnosis of DM during the winter months is the potential increase in body 
weight secondary to reduced exercise and increased food intake during the winter months. 
However, changes in the incidences have been noted even without any appreciable 
difference in body weight.245 A similar seasonal pattern of cardiovascular events has also 
been noted.244-249 
 
Vitamin D production is closely linked to exposure to sunlight and seasonal and 
geographical variation in 25 (OH) D levels have been noted, with vitamin D displaying a 
cyclical pattern of peaks in late summer and troughs during winter months.250 This seasonal 
change in Vitamin D may play a role in the glucose homeostasis and the subsequent 
development of DM. 
 
Janghorbani et al conducted a large prospective cohort study of 4,942 white women and 
examined the prevalence and seasonal variation of GDM. Although the prevalence of GDM 
was higher in summer months (2.9% in June) and lower in winter months (1.1% in 
November), the difference was not statistically significant for the change in months or 
seasons.251 The association between vitamin D levels, seasons and GDM requires further 
exploration.  
 
2.14.4 Vitamin D and pregnancy  
The metabolism of vitamin D is uniquely different during pregnancy than any other time in 
human physiology. Although the conversion of vitamin D to 25(OH) VitD remains the same 
in pregnant and non-pregnant individuals, the similarities end there. During pregnancy the 
levels of 1, 25 (OH)2  D, the active form of vitamin D, increase approximately 2 fold by the 
first trimester and reach a maximum during the third trimester.252-3 Pregnancy itself is thought 
to be the main driver for the large increase in 1, 25 (OH)2  D but the exact  mechanism of 
this the changes in metabolism remains unclear and  is thought to be independent of 
calcium and parathyroid hormones.254-66 
 
1, 25 (OH)2  D does not readily cross the placenta and this is supported by low levels of 1, 
25 (OH)2  D in the fetus in comparison to mothers. However, 25(OH) VitD readily crosses the 
placenta, resulting in similar 25(OH) VitD levels in both mother and fetus.257 
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In pregnancy, the calcium demand increases as more calcium is needed to support not just 
maternal calcium requirements but also those for fetal growth and development. The 
transport of calcium to the fetus is facilitated by the concentrations of 1, 25 (OH)2  D being 
higher in the maternal circulation than in the fetal circulation. Vitamin D has an important role 
during pregnancy and influences both maternal and fetal outcomes. 
 
Maternal vitamin D levels are associated with maternal health and obstetric outcomes. In the 
mother, in some studies, vitamin D deficiency is associated with shorter gestations258-262, 
pre-eclampsia and hypertensive disorders of pregnancy.258 In the fetus, vitamin D deficiency 
influences fetal development and therefore is associated with neonatal hypocalcaemia and 
rickets.259 In the long term, children deficient in vitamin D have an increased risk of low bone 
mineral density, diabetes and eczema.260-1 
 
Yu et al262 examined the distribution of vitamin D levels within a multi-ethnic population and 
found that maternal serum concentration of 25(OH)D  measured in the first trimester 
increased with maternal age and decreased with BMI. Maternal serum levels were also 
lower in non-white racial groups in comparison to white racial groups and levels were higher 
if sampled during the summer months. These variations make it difficult to describe normal 
levels of vitamin D during pregnancy, which can be applied to all pregnant women, without 
determining if there is a link between the various levels and maternal/fetal outcomes. This in 
turn makes it problematic to make recommendations regarding supplementation. In addition, 
some studies have failed to find an association between vitamin D levels and poor obstetric 
outcome. As a result of the variations in 25(OH)D levels described, and concerns to avoid 
overdosage, which may be harmful, some authorities have recommended a cut-off for the 
diagnosis of vitamin D deficiency in pregnant women as low as 10ng/ml in blood.262 
 
Current guidelines from NICE 263 recommend maternal daily vitamin D supplementation 
(10mcg) in order to maintain adequate vitamin D stores during pregnancy. The importance 
of vitamin D supplementation should be stressed to those women who are considered at an 
increased risk of vitamin D deficiency and associated poorer obstetric outcomes. These 
include the following: 
 
 women of South Asian, African Caribbean or Middle Eastern family origin 
 women who have limited exposure to sunlight, such as women who are 
predominantly housebound or usually remain covered when outdoors 
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 women who eat a diet particularly low in vitamin D, such as women who do not 
consume oily fish, eggs, meat, vitamin D-fortified margarine or breakfast cereal 
 women with a pre-pregnancy BMI above 30 kg/m2 
 
The appropriate supplementation dosage of Vitamin D during pregnancy remains uncertain 
and requires further investigation. 
 
2.14.5 Vitamin D and GDM 
The association between maternal 25(OH)D levels and development of GDM has been 
controversial (Table 16). The data regarding the potential use of 25(OH)D as a biomarker in 
the first trimester in the prediction of GDM are both sparse and conflicting.259-64 Baker et al,264 
conducted a nested case control study exploring the relationship between first trimester 
maternal vitamin D levels and prediction of GDM. The prevalence of vitamin D deficiency, 
classified as serum 25(OH )D <50nmol/l was similar between GDM and controls (5/60 vs 
8/120, p=0.90). These findings contrast with Zhang et al265 who measured plasma 25(OH)D 
levels at 16 weeks gestation and found that plasma 25(OH)D levels were significantly lower 
in those who later developed GDM in comparison to those who remained normoglycaemic 
(24.2 vs. 30.1 ng/ml, p<0.01). This difference remained even after adjusting for confounders 
and vitamin D deficiency was associated with a 2.66-fold (OR: 2.66 (95%CI 1.01–7.02)) 
increased GDM risk. However, the small number of incident cases of GDM (<60) may 
account for the inconsistent results between studies. 
 
Table 16 Summary of studies assessing maternal Vitamin D levels in GDM 
Study  
 
Cohort Gestation Results Comments 
Clifton-Bligh 
2008
269 
N=307 
GDM=81 
3
rd
 
trimester 
48.6 ± 24.9 nmol/l vs 55.3 ± 23.3 
nmol/l, p = 0.04 
 
Lower Vit D levels 
in GDM but ORs 
not significant  
Zhang 
2008
265 
Controls =114 
GDM=57 
16 wks  24.2ng/ml vs 30.1 ng/ml, p<0.01 
 
Lower Vit D levels 
in GDM  
Wang 
2012
267 
Controls =200 
GDM=200 
26-28 wks 25OHD levels <25 nmol/L had a 
1.8-fold higher risk of GDM ,  
aOR= 1.588 (1.03-2.44) 
 
 
Vit D deficiency 
was associated 
with increased risk 
of GDM 
Burris 
2012
266 
N=1087 
GDM=68 
2
nd
 and 3
rd
 
trimesters 
 25(OH)D levels of <25 nmol/L in 
13.2% with GDM vs 4% NGT 
OR=2.2 (95%CI 0.8–5.5) 
Vit D deficiency 
was associated 
with increased risk 
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of GDM 
Baker 
2012
264 
Controls =120 
GDM=60 
1
st
 
trimester 
Deficiency defined as 
25(OH)D < 50 nmol/L, p<0.05 
between groups 
 
Vit D deficiency 
not associated 
with GDM 
aOR= Adjusted Odds Ratio, N: Number overall in study,  NGT: Normal Glucose Tolerance, OR= Odds Ratio 
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3.1 Hypotheses 
I hypothesised that: 
 
1. There is an interaction between maternal characteristics, in particular maternal age, BMI 
and racial origin on the prevalence of GDM and birth weight. 
 
‗there is a differential effect of maternal racial origin on the association between 
advancing maternal age and BMI on the prevalence of GDM and there is an 
influence of advancing maternal age, BMI, racial group and diabetic status (GDM or 
not) on birth weight’ 
 
and 
 
2. First trimester maternal biomarkers can be used to improve early prediction of GDM. 
 
‘maternal biomarkers measured in the first trimester can improve the early prediction of 
gestational diabetes’ 
 
 
 
 
 
3.2 Aims 
 
1. To examine the relationships between maternal age, BMI and race separately and 
together, and the development of GDM. 
 
2. To examine the relationships between maternal age, BMI, race, GDM, and birth 
weight 
 
3. To investigate the role of traditional and novel first trimester maternal biomarkers on 
the prediction of GDM. 
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4. Research Methods 
 
Contributions 
 
Hyothesis 1: 
 
I was involved with formulating the hypotheses based on the wide literature search, 
the description of the SMMIS dataset and creating the study populations for the 
analysis. I carried out the analysis of the study population and the interpretation of 
the results under the guidance of my supervisors. Confirmation of the use of the 
appropriate statistical methods was obtained during consultation with Dr Ioanna 
Tzoulaki of the Department of Epidemiology and Public Health at St.Mary‘s Hospital.  
 
Hypothesis 2: 
I was responsible for organising the collection of blood samples for the creation of 
the dataset, from October 2008- April 2009. I also organised the transportation of the 
samples for analysis of the biomarkers, which was carried out at the research centre 
in an accredited laboratory at the University of Glasgow. Statistical analysis and 
interpretation of the data was carried out under the guidance of my supervisors.  
 
4.1 The Dataset: St. Mary’s Maternity Information System (SMMIS) 
4.1.1 Background  
The St. Mary‘s Maternity Information System (SMMIS) was first designed and piloted 
at St Mary‘s Hospital in Paddington in 1978, trialled in other maternity units from 
1984, and then used in the majority of maternity units located in the former North 
West Thames Health region from 1988-2000. The region has a population of 3.5 
million, a wide variety of racial groups, and included rural areas, suburbs and 
metropolitan areas. The boundaries of this region were defined by the Regional 
Health Authorities that existed in England until 1994 and covered northwest London, 
Hertfordshire and Bedfordshire.  
 
Participating hospitals used SMMIS to collect data on every pregnancy booked at 
their unit. From 1988 to 2000, data was collected prospectively from all pregnancies 
(585, 291) booked at 15 maternity units in North West London (Table 17). 
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Table 17: Hospitals in the area formerly covered by the North West Thames region 
and the number of births within each unit between1988-2000. 
                     Hospital Name                   Births from 1988-2000 
Edgware Hospital 47170 
Ealing Hospital 18909 
Northwick Park Hospital 50894 
QE2 Hospital (Welwyn Garden City) 36775 
Lister Hospital (Stevenage) 38565 
Hemel Hempstead Hospital 40745 
Watford Hospital 46185 
Hillingdon Hospital 48675 
Ashford Hospital 16207 
West Middlesex Hospital 34604 
Central Middlesex Hospital 18569 
St Mary‘s Hospital 46681 
Chelsea and Westminster Hospital 44814 
Luton and Dunstable Hospital 62854 
Bedford Hospital 33644 
 
 
The SMMIS database with attributable data was stored on a private network in the 
Department of Epidemiology and Public Health located at St. Mary‘s Hospital. The 
database contained over 200 variables, which can be grouped into different sections: 
demographic, medical information about the pregnancy, labour, delivery and 
pregnancy outcome. The data were cleaned and validated (by running cross-checks 
and plausibility assessments) and then copied to a non-attributable dataset with the 
identifiers such as the mother‘s name and address removed. All subsequent 
analyses have been done on this non-attributable dataset. Because it is possible to 
identify women and their babies by cross-checking items such as date of birth of the 
baby, and maternal characteristics such as height and weight, against the original 
hospital files, the non-attributable dataset is correctly called ‗pseudo-anonymised‘ 
rather than anonymised. However, a harmonised edition of the Governance 
Arrangements for Research Ethics Committees (GAfREC) was issued by the UK 
Health Departments in May 2011 and came into effect from 1 September 2011. 
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The harmonised GAfREC set out the requirements for review of research by 
Research Ethics Committees within the UK Health Departments‘ Research Ethics 
Service. These include both policy requirements and requirements under legislation 
applicable to the whole of the UK or to certain countries of the UK, and research 
involving previously collected, non-identifiable information. Under the 2001 edition, 
REC review was required for any research involving the data of NHS patients. Under 
the 2011 edition, REC review continues to be required for research involving 
collection of information from patients or service users for research (rather than for 
routine clinical care). 
 
―REC review is also required for research involving use of previously collected 
information from which patients or service users could be identified by researchers 
outside the usual care team (either directly from that information or in combination 
with other information in, or likely to come into their possession). 
 
However, REC review is not required under the harmonised GAfREC for research 
limited to use of previously collected, non-identifiable information. This exception also 
applies to research undertaken by staff within a care team using information 
previously collected in the course of care for their own patients or clients, provided 
that data is anonymised or pseudonymised in conducting the research. Such 
research would involve no breach of the duty of confidentiality owed by care 
professionals.‖ 270 
 
Accordingly, no REC permission was required for the analysis of the non-attributable 
dataset used in this study. This was confirmed in an email from Mr Atul Patel, NRES 
(REC) Coordinator for Proportionate Review Service London‘ Health Research 
Authority, NRES Committee London – Dulwich, East, Fulham, Surrey Borders and 
Wandsworth, Research Ethics Committee (REC) Centre Charing Cross, Room 12, 
4th Floor West, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, 
dated 18th January 2012. 
 
Demographic variables  
Mother‘s date of birth, age at booking, racial group, smoking, marital status and 
Carstairs Index were recorded in the database. Carstairs index (CI) is a measure of 
social deprivation allocated on the basis of postcode (calculated from four previous 
census indicators: low social class, lack of car ownership, overcrowding and male 
unemployment). The higher the score, the higher the measure of deprivation.  
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Medical variables about the mother  
Height and weight at booking, as well as a history of DM or epilepsy, pre-pregnancy 
BMI and blood pressure at booking. 
 
Information about the pregnancy 
Weeks of gestation at booking, DM in pregnancy and highest diastolic pressure in 
pregnancy were recorded. 
 
Information about the labour, delivery and outcome 
Labour onset, augmentation, analgesia administered, meconium liquor, mode of 
delivery, perineal trauma, birthweight, admission to Neonatal Intensive Care Unit 
(NICU) and perinatal morbidity and mortality were recorded. 
 
The data have been extensively validated271 and the analysis of subsets reported in 
many papers to date.272- 293 
 
At the first antenatal visit, BMI was calculated as weight (kg) (self-reported or 
measured by weighing if the woman did not know her weight), divided by height (m) 
squared. Racial groups were classified by self-reporting and are therefore self 
perceived classifications. Initially the categories available were White European, 
Black African, Black Caribbean, South Asian, Oriental, Mediterranean and as ‗other 
racial group‘. As the decade advanced, more categories were available, but they 
have subsequently been mapped to the same seven main groups to facilitate 
analysis. We chose to focus on White European, Black African, Black Caribbean and 
South Asian racial groups as these comprise the majority of the subjects in the 
dataset. Information regarding diabetes in pregnancy was reported by the midwives 
at delivery and classified as no diabetes in pregnancy, pre-existing diabetes and 
diabetes that was diagnosed for the first time during the index pregnancy (GDM). At 
delivery, mean birthweight percentile calculation was based on percentiles derived 
from the Aberdeen survey.296 The percentiles take into consideration the neonatal 
gender and gestational age at delivery. 
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4.2 Description of the study population 
There were 517,381 births in the SMMIS dataset from 1988 to 2000 that included 
information about birthweight. All births of 24 weeks gestation and over with a 
birthweight of at least 500g that included information regarding development of 
diabetes during pregnancy, maternal age, height, weight, BMI at booking and 
maternal ethnic group were included in the study. Births before 24 weeks gestation 
and weighing less than 500g were not considered to be viable. 389,784 births fitted 
the inclusion criteria (Fig 4.1). This was irrespective of parity. 
 
Fig 4.1 Flow diagram of study subset derived from the original dataset 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.1 Final dataset 
The final dataset included details on all births of 24 weeks 
gestation and over with a birthweight of 500g and over that included information 
regarding development of diabetes during pregnancy, maternal age, height, weight, 
BMI at booking and maternal race.  
 
SMMIS dataset 1988 - 2000 
     (including  birth weight) 
      n = 517381 pregnancies 
Study population  
n = 389784 
pregnancies 
n = 503003 
n = 416945 
n = 395975 
n = 394627 
n = 390869 
n = 389970 
Excluded if missing height, 
n = 86058 
Excluded if missing weight 
at booking (Kg), n = 20970 
Excluded if missing maternal 
age at booking, n = 3758 
Excluded if birth weight 
<500g, n = 186 
Excluded if missing Diabetes 
status in pregnancy,  
n = 1348 
Excluded if completed weeks 
of gestation <24, n = 899 
Excluded if no data on race 
(n=14,378)  
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I excluded subjects with missing information regarding: racial group (n=14,378), 
height (n=86,058), weight (n=20,970), diabetes status during pregnancy (n=1,348), 
maternal age at booking (n=3,758), women giving birth before 24 weeks gestation 
(n=899) or with babies weighing less than 500g (n=186) as their babies were not 
considered to be viable. 389,784 births fitted the inclusion criteria (Fig 4.1). 
 
4.2.2 Special cases 
The outcomes of the 389784 pregnancies were checked by looking at the variables 
labelled as perinatal death by timing (i.e. less than 24 weeks gestation, antepartum, 
intrapartum or neonatal death) and recompleted weeks at delivery. Three 
pregnancies were identified as being coded as either a miscarriage or termination of 
pregnancy (TOP). Two occurred at 24 completed weeks of gestation and the other at 
26 completed weeks of gestation.  Miscarriage is defined as the spontaneous loss of 
a pregnancy before 24 weeks gestation and therefore these pregnancies were 
investigated as follows: 
 
24 weeks gestation 
Both pregnancies had birthweights over 500g. They also both had a record of 
amniocentesis, chorionic villous sampling, induced abortion and congenital 
abnormalities. Therefore they remained as being coded as TOP, possibly for fetal 
abnormalities. 
 
26 weeks gestation 
One pregnancy was identified and had a birthweight of 800g recorded.  This 
pregnancy had no congenital abnormalities, no Apgar scores were recorded, no fetal 
monitoring was performed during labour and labour was induced. This was recoded 
as an antepartum stillbirth. 
 
 
 
 
The above study population was split into three datasets: 
 Group 1 (diabetespregnullips) – This dataset includes all women in their first 
ongoing viable pregnancy who meet the inclusion criteria. 
 Group 2 (diabetespregpara 1) - This dataset includes all the women during 
their second ongoing viable pregnancy, who meet the inclusion criteria. 
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 Group 3 (diabetespreg) - This dataset includes all the women regardless of 
parity who meet the inclusion criteria.  
The analyses reported in this Thesis were performed on the dataset of Group 1 
(diabetespreg nullips).  
 
The reason for creating the separate parity groups and focusing the analyses on 
Group 1 was to exclude any possible bias due to including the same women more 
than once in the analysis. The combined data set does not allow us reliably to link 
women‘s first, second etc pregnancies. Thus, some women are represented in the 
dataset more than others, and if for example highly parous women are more likely to 
be diabetic, this could introduce bias. However, a woman can have her first baby 
only once, ditto her second baby. Thus the datasets of nullips and second baby by 
definition include women only once in each dataset, making this a true cross-
sectional study. 
 
It should also be noted that by examining only women in their first pregnancy, this 
group represents a small sub group of the women who will develop GDM. By not 
including parous women it excludes a group of women who are at increased risk of 
GDM.  
 
The analysis of Group 1 (diabetespreg nullips) will be reported in this Thesis.  
 
 
 
 
 
 
 
 
 
 
 
4.3 Description of the variables 
The following table lists all the variables that will be used in the study: 
 
Table 18 Outcome and explanatory variables within dataset 
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Variable Description 
 
Explanatory variables 
Maternal age 
Maternal weight at booking 
Maternal height 
Maternal BMI 
Mother‘s racial group 
 
years 
kg 
cm 
kg/m² 
White European, Black African, 
Black Caribbean, South Asian, other 
(including Mediterranean, Oriental) 
Outcomes 
Diabetes in pregnancy  
 
Birthweight 
GA at delivery 
Sex of the neonate 
 
0=non-diabetic, 1=gestational 
diabetes, 2=pre-existing  diabetes 
grams 
weeks 
female or male 
 
4.3.1 Diabetes in pregnancy 
The following table shows the distribution of women with diabetes in pregnancy 
(gestational and established diabetes) and no diabetes within the study population 
(dataset diabetespreg). Gestational diabetes had a prevalence of 1.2% in this study 
population. 
 
Table 19 Frequency of diabetes in pregnancy in study population 
 
Diabetes in 
pregnancy 
 
Frequency, N Percentage (%) Cumulative 
Percentage (%) 
None 
 
383883 98.5 98.5 
Gestational  
 
4756 1.2 99.7 
Pre-existing  
 
1145 0.3 100.0 
Total 
 
389784 100.0  
 
The demographic and clinical characteristics of the study population (diabetes preg) 
according to the development of diabetes are given in Table 19. 
 
Table 20 Demographic and clinical characteristics of the study population according 
to the development of diabetes prior or during pregnancy. Numerical data are 
expressed as mean (standard deviation). 
 
Variables  Non-Diabetic Gestational Pre-existing 
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 N=383883 Diabetes, N=4756 Diabetes, N=1145 
 
Maternal Age (yrs) 
 
 
28.5 (5.3) 
 
31.6 (5.3)* 
 
29.5 (5.2)* 
 
Maternal Height (cm) 
 
 
162.6 (6.8) 
 
160.1 (7.1)* 
 
162.2 (7.4)* 
Maternal Weight at 
booking (kg) 
 
 
64.3 (12.37) 
 
71.2 (16.4)* 
 
69.4 (13.8)* 
 
BMI at booking (kg/m2) 
 
 
24.3 (4.4) 
 
27.7 (5.8)* 
 
26.4 (5.0)* 
 
Birthweight (kg) 
 
 
3319.8 (569.4) 
 
3420.1 (656.9)* 
 
3444.6 (735.1)* 
*p<0.001 in comparison with the non-diabetic group  
 
As explained previously, for this Thesis, only first pregnancies were studied to avoid 
bias.  
This resulted in one third of the SMMIS dataset being appropriate to study (Fig 4.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.2 Final dataset used 
for subsequent analysis 
 
 
N=389,784 
No diabetes=383,883 
GDM=4756 
(Pre-existing diabetes=1,145) 
N=174,320 
(Nulliparous) 
No diabetes=172,632 
GDM=1,688 
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Initial numbers in the dataset  
Study population in this thesis 
(diabetespreg nullips) 
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The final dataset (diabetespreg nullips) consisted of the following distribution of 
women with diabetes during pregnancy within the study population (Table 20). 
Gestational diabetes had a prevalence of 1.0% in this study population. 
 
Table 21 Frequency of diabetes in pregnancy within the study population (nulliparous 
women only) 
 
Diabetes in pregnancy Frequency Percentage (%) 
None 
 
172,632 99.0 % 
Gestational diabetes  
 
1688 1.0 % 
Total   
 
174,320 100% 
 
4.3.2 Maternal Characteristics 
Maternal Age  
The following table shows the range of maternal age within the dataset irrespective 
of diabetic status (Table 22). 
 
Table 22 Description of maternal age within the study population irrespective of 
diabetic status 
 Number Min Max Mean (SD) 
Maternal age 
 (at booking) 
174320 12 50 26.8 (5.2) 
 
SD= Standard deviation 
 
Maternal BMI 
The following table shows the range of BMI within the dataset irrespective of diabetic 
status (Table 23). 
 
 
 
4. Research Methods 
The Epidemiology and Prediction of Gestational Diabetes Mellitus   65 
Table 23 Description of body mass index within the study population irrespective of 
diabetic status 
 Number Min Max Mean (SD) 
Body Mass Index  174320 11 70 23.6 (4.1) 
 
SD= Standard deviation 
 
Maternal race 
The following table (Table 24) shows the numbers in each racial group within the 
dataset.  
Table 24 The distribution of racial groups within the dataset irrespective of diabetic 
status 
 
Racial group Frequency, (N) Percentage (%) 
White European 131201 75.3 
Black African 4927 2.8 
Black Caribbean 4698 2.7 
South Asian 20086 11.5 
Any other ethnic group 13408 7.7 
Total 174320 100.0 
 
 
White European women formed the majority of the dataset. South Asians were the 
largest non-white racial group. 
 
4.3.3 Birthweight 
At delivery, mean birthweight percentile calculation was based on percentiles derived 
from the Aberdeen survey.294 These birthweight percentiles take into consideration 
the baby‘s gender and gestational age at delivery. Z-scores (birthweight in relation to 
the mean and standard deviation for each gestational week) were produced as an 
alternative to the actual birthweight.  
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4.4 Hypotheses 
 
4.4.1 Hypotheses 1(a):  
 
 There is a differential effect of maternal racial origin on the association 
between advancing maternal age and BMI on the prevalence of GDM. 
 
Statistical analysis 
The statistical analysis involved descriptive statistics and exploratory analysis to 
study the data and look at patterns. This was done using the statistical package 
SPSS Version 17.0 for Windows.  
 
Exploratory analysis 
Maternal characteristics and pregnancy outcomes in the two groups studied (GDM 
and non-GDM) were compared using the Student‘s t-test and Chi-square x2 test for 
numerical and categorical data respectively. Maternal age was divided into the 
following groups: below 20, 20-24, 25-29, 30-34, 35-39 and 40 and above years of 
age. Maternal BMI was also divided according to the WHO international classification 
of BMI as follows: less than 18.5 (underweight), 18.50-24.99 (normal weight), 25.00-
29.99 (overweight) and more or equal to 30.00 (obese).78 
 
Univariate analysis was initially used to examine the influence of maternal age and 
BMI on GDM development in each racial group. Binary logistic regression was used 
to develop statistical models for development of GDM including the risk variables of 
maternal age, BMI and race as well as the interactions between these variables.  
Models were constructed to examine the magnitude and significance of predictor 
variables on the prevalence of GDM. The results are presented as Odds Ratios 
(ORs), 95% Confidence Interval (CI) and p-values. 
 
Hypothesis 1(b): 
 
 
 There is an association of advancing maternal age, BMI, racial group and 
diabetic status (GDM or not) with birth weight. 
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The previous dataset was modified further. Cases where the baby‘s gender was 
classiﬁed as ‗indeterminate‘ (n = 20) were excluded. As maternal booking weight and 
BMI change very little up to 20 weeks of gestation, but do increase thereafter (see fig 
4.3.1 and 4.3.2), all women booking after 20 weeks of gestation were also excluded 
from the analysis (n = 43751). This created a further dataset for the investigation of 
maternal characteristics and the influence on birthweight.  
 
Fig 4.3.1 Maternal weight variation with advancing gestation 
 
 
Nulliparous women. N=177,590 
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Fig 4.3.2 Maternal BMI variation with advancing gestation 
 
 
 
 
Nulliparous women. N = 162,047 
 
The gender specific percentile birthweight for gestational age was calculated, based 
on the Aberdeen survey norms.294 Gender specific birthweight z-score, a measure of 
how many standard deviations the birthweight was from the expected mean was also 
calculated in relation to the total population.  
 
A Z-score is a measure of how far a measurement is from the mean, measured in 
standard deviations and was calculated by the following equation: 
 
Z = Observed birthweight- expected birthweight 
                                              Standard deviation (SD) 
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The outcomes studied were birthweight, percentile and z-scores, in GDM and non-
GDM groups, within the three main racial groups: White European, Black and South 
Asian, who comprised the majority of the subjects in the dataset. 
 
Simple and multiple linear regressions were used to explore the influence of 
variables on birthweight z-scores. 
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4.4.2 Hypothesis 2: 
 
  First trimester maternal biomarkers can improve early prediction of GDM 
 
 
Material and Methods 
We performed a nested case-control study using first-trimester samples that were 
taken and stored as part of a large prospective observational ongoing study aimed at 
identifying first-trimester predictors of adverse pregnancy outcomes. The study 
involved women attending for their routine hospital visit at King‘s College Hospital. In 
this visit, which is held at 11+0 to 13+6 weeks‘ gestation, all women have an 
ultrasound scan to confirm gestational age, diagnose any major fetal abnormalities, 
and measure fetal nuchal translucency thickness, which together with maternal free 
β-chorionic gonadotrophin and pregnancy-associated plasma protein A, is used for 
screening for chromosomal abnormalities. Patients were asked to complete a 
questionnaire on maternal age, racial group, cigarette smoking during pregnancy, 
method of conception, parity and obstetric and family history of diabetes. The 
maternal weight and height were measured and BMI was calculated. Peripheral 
maternal blood pressure was measured in a seated position using an ambulatory 
blood pressure monitor (3BTO-A2;Microlife Medical, Taipei, Taiwan), which has been 
validated in pregnancy.295 Maternal blood was taken and stored at -80°C for future 
biochemical analyses. All women had phenotypically normal neonates. Women had 
given written consent and the project had been approved by the local Research 
Ethics Committee. 
  
All women underwent routine screening for GDM between 24-28 weeks. This 
involved a random blood sugar, which if abnormal i.e. ≥ 6.7 mmol/l was followed by a 
2 hour 75g OGTT. If women had a prior history of GDM then they would have a 
OGTT between 16-20 weeks and at 28 weeks if the previous result was normal. If 
after 34 weeks following a negative screen at 28 weeks GDM was suspected due to 
the developed of apparent risk factors such as polyhydramnios or a large-for-
gestational-age fetus a one-hour post meal glucose would be performed as well as 
an HbA1c. A plasma glucose ≥ 6.7 mmol/l or an HbA1c over 5.5% would require 
referral to the Diabetes Centre. Gestational diabetes mellitus was defined according 
to the WHO criteria.  For each woman who developed GDM, two control subjects 
were selected who were matched according to the date of the ultrasound scan and 
consequently storage time of the samples. 
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We measured novel and traditional maternal serum biomarkers including 
adiponectin, lipids (HDL-cholesterol, LDL-cholesterol, total cholesterol and 
triglycerides), γ-GT, E-selectin, t-PA and CRP. In a subset of the study population, 
maternal serum vitamin D (25OHD3 and D2) was also measured.  
 
Biochemical analysis 
Lipids, CRP and γ-GT were measured by routine automated methods in an 
accredited laboratory (University of Glasgow, UK).  adiponectin, e-selectin, and t-PA 
were measured by enzyme-linked immunosorbent assay (R&D Systems, Abingdon, 
UK) on previously unthawed serum samples stored at -80°C. Samples were 
processed by technicians who were blinded to the identity of the samples.  
 
Maternal first trimester serum 25OHD3 and D2 were measured using an automated 
solid-phase extraction (SPE) procedure with liquid chromatography-tandem mass 
spectrometry. Results are reported as total 25OHD (25OHD2 + 25OHD3). Vitamin D 
deficiency was defined as 25(OH)D<25nmol/l as this a common definition used in 
clinical practice.  
 
Statistical analysis 
Descriptive statistics were used to summarise maternal characteristics, comparing 
those with GDM to controls. Categorical variables were compared using Fisher‘s 
exact test and continuous variables were compared using Student‘s t-test or 
Wilcoxon rank sum tests as appropriate.  
 
Regression analysis was used to examine the role of each variable in the prediction 
of GDM. Logistic regression models were fitted and adjusted for confounding factors.  
HDL cholesterol, triglycerides, and CRP were log transformed as this enhanced 
model fit. Stepwise variable selection procedures were used to identify the most 
important predictors and effect estimates were reported along with 95% CIs and p 
values. The predictive abilities of the different models were illustrated using ROC 
curves. The same analyses were repeated in the subgroup of mothers who had not 
had previous GDM. 
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5. Results 
 
5.1 Hypothesis 1 (a):  
 
 There is a differential effect of maternal racial origin on the association 
between advancing maternal age and BMI on the prevalence of GDM 
 
5.1.1 Hospital 
 
A concern in the current study was that 15 Hospitals with different screening policies 
for GDM were included which could result in a different proportion of the population 
being designated as ‗gestational diabetic‘. This could be important, because not all 
the hospital services used the same screening techniques to assess carbohydrate 
tolerance. Moreover, this was further complicated by the fact that not all the hospitals 
had the same racial mix.  We found that the addition of centre did add to the models 
by explaining variation over and above the effects of race, maternal age and BMI. 
 
In order to investigate this variable more fully we created a figure showing the rates 
of GDM within each hospital (Fig 5.1) and then the racial mix within each hospital 
(Fig 5.2). 
 
The highest rates of GDM were in West Middlesex hospital (1.58%), St Mary‘s 
hospital (1.43%) and Hemel Hempstead Hospital (1.11%). However, the racial mix 
within these hospitals was very different. It would have been expected that Hemel 
Hempstead Hospital would have had the lowest rate of GDM due to its population, 
which consisted mainly of White Europeans. The most likely explanation is different 
screening programmes within each hospital as there wasn‘t at the time of the study 
(and isn‘t) a general consensus regarding screening for GDM. Most units adopted 
their own screening guidelines for GDM. The rates of GDM diagnosis in White 
Europeans by centre was highly correlated with that in both Blacks (Pearson 
correlation coefficient 0.864) and South Asians (Pearson correlation coefficient 
0.863) in the same centre. Multiple regression analysis including each individual 
centre as a variable confirmed that although five units contributed significantly to the 
birthweight z-scores, this contribution was much smaller than the effects of racial 
group, BMI, GDM or smoking (maximum t value for centre 7.8 compared with -67.1 
for being South Asian, -47.9 for smoking, 46.4 for BMI, -23.1 for being Black, and 
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14.5 for the presence or absence of GDM). This means that although the incidence 
of GDM might have been underestimated in centres without a routine screening 
policy, this effect applied similarly across racial groups, and the differences between 
racial groups was consistent across the centres. 
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Fig 5.1 The frequency distribution of diagnosed gestational GDM within the 15 Maternity units in the SMMIS database. 
 
 
 
5. Results 
The Epidemiology and Prediction of Gestational Diabetes Mellitus   75 
Fig 5.2 The racial variation of women with pregnancies complicated with GDM within each hospital (NWP: Northwick Park Hospital) 
 
 
5. Results 
The Epidemiology and Prediction of Gestational Diabetes Mellitus   76 
5.1.2 Missing Information  
Women who had missing information on maternal age, BMI (weight or height), racial 
group, diabetes in pregnancy or birthweight were excluded from further analysis. The 
study population was compared with the non-studied population to exclude any bias 
(Table 25).  
 
Table 25 Comparison of demographic details, clinical characteristics and pregnancy 
outcomes in missing dataset vs study dataset. 
 
Maternal characteristic Non-studied 
dataset 
(N= 1594) 
Study dataset 
(N= 174,320) 
P value 
Maternal age (yrs) 27.7 ± 5.5  26.8 ± 5.2 p<0.001 
BMI (kg/m2) 25.7 ± 4.6 23.8 ± 4.0 p<0.001 
Racial Group 
White European, n (%) 
Black African, n (%) 
Black Caribbean, n (%) 
South Asian, n (%) 
Oriental, n (%) 
Mediterranean, n (%) 
Other, n (%) 
 
1038 (67.2) 
87 (5.6) 
83 (5.4) 
176 (11.4) 
26 (1.7) 
50 (3.2) 
85 (5.5) 
 
131,201 (75.3) 
4,927 (2.8) 
4,698 (2.7) 
20,086 (11.5) 
2,949 (1.7) 
4,469 (2.6) 
5,990 (3.4) 
 
p<0.001 
Diabetes in pregnancy 
No diabetes, n(%) 
Gestational diabetes,n(%) 
 
 
1787 (52.3) 
3 (0.2) 
 
172,632 (99.0) 
1,688 (1.0) 
 
p<0.001 
Birthweight (grams) 1711.92 ±1557.92 
 
3254.3 ± 567.6 p<0.001 
Mean birthweight centile  
44.42 ± 39.39 
 
57.9 ± 28.2 
 
p<0.001 
Mode of delivery 
Vaginal, n (%) 
Caesarean section, n (%) 
 
731 (60.5) 
478 (39.5) 
 
 
142,865 (82.0) 
31,450 (18.0) 
 
p<0.001 
Values are expressed as mean ± standard deviation or as median (interquartile range)  
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Women in the missing dataset were significantly older, had a higher BMI and were 
more likely to be in the non-white racial group than the study dataset. Women in the 
missing dataset were also more likely to deliver smaller babies and more likely to 
deliver by Caesarean section.  
 
The study population had a different proportion of women with pregnancies 
complicated by gestational diabetes (1% in the study population vs 0.2% in the non 
studied population).  However, the non-studied population only contained 3 women 
with GDM and therefore the non-studied population was not considered further as it 
was felt that the study population adequately represented the whole population in the 
database in terms of the outcome ―diabetes‖ in pregnancy. 
 
The study included 1,688 women that developed GDM and 172,632 that did not. The 
prevalence of GDM in our study population was 1%.  
 
5.1.3 Variables 
 
Initially, it was necessary to determine whether the continuous variables such as 
maternal age and BMI, were normally distributed. This would influence the types of 
analyses that could be used to compare the variables. However, we were unable to 
confirm the normality of the data with N-Par tests due to the size of the database. 
Histograms displaying normal curves were therefore created. From these 
histograms, it can be seen that variables such as maternal age and BMI within our 
study population are sufficiently close to a Gaussian distribution for parametric 
statistics to be applied. (Fig 5.3 and 5.4; histograms with normal curve 
superimposed). 
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Fig 5.3 The distribution of maternal age within study population 
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Fig 5.4 The distribution of body mass index within study (nulliparous) population 
 
 
 
 
Maternal BMI 
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The maternal demographic, clinical characteristics and pregnancy outcomes in the 
GDM and control group are given in Table 26. 
 
Table 26 Maternal demographic, clinical characteristics and pregnancy outcomes of 
the non-GDM and GDM groups. 
 
Characteristic Non -GDM 
(N=172,632) 
GDM 
(N=1,688) 
Age (years)  26.8 ± 5.1 29.6 ± 5.2* 
Gestational age at first antenatal visit 
(wks) 
13.0 (12.0-16.0) 13.0 (12.0-16.0) 
Body mass index (kg/m²) 23.7 ± 4.0 26.6 ± 5.5* 
Racial group 
 
   White European, n (%) 
   Black African, n (%) 
   Black Caribbean, n (%) 
   South Asian, n (%) 
   Oriental, n (%) 
   Mediterranean, n (%) 
   Other, n (%) 
 
130325 (75.5) 
4840 (2.8) 
4648 (2.7) 
19685 (11.4) 
2874 (1.7) 
4390 (2.5) 
5870 (3.4) 
 
876 (51.9)* 
87 (5.2) 
50 (3.0) 
401 (23.8) 
75 (4.4) 
79 (4.7) 
120 (7.1) 
Gestational age at delivery (wks) 40.0 (39.0-41.0) 39.0 (38.0-40.0)* 
Birthweight (grams) 3305.9 ± 639.3 3523.8 ± 566.9* 
Birthweight percentile 57.9 ± 28.2 63.9± 29.6* 
Birthweight >90th percentile, n (%) 16,598 (9.6) 248 (14.6)* 
Mode of delivery 
    
   Vaginal delivery, n (%) 
   Caesarean Section, n (%) 
 
141,764 (82.1) 
30,868 (17.9) 
 
1,101 (65.3) 
587 (34.7) 
Values are expressed as mean ± standard deviation or as median (interquartile range), * p<0.001 
 
 
Compared to the non-diabetic group, women who developed GDM were more likely 
to be older, heavier, of non-white racial origin and deliver large for gestational age 
babies earlier. 
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5.1.3.1 Maternal age 
 
Although most cases of GDM were in the age groups 20-35 because that is when 
most women were pregnant (fig 5.5), there were increasing proportions of GDM with 
increasing age groups (fig 5.6). This was more apparent over the age of 25. 
 
Fig 5.5 The proportions of women falling within the different maternal age groups. 
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Fig 5.6 The prevalence of GDM (95% Confidence Intervals shown as error bars) in 
the different maternal age groups, for the total population.  
 
 
 
 
 
The rates of GDM were generally higher within non-white racial groups. In Black 
Caribbean groups, rates of GDM were higher from age 25, except for age group 35-
39 compared to White Europeans. Black African and South Asian groups had higher 
rates of GDM within all age groups compared to White Europeans (Table 27). 
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Table 27 The rates of GDM and non-GDM in the study population according to maternal age, within each different racial group. 
 
 
Variable    
 
White European 
 
Black African 
 
Black  Caribbean 
 
South Asian 
 
 GDM, n (%)                 Non GDM, n (%) 
 
GDM, n (%) Non GDM, n (%) 
 
GDM, n (%) Non GDM, n (%) 
 
GDM, n (%) Non GDM, n (%) 
 
Age groups   
 
  
 
    
<20 26 (0.2)                  11478 (99.8) 1 (0.3) 
 
351 (99.7) 
 
1 (0.1) 
 
825 (99.9) 
 
7 (0.5) 
 
1541 (99.5) 
 
20-24 
 
134 (0.5)              
 
28559 (99.5) 10 (0.7) 1335 (99.3) 
 
4 (0.3) 1320 (99.7) 
 
77 (1.1) 
 
7115 (98.9) 
 
25-29 
 
263 (0.5)               
 
48194 (99.5) 33 (1.6) 
 
2064 (98.4) 
 
22 (1.5) 
 
1441 (98.5) 
 
129 (1.8) 
 
7133 (98.2) 
 
30-34 
 
308 (0.9)               
 
32167 (99.1) 
 
26 (2.9) 
 
882 (97.1) 
 
20 (2.4) 
 
814 (97.6) 
 
125 (4.0) 
 
3037 (96.0) 
 
35-39 
 
122 (1.4) 
 
8128 (98.6) 
 
12 (6.0) 187 (94.0) 
 
2 (0.9) 
 
217 (99.1) 
 
50 (6.2) 
 
750 (93.8) 
 
≥ 40 23 (1.9) 
 
1199 (98.1) 5 (21.7) 18 (78.3) 1 (3.1) 31 (96.9) 13 (11.4) 101 (88.6) 
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As expected, there was a strong positive association between advancing maternal age and 
the proportion of women with GDM (p<0.001) (Table 27). This positive association was 
present in all maternal racial groups but was more pronounced in Black Africans and South 
Asians in comparison to White Europeans (p<0.001 for all groups).  (Table 28) 
 
Table 28 Univariate analysis of the influence maternal age, BMI and racial group on 
development of GDM. 
 
Maternal characteristic Odds Ratio (OR) p value 
Maternal age (yrs) 1.09 (1.08-1.10) <0.001 
BMI (kg/m²) 1.11 (1.10-1.12) <0.001 
Racial origin 
Black African * 
Black Caribbean* 
South Asian* 
 
2.67 (2.14-3.34) 
1.60 (1.20-2.13) 
3.03 (2.69-3.41) 
 
<0.001 
<0.001 
<0.001 
* Comparisons made between White European women age 29-24 as a reference group 
 
Using White European women age 20-24 as a reference group, White European women 
over the age of 30 had higher ORs for GDM development. Non-white racial groups had 
significantly higher ORs at younger ages: over age 25 for Black African and Caribbean 
women and over 20 for South Asian women. White European women under the age of 20 
had a significantly reduced OR for GDM development in comparison to the reference group. 
This was not the same for non-white racial groups below the age of 20 (Table 29 and Fig 
5.7) 
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Table 29 Odds ratios (95%CI) for development of GDM according to advancing maternal age within each racial group. The reference group 
was White European women of 20-24 years old.  
 
 
 
Age groups 
 
White European 
 
Black African Black Caribbean South Asian 
<20 
 
0.48 (0.31-0.73)*     0.60 (0.08-4.35) 0.25 (0.03-1.85) 0.96 (0.45-2.07) 
20-24 1.00 
 
1.59 (0.33-3.03) 0.64 (0.23-1.74) 2.30 (1.74-3.05)* 
25-29 1.16 (0.94-1.43) 
 
3.40 (2.32-5.00)* 3.25 (2.06-5.12)* 3.85 (3.02-4.91)* 
30-34 2.04 (1.66-2.50)* 
 
6.28 (4.10-9.61)* 5.23 (3.25-8.42)* 8.77 (6.85-11.22)* 
35-39 2.97 (2.32-3.81)* 
 
13.67 (7.44-25.11)* 1.96 (0.48-7.98) 14.05 (10.08-19.60)* 
≥40 4.08 (2.61-6.38)* 
 
59.20 (21.66-161.37)* 6.87 (0.93-50.72) 27.43 (15.02-50.08)* 
*p<0.001 
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Fig 5.7 The prevalence of GDM in the different maternal age groups according to race. The 
maternal age is given as continuous variable. Regression lines for non-white racial groups 
are compared to White Europeans.  
 
 White European         Black Caribbean         Black African          South Asian 
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5.1.3.2 Body Mass index 
Although most cases of GDM were in the BMI groups 20-29.9 because that is when most 
women were pregnant (Fig 5.8), the prevalence of GDM was higher in higher BMI groups 
(Fig 5.9).  
 
 
Fig 5.8 The proportions of women falling within the BMI groups. 
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Fig 5.9 The prevalence of GDM (95%CI) in the different maternal BMI groups. 
 
 
 
 
Similarly, there was a strong positive association between increasing BMI and the proportion 
of women with GDM (p<0.001) (Table 29), which was more pronounced in Black Africans 
and South Asians in comparison to White Europeans (p<0.0001 for all groups) (Table 29). 
 
Using White European women with a BMI of 18.5-24.9 as a reference group, increasing BMI 
category was associated with higher ORs for GDM development within White European 
group. Compared to the reference group, non-white racial groups (with the exception of 
Black Caribbean) had higher ORs for GDM development within all BMI categories including 
the normal BMI group (Table 30 and Fig 5.10). 
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Table 30 The rates of gestational diabetes mellitus (GDM) and non-GDM in the study population according to the BMI within each different 
racial group.  
 
Variable    White European 
 
Black African 
 
Black Caribbean 
 
South Asian 
 
Body Mass Index 
groups 
 
GDM, n 
(%)                 
Non GDM, n 
(%) 
 
GDM, n 
(%) 
Non GDM, n 
(%) 
 
GDM, n 
(%) 
Non GDM, n 
(%) 
 
GDM, n 
(%) 
Non GDM, n 
(%) 
 
Normal (18.5-24.9) 396 (0.5)              85823 (99.5) 33 (1.2) 
 
2729 (98.8) 15 (0.6) 2687 (99.4) 184 (1.4) 13283 (98.6) 
Overweight (25.0-
29.9) 
217 (0.8)    
 
26556 (99.2) 20 (1.6) 
 
1234 (98.4) 17 (1.5) 1097 (98.5) 111(3.4) 3122 (96.6) 
Obese (≥ 30) 221 (2.1)              10175 (97.9) 27 (5.6) 
 
456 (94.4) 15 (2.6) 555 (97.4) 68 (7.4) 847 (92.6) 
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Fig 5.10 The prevalence of GDM (95%CI) in the different maternal BMI groups according to 
race. The maternal BMI is shown as continuous variable. Regression lines for non-white 
racial groups are compared to White Europeans 
 
White European           Black Caribbean            Black African            South Asian 
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5.1.3.3 Interactions between variables 
 
A stepwise approach was used to create models looking at racial group, BMI and age and 
the interactions between the variables.  
The following models were created: 
 age, BMI, race and the interaction between BMI and race 
 age, BMI, race and the interaction between age and race 
The interaction term BMI x race was statistically significant only in the South Asians and the 
interaction term age x race was significant in Black Africans and South Asians, as shown in 
Tables 31 and 32, respectively. 
 
Table 31 Logistic regression model: the influence of maternal age, BMI, racial group and 
BMI X race (interaction term) on development of GDM. Odds ratios with 95% confidence 
interval (95%CI) are given.  
 
Maternal characteristic Odds Ratio  (95%CI) P value 
Age 1.103 (1.092-1.115) <0.001 
Body mass index (kg/m2) 1.120 (1.122-1.149) <0.001 
Race *  -overall 
   Black African 
   Black Caribbean 
   South Asian 
 
3.721 (1.060-11.077) 
3.027 (0.724-11.759) 
1.881 (1.291-4.732) 
0.013 
0.018 
0.086 
0.036 
BMI x race interaction*-overall 
   Black African 
   Black Caribbean 
   South Asian 
 
0.989 (0.950-1.033) 
0.977 (0.931-1.027) 
1.032 (0.998-1.046) 
0.018 
0.565 
0.305 
0.006 
* in comparison to White Europeans 
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Table 32 Logistic regression model: the influence of maternal age, BMI, racial group and 
age x race (interaction term) on development of GDM. Odds ratios with 95% confidence 
interval (95%CI) are given.  
 
Maternal characteristic Odds Ratio (95% CI) P value 
Age 1.089 (1.075-1.103) <0.001 
BMI (kg/m2) 1.124 (1.127-1.149) <0.001 
Race *  -overall 
   Black African 
   Black Caribbean 
   South Asian 
 
0.427 (0.093-1.526) 
1.093 (0.255-5.373) 
1.616 (0.626-3.221) 
0.258 
0.230 
0.908 
0.103 
Age x race interaction*- overall 
Black African 
Black Caribbean 
South Asian 
 
1.065 (1.020-1.119) 
1.012 (0.959-1.063) 
1.033 (1.009-1.057) 
0.005 
0.007 
0.647 
0.005 
* in comparison to White Europeans 
 
 
A similar model with the interaction age X BMI was constructed. However, when the variable 
maternal age x BMI was included into the model for development of GDM, the interaction 
was not significant for any racial group (p=0.974) (i.e. the influence of BMI does not vary with 
age) (Table 33) 
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Table 33 Multiple Regression Model: the influence of maternal age, BMI, racial group and 
age x BMI (interaction term) on development of GDM. Odds ratios with 95% confidence 
interval (95%CI) are given.  
 
Risk Factor Odds Ratios (95% CI) p value 
Age 1.10 (1.05-1.15) <0.001 
 
BMI 1.12 (1.07-1.18) <0.001 
 
Race* 
 
Black African 
Black Caribbean 
South Asian 
 
2.71 (2.16-3.39) 
1.55 (1.16-2.08) 
4.17 (3.69-4.72) 
<0.001 
 
<0.001 
0.003 
<0.001 
 
Age x BMI interaction 1.00 0.974 
 
* in comparison to White Europeans  
 
Summary**: 
 There is strong association between advancing maternal age and increasing BMI on 
the development of GDM, which varies within each racial group. 
 
 The association between risk factors and GDM development is different within Black 
sub-populations- Black African and Black Caribbean. 
 
 The influence of advancing age is on GDM development is more pronounced in 
Black African and South Asian groups. 
 
 The influence of increasing BMI is more pronounced in South Asian groups.  
 
 There is no significant interaction between maternal age and body mass index on the 
development of GDM. 
** Summary findings relate to women in their first pregnancy 
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5.2 Hypothesis 1(b): There is a relationship between advancing maternal age, BMI, racial 
group and diabetic status (GDM or not) and birth weight. 
 
The dataset was modified in order to examine the influence of variables maternal age, BMI, 
racial origin and GDM on neonatal birthweight, represented as z-scores. A further 20 women 
were excluded from this analysis, because the sex of the baby was reported as 
indeterminate. The dataset therefore included 1,688 women with GDM and 172,612 women 
without GDM. As shown previously in figures 4.3.1 and 4.3.2, maternal weight and BMI 
increase with gestation. However, there is little variation in maternal BMI between 8 and 20 
weeks gestation. The dataset was therefore modified further to exclude all women who 
booked after 20 weeks gestation (n=43,751).  
 
Maternal demographic, clinical characteristics and pregnancy outcomes are given in Table 
34. 
 
Table 34 Maternal demographic, clinical characteristics and pregnancy outcomes of the 
non-GDM and GDM groups. 
 
Maternal Characteristic  Non-GDM 
  (N=139,267) 
GDM 
      (N=1,307) 
P value 
Maternal age (years) 27.14 ± 5.1 29.6 ± 5.1 <0.001 
Gestational age at first antenatal visit 
(wks) 
13.0 (9.0-17.0) 13.0 (9.0-76.0)   0.457 
BMI (kg/m2) 23.6 ± 4.0 26.6 ± 5.5 <0.001 
 
Racial group 
 
   White European, n (%) 
   Black African, n (%) 
   Black Caribbean, n (%) 
   South Asian, n (%) 
   Other, n (%) 
 
 
 
 
107,199 (77.0) 
3269 (2.3) 
3455 (2.5) 
15513 (11.1) 
9831 (7.0) 
 
707 (54.1) 
63 (4.8) 
39 (3.0) 
304 (23.3) 
194(14.8) 
 
 
 
<0.001 
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Gestational age at delivery (wks) 40.0 (38.0-42.0) 39.0 (37.0-41.0) <0.001 
 
Birthweight (grams) 3273.2 ± 547.1 3337.4 ± 628.2 <0.001 
 
 Birthweight percentile 58.4 ± 28.1 64.8 ± 29.6 <0.001 
 
Birthweight z-score 0.000± 1.0 0.421 ± 1.3 <0.001 
Birthweight<10th centile, n (%) 16870 (9.7) 192 (11.3) <0.001 
Birthweight >90th centile, n (%) 16598 (9.6) 248 (14.7) <0.001 
Mode of delivery 
    
    Vaginal, n (%) 
    Caesarean section, n(%) 
 
 
114,470 (82.2) 
24, 793 (17.8) 
 
873 (66.8) 
434 (33.2) 
 
<0.001 
 
Values are expressed as mean ± standard deviation or as median (interquartile range). 
 
Compared to the non-GDM group, women in the GDM group were more likely to be older, 
heavier, of a non-white racial group and more likely to deliver both large for gestational age 
babies (birthweight >90th percentile) and small for gestational age babies (<10th percentile) 
earlier. (p<0.01 for both).  
 
The final dataset included 130,549 women of whom 82.7% were White European, 5.2% 
were Black and 12.1% were South Asian. The prevalence of GDM varied within the racial 
groups and was higher in non-White women (1.9% and 1.5% for South Asians and Blacks 
respectively) compared to White Europeans (0.7%; p<0.001 for both comparisons) (Table 
35). 
 
In pregnancies complicated by GDM, South Asian women had significantly lower BMI and 
smaller babies in comparison to White European women. Maternal characteristics were not 
significantly different between White European and Black groups. Compared to White 
Europeans, Black women had larger babies, although this was not statistically significant, 
and a higher rate of caesarean section (Table 36). 
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The Carstairs Index was higher in non-white racial groups. This was irrespective of 
glycaemic status, which suggests increased measures of social deprivation within these 
groups.  
 
Rates of macrosomia, defined as birthweight >90th percentile, were significantly higher in 
non-white racial groups for those pregnancies not complicated by GDM (Table 34). In those 
pregnancies complicated by GDM, rates of macrosomia were not different between White 
European and Black women but significantly lower rates of macrosomia were found for 
South Asian women (Table 36).  
 
There were increased rates of babies delivered with birthweight <10th percentile in non-
white racial groups in women whose pregnancy was not complicated by GDM. In those 
pregnancies complicated by GDM, South Asian women had higher rates of babies delivered 
with birthweight<10 percentile (Table 36).  
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Table 35 Maternal demographic, clinical characteristics and pregnancy outcomes within the racial groups in pregnancies not complicated by 
GDM (non-GDM). Values are expressed as mean ± standard deviation or median (interquartile range). 
 
Maternal characteristic White European  
n= 107,199 
 
            Black  
            n= 6,724 
South Asian 
n= 15,513 
Maternal age (yrs) 
 
27.3 ± 5.0              26.1 ± 5.0*  25.8 ± 4.6*  
BMI (kg/m2) 23.8 ± 4.0            24.3 ± 4.4*  22.2 ± 3.6*  
Gestational age at booking (wks) 13.0 ± 2.8             13.6 ± 2.9 *  13.4 ± 2.8*  
Gestational age at delivery (wks) 39.4 ± 1.8            39.0 ± 2.2*  39.0 ± 1.9 *  
Birthweight (g) 
 
3,326.8 ±536.8            3,134 ±571.8*  
 
2,993.8 ± 507.7* 
 
 
Birthweight percentile 61.2 ± 27.3           52.2 ± 28.5*  42.02±27.4*  
Birthweight >90th percentile, n (%) 12,175 (11.4)           417(6.2) *  391(2.5) *  
Birthweight <10th percentile, n (%) 8,961 (8.4)           928 (13.8) *  2,954 (19.0) *  
Birthweight (z-score) 
 
0.091 ± 0.981          -0.173 ± 0.966*  -0.526 ± 0.932*  
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Maternal characteristic White European  
n= 107,199 
 
         Black  
        n= 6,724 
 South Asian 
n= 15,513 
 
Carstairs Index, score -1.0 (-4.0-2.0)  1.0 (-4.0-6.0)*  0.0 (-4.0-4.0)*  
Diastolic Blood Pressure 
at booking (mmHg) 
67.5 ± 8.5  66.9 ± 8.4*  65.3 ± 8.3*  
Smoking,n (%) 
 
22,062  (20.6)  780 (11.6) *  266 (1.7) *  
Mode of delivery 
      
  Caesarean section,n (%) 
  Vaginal,n (%) 
 
18,007 (16.8) 
89,190 (83.2) 
 
 
 
1,594(23.7)* 
5,129(76.3) 
 
 
 
3,003 (19.4)* 
12,509 (80.6) 
 
 
All comparisons were done with White Europeans. Variables compared using t-test/ Mann–Whitney U-testand chi-square tests for continuous and categorical data, 
respectively, with post hoc Bonferroni correction, where appropriate. *P<0.001  
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Table 36 Maternal demographic, clinical characteristics and pregnancy outcomes within the racial groups in pregnancies complicated by GDM 
(GDM). Values are expressed as mean ± standard deviation or median (interquartile range). 
 
Maternal characteristic 
 
White European  
n= 707 
 
  Black  
n= 102 
South Asian 
n= 304 
Maternal age (yrs)
  
 
29.4 ± 5.0 30.0 ± 4.8 
 
 
28.4 ± 5.1 
BMI (kg/m2)
  26.7 ± 5.8 
 
27.3 ± 5.5 
 
 
25.3 ± 4.9
* 
 
Gestational age at booking (wks)
  13.1 ± 2.6  13.6 ± 3.4 
 
 
13.4 ± 2.8  
Gestational age at delivery (wks)
  
38.8 ± 1.8  38.5 ±1.8 
 
 
38.4 ± 1.8  
Birthweight (g)
 
 
3,408.8 ± 615.7 3,429.9± 619.4 
 
 
3,172.7 ± 582.8
* 
 
Birthweight centile
 
67.65 ± 28.7 68.6 ± 29.0 
 
 
56.4 ± 30.8
* 
 
Birthweight >90th percentile, n (%)
 
133 (18.8) 19(18.6) 
 
 
28 (9.2) 
* 
Maternal characteristic White European  
n= 707 
  Black  
n= 102 
South Asian 
n= 304 
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Birthweight (z-score)
 
 
0.528 ± 1.266 0.632 ± 1.341 
 
 
0.092 ± 1.224
* 
 
Carstairs Index, score -2.0 (-5.0-1.0) 2.0 (-2.0-6.0)* 
 
 
1.0 (-3.0-5.0)
* 
Diastolic Blood Pressure at 
booking  
70.2 ± 9.1 68.9 ± 8.6 
 
 
69.4 ± 9.4 
Smoking n (%) 121 (17.1) 6 (5.9)  
 
 
5 (1.6)
* 
Mode of delivery 
     Caesarean section n (%) 
      Vaginal n (%) 
 
198 (28.0) 
509 (72.0) 
 
46 (45.1) 
56 (54.9) 
 
 
121(39.8) 
183 (60.2) 
All comparisons were done with White Europeans. Variables compared using t-test/ Mann–Whitney U-test and chi-square tests for continuous and categorical data, 
respectively, with post hoc Bonferroni correction, where appropriate. *P<0.001  
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Babies born to women with pregnancies complicated by GDM were generally larger in 
comparison to those not complicated by GDM (Table 37). This was more prominent in Black 
women. 
 
Table 37 Mean birthweight z -scores and differences between z-scores for Non-GDM and 
GDM women within each racial group. 
 
Racial group 
 
Non GDM GDM Difference 
White European 
 
0.091 0.528 0.437 
Black  
 
-0.173 0.632 0.805 
South Asian 
 
-0.526 0.092 0.618 
 
5.2.1 Exploratory analysis 
Univariate analysis revealed a significant association between advancing maternal age, BMI, 
racial group and diabetic status on birthweight (p<0.001 for all variables).  
 
Univariate analysis also revealed that the influence of maternal age and BMI on the outcome 
variable birthweight z-score was very similar between Black African and Black Caribbean 
groups and therefore Black African and Black Caribbean racial groups were grouped 
together in this part of the study. 
 
Multivariate analysis revealed that only BMI, racial group and diabetic status were 
significantly associated with birthweight (p<0.001 for all variables).  
 
Multiple regression analysis was used to identify important determinants of birthweight and 
stratified according to racial groups and diabetic status (non-GDM and GDM). The final 
models for White Europeans are shown in Tables 38 and 39. 
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Table 38 Multivariate analysis investigating possible determinants of birthweight z-score for 
non GDM within White European women. 
 
Dependent variable 
z score 
   
95%Confidence Interval 
Parameter 
Correlation 
Coefficient 
 
Std Error t P value Lower bound 
Upper 
bound 
Intercept 
 
-0.464 
 
0.025 
 
-18.455 
 
<0.001 
 
-0.513 
 
-0.414 
 
Age 
-0.004 
 
0.001 
 
-5.885 
 
<0.001 
 
-0.005 
 
-0.003 
 
BMI 
 
0.300 
 
0.001 
 
39.268 
 
<0.001 
 
0.029 
 
0.032 
 
Smoking 
-0.351 
 
0.008 
 
-43.799 
 
<0.001 
 
-0.0367 
 
-0.336 
 
Carstairs 
Index 
-0.009 0.001 -6.606 
<0.001 
 
-0.012 -0.007 
 
 
 
Table 39 Multivariate analysis investigating possible determinants of birthweight z-score for 
GDM within white European women. 
 
 
Dependent variable 
z score 
   
95%Confidence Interval 
Parameter 
Correlation 
Coefficient 
Std Error t P value Lower bound 
Upper 
bound 
Intercept 
 
-0.745 0.217 -3.432 0.001 -1.174 -0.319 
BMI 
 
0.05 0.008 6.259 0.001 0.034 0.065 
Smoking -0.329 0.123 -2.671 0.008 -0.571 -0.087 
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Summary: 
  
 Within White European women, BMI and smoking were important determinants of 
birthweight, irrespective of the development of GDM. 
 In the non-GDM group maternal age and Carstair‘s index appear to be additional 
independent variables for birthweight.  
 
 
The final models for Black women are given in Tables 40 and 41. 
 
Table 40 Multivariate analysis investigating possible determinants of birthweight z-score for 
Non GDM group within Black women. 
 
Dependent variable 
z score 
   
95%Confidence Interval 
Parameter 
Correlation 
Coefficient 
Std Error t P value Lower bound 
Upper 
bound 
Intercept 
 
-0.831 0.066 -12.612 0.001 -0.96 -0.702 
BMI 
 
0.028 0.003 10.56 0.001 0.023 0.033 
Smoking -0.213 0.036 -5.852 0.001 -0.285 -0.142 
 
 
Table 41 Multivariate analysis investigating possible determinants of birthweight z-score for 
GDM group within Black women. 
 
 
Dependent variable 
z score 
   
95%Confidence Interval 
Parameter 
Correlation 
Coefficient 
Std Error t P value Lower bound 
Upper 
bound 
 
Intercept 
 
-1.092 0.659 -1.657 0.101 -2.399 0.216 
BMI 0.063 0.024 2.669 0.009 0.016 0.11 
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Summary: 
 
 Within Black women, BMI was an independent determinant of birthweight, 
irrespective of the development of GDM. 
 
 In the non-GDM group smoking appears to be an additional independent variable 
determining birthweight. 
 
 
The final models for South Asian women are given in Tables 42 and 43. 
 
 
 
Table 42 Multivariate analysis investigating possible determinants of birthweight z-score for 
Non GDM group within South Asian women. 
 
 
Dependent variable 
z score 
   
95%Confidence Interval 
Parameter 
Correlation 
Coefficient 
Std Error t P value Lower bound 
Upper 
bound 
 
Intercept 
 
-1.63 0.076 -1.657 0.001 -1.779 -1.481 
BMI 0.034 0.002 15.68 0.001 0.03 0.038 
DBP 0.003 0.001 3.106 0.002 0.001 0.005 
Age 0.006 0.002 3.65 0.001 0.003 0.009 
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Table 43 Multivariate analysis investigating possible determinants of birthweight z-score for 
GDM group within South Asian women. 
 
 
Dependent variable 
z score 
   
95%Confidence Interval 
Parameter 
Correlation 
Coefficient 
Std Error t P value Lower bound 
Upper 
bound 
 
Intercept 
 
-1.766 0.355 -4.975 0.001 -2.464 -1.067 
BMI 0.073 0.014 5.325 0.001 0.046 0.1 
 
 
 
Summary: 
 
 Within South Asian women BMI was an independent determinant of birthweight, 
irrespective of the development of GDM 
 
 In the non-GDM group, maternal age and diastolic blood pressure appear to be 
additional independent variables to birthweight.  
 
The positive association between maternal BMI and birthweight, regardless of diabetic 
status, continued and was significant within all racial groups. As BMI was the most 
consistently independent predictor of birthweight z-scores within all three racial groups, we 
chose to focus on this variable. 
 
Graphs with regression lines were created to illustrate the association between increasing 
maternal BMI and birthweight, represented as z-scores, within non-GDM and GDM groups 
for each racial group (Figure 5.11 a, b and c).  
 
Two methods were used to calculate the difference in the slopes. In the first method, it was 
calculated at t=(b1-b2)/Sb1, =b2, where b1 and b2 are the two slope coefficients and Sb1,b2 is 
the polled standard error of the slope. The results according to the maternal racial group 
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were: for White European women, t=0.020/0.001=20, df=107 905 and two-tailed P<0.0001; 
for black women, t=0.036/0.003= 12.3, df=6826 and two-tailed P<0.0001; and for South 
Asian women, t=0.039/0.002=19, df =15 817 and two-tailed P<0.0001.  
 
In the second method, analysis of variance was used: F=138.9 and two-tailed P<0.0001. 
The difference in birthweight z-scores between women who developed GDM or not was 
much greater at high BMIs than at low BMIs: there was a statistically significant difference 
between the slopes in GDM versus non-GDM pregnancies in all racial groups (P<0.001 for 
all). Thus, as far as birthweight is concerned, maternal BMI has a much greater effect in 
women with GDM than in those without, an effect that is especially marked in back women 
and South Asian women.  
 
This was performed using the following equations calculated from the above multivariate 
analysis (Table 44). 
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Table 44 Multivariate analysis equations of independent predictors of birthweight for GDM and non-GDM within all racial groups. 
 
 Non-GDM  
 
GDM 
 
 
White European 
 
y = 0.030BMI - 0.004Age - 0.351Smoking - 0.009CI - 0.464  
(r2=0.036) 
 
y=0.050BMI - 0.329Smoking - 0.745 
(r2=0.059) 
 
Black 
 
y = 0.028BMI - 0.213Smoking + 0.831  
(r2=0.021) 
 
y = 0.063BMI - 1.092 
(r2=0.066) 
 
South Asian 
 
y = 0.034BMI + 0.006Age + 0.003DBP - 1.630 (r2=0.022) 
 
 
y = 0.073BMI - 1.766 (r2=0.086) 
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Fig 5.11 Regression lines for the association between increasing maternal BMI and birthweight z-scores in non-GDM and GDM groups for 
white European, black and South Asian groups, adjusted for all signiﬁcant confounding factors. There was a statistically signiﬁcant difference 
between the slopes in GDM vs non-GDM pregnancies in all racial groups (P < 0.001 for all). Non-GDM           GDM  
 
 
Only one pregnancy per woman studied 
5.11 a) White European  b) Black c) South Asian  
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Summary: 
 
 The presence of maternal GDM is an independent predictor of neonatal 
birthweight within all racial groups, irrespective of BMI.  
 
 There is a strong positive association between maternal BMI and birthweight z-
scores within all racial groups. Development of GDM accentuates this 
association, which is more pronounced within the black group.  
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5.3 Hypothesis 2: First trimester maternal biomarkers can improve early prediction of GDM 
 
The dataset for hypothesis 2 consisted of 124 women who subsequently developed GDM 
and 248 that remained normoglycaemic. Characteristics of the populations studied are given 
in Table 45. Women who developed GDM were older, with greater BMI and more had prior 
GDM and family history of Type 2 DM. They also had higher systolic blood pressure, but 
there were no differences in parity, smoking history or method of conception. 
 
Table 45 Maternal demographic, clinical characteristics and pregnancy outcomes of the 
non-GDM and GDM groups. 
 
Maternal Characteristics 
 
Non-GDM 
(N=248) 
GDM 
(N=124) 
P value 
Maternal age (yrs) 32.6 ± 5.2 
 
34.3± 5.0 0.002‡ 
BMI (kg/m2) 
 
25.4 ± 5.2 29.2± 7.9 <0.001§ 
Parity, n(%) 
   
   Nulliparous 
   Parous 
 
89 (35.9) 
159 (64.1) 
 
45 (36.3) 
79 (63.7) 
 
1.000 † 
 
Racial group, n(%) 
    
   White 
   Black 
   Asian 
   Other 
 
148 (59.7) 
62 (25.0) 
29 (11.7) 
9 (3.6) 
 
 
73 (58.9) 
34 (27.4) 
11 (8.9) 
6 (4.8) 
 
0.769 † 
 
Previous GDM, n(%) 
    
   Yes  
   No 
   Nulliparous 
 
158 (63.7) 
1 (0.4) 
89 (35.9) 
 
44 (35.5) 
35 (28.2) 
45 (36.3) 
 
 
<0.001 † 
Family history of diabetes n(%) 
   
   Yes 
   No 
 
218 (87.9) 
30 (12.1) 
 
76 (61.3) 
48 (38.7) 
 
<0.001† 
 
Smoker n(%) 
    
    Yes 
    No 
 
230 (92.7) 
18 (7.3) 
 
115 (92.7) 
9 (7.3) 
 
1.000 † 
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Maternal Characteristics 
 
 
Non-GDM 
(N=248) 
GDM 
(N=124) 
P value 
Gestational age at booking (days) 87.4 ± 3.2 
 
87.3 ± 3.6 0.737‡ 
Systolic Blood Pressure (mmHg) 
 
111.7  ± 16.6 
 
118.4 ± 14.1 0.001§ 
 
Diastolic Blood Pressure (mmHg) 
 
71.4 ±  8.9 72.9 ± 8.4 0.103‡ 
Mode of delivery, n(%) 
    
   Vaginal 
   Emergency Caesarean 
   Elective Caesarean 
   Ventouse 
 
190 (77.2) 
36 (14.6) 
19 (7.7) 
1 (0.4) 
 
80 (65.0) 
25 (20.3) 
18(14.6) 
0 (0.0) 
 
0.037 † 
 
 
Fetal sex, n(%) 
      
    Male 
    Female 
 
118 (47.8) 
129 (52.2) 
 
62 (50.0) 
62 (50.0) 
 
0.741 † 
 
Birthweight (g) 3382.8 ± 540.3 3343.2 ± 495.0 
 
0.378‡ 
‡students t-test, § Wilcoxon test, † Fisher exact test. Data are means ± SD, n (%) 
 
The levels of different biomarkers in the two study groups are given in Table 46. 
Table 46 Maternal serum first trimester biomarkers in the non-GDM and GDM groups. 
 
Biomarker Non-GDM 
(N=248) 
GDM 
(N=124) 
P value P value 
(adjusted)* 
P value 
(adjusted)† 
Total cholesterol 
(mmol/l) 
4.59 ± 0.85 4.88 ±  0.90 0.003‡ 0.040 0.038 
HDL cholesterol 
(mmol/l)*   
1.68 ±  0.36 1.55 ±  0.38 0.002‡ 0.003 0.001 
LDL cholesterol 
(mmol/l) 
2.29  ± 0.71 2.59±  0.78 <0.001 0.003 0.003 
Triglycerides (mmol/l)*   1.23 (0.95–1.62) 1.49 (1.14–2.05) <0.001§ 0.017 0.012 
Adiponectin (g/mL)  9.88 ± 5.57 7.38 ± 4.19 <0.001§ 0.027 0.040 
E-selectin (ng/ml)  31.3 (23.2–40.4) 31.3 (24.7–44.2) 0.308§ 0.867 0.827 
γ-GT (U/l) 11.0 (9.0–16.0) 12.0 (9.8–17.0) 0.063§ 0.632 0.566 
CRP (mg/l)*  3.21 (1.62–6.97) 5.77 (2.7–11.6) <0.001§ 0.030 0.024 
t-PA 5.32 (4.23–6.58) 6.41 (5.19-8.27) 0.001§ 0.001 <0.001 
 
Data are means ± SD, medians (interquartile range). Log transformed for regression analysis. *Adjusted for 
maternal age, BMI, gestational age at sampling, smoking, ethnicity, parity, conception status and previous GDM. 
†Women without previous GDM (nulliparous or previous pregnancies without GDM) adjusted for maternal age, 
BMI, gestational age at sampling, smoking, ethnicity, parity, and conception status. ‡ student‘s t-test, § Wilcoxon 
test. 
5. Results 
The Epidemiology and Prediction of Gestational Diabetes Mellitus   112 
After adjustment for confounding factors, women who subsequently developed GDM had 
significantly higher total cholesterol, LDL-cholesterol, triglycerides, CRP and t-PA in 
comparison to controls. HDL- cholesterol and adiponectin were significantly lower in women 
who subsequently developed GDM than controls. There was no significant difference 
between E-selectin and γ-GT levels between controls and women who developed GDM later 
on in pregnancy. 
 
Stepwise regression analysis was used to determine the predictive value of biomarkers and 
revealed only an elevated t-PA and low HDL-cholesterol as significant independent 
predictors of GDM. The ability to predict the development of GDM using demographic and 
clinical information obtained at booking, demonstrated an AUC-ROC=0.824. This increased 
to 0.861 with the inclusion of t-PA and HDL cholesterol (Fig 5.12), which is clinically 
significant. Upon repeating the same analyses but removing all women with prior GDM, the 
AUC-ROCs were 0.751 and 0.806, respectively. 
 
Fig 5.12 ROC curve and summary for all mothers using a basic model (including age, 
gestational age at sampling, BMI, race, family history of diabetes and prior GDM) and with 
addition of independent predictors (HDL cholesterol and t-PA). 
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A subset of the dataset for Hypothesis 3 was used to investigate the association of first 
trimester maternal 25(OH)D and GDM development. This dataset consisted of 158 women 
who remained normoglycaemic during pregnancy and 90 women who developed GDM. The 
maternal characteristics of the population are given in Table 47. 
 
Table 47 Maternal demographic, clinical characteristics and pregnancy outcomes of the 
non-GDM and GDM groups. 
 
Maternal Characteristics 
 
Non-GDM 
(N=158) 
GDM 
(N=90) 
P value 
Maternal age (yrs) 33.1 ± 4.7 34.2 ± 4.9 0.104‡ 
 
BMI (kg/m2) 
 
25.2 ± 4.0 30.0 ± 7.9 <0.001§ 
Parity, n (%)  
    
   Nulliparous 
   Parous 
 
67 (42.4) 
91 (57.6) 
 
38 (42.2) 
52 (57.8) 
 
 
1.000 † 
 
Racial group, n (%) 
    
   White 
   Black 
   Asian 
   Other 
 
108 (68.4) 
31 (19.6) 
12 (7.6) 
97 (4.4) 
 
58 (64.4) 
23 (25.6) 
6 (6.7) 
3 (3.3) 
 
 
0.735 † 
 
Previous GDM, n (%) 
    
   No 
   Yes    
 
158 (100) 
0 (0) 
 
69 (76.6) 
21 (23.3) 
 
 
<0.001 † 
Family history of diabetes, n (%) 
    
   No 
  Yes 
 
141 (89.2) 
17 (10.8) 
 
 
55 (61.1) 
35 (38.9) 
 
 
<0.001† 
 
Smoker, n (%) 
    
   No 
   Yes  
 
148 (93.7) 
10 (6.3) 
 
83 (92.2) 
7 (7.8) 
 
 
0.795 † 
 
Gestational age at booking  
(days) 
 
87.4 ± 3.0 87.4 ± 3.6 0.916‡ 
Systolic Blood Pressure (mmHg) 
 
112.5  ± 15.8 118.5 ± 11.6 0.003§ 
 
Diastolic Blood Pressure (mmHg) 
 
70.2 ± 8.5 71.7 ± 7.2 0.218‡ 
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Maternal Characteristics 
 
Non-GDM 
(N=158) 
GDM 
(N=90) 
P value 
Fetal sex, n (%) 
 
    Male 
    Female 
 
80 (51.0) 
77 (49.0) 
 
40 (44.4) 
50 (55.6) 
 
 
 
0.356† 
 
 
 
 
 
Birthweight (g) 
 
3403.1  571.4 3283.6  418.9 0.081‡ 
OGTT 
 
    Fasting  
    2hr glucose 
 
 
 
5.3  1.8 
9.1  1.8 
 
 
Hba1c 
 
 5.8  0.9  
25 (OH) D (ng/ml) 
25 (OH) D (nmol/l) 
19.0  10.7 
47.6  26.7 
18.9  10.7 
47.2  26.7 
0.874† 
0.863† 
Deficient 25(OH)D (<25nmol/l) 
 
  No 
  Yes 
 
122 (77.2) 
36 (22.8) 
 
72 (80.0) 
18 (20.0) 
 
 
0.635‡ 
 
Insufficient 25 (OH)D (< 50nmol/l) 
 
 No 
 Yes 
 
68 (43.0) 
90 (57.0) 
 
34 (37.8) 
56 (62.2) 
 
 
0.502‡ 
Total Cholesterol (nmol/l) 4.62  0.76 4.86  0.90 0.033* 
HDL Cholesterol (nmol/l) 1.74 (0.35) 1.58 (0.38) 0.001* 
Truglcerides (nmol/l) 1.20 (0.95-1.56) 1.38 (1.08- 2.01) 0.002* 
‡students t-test, § Wilcoxon test, † Fisher exact test. Data are means ± SD, n (%), median (interquartile range) 
 
Women with pregnancies complicated by GDM had significantly higher BMI and were more 
likely to have a previous history of GDM and family history of DM. Systolic blood pressure 
was significantly higher in GDM group compared to non-GDM group. 
 
Vitamin D (25OHD) levels were similar in the non-GDM and GDM groups (18.9 ng/ml vs 
19.0 ng/ml respectively). Cut-offs for 25(OH)D insufficiency and deficiency revealed similar 
rates within GDM and non-GDM groups. 
 
Univariate analysis revealed that 25OHD levels at booking after adjustment for confounders 
(maternal age, BMI, gestational age at sampling, smoking, race, parity, conception status 
and previous GDM) were negatively correlated with 2-hour glucose levels and positively 
associated with HDL cholesterol (Table 48).  
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Table 48 Effect size refers to increase in variables per 1 ng/ml increase in 25OHD, p<0.05 
after adjustment for confounding factors. 
 
 Correlation Coefficient 95% CI 
OGTT 
2hr glucose (mmol/l) 
 
-0.738* 
 
-1.467 
 
-0.008 
OGTT 
Fasting glucose (mmol/l) 
 
-0.413 
 
-1.089 
 
0.264 
Hba1c 
 
-0.209 -0.559 0.142 
Total Cholesterol (mmol/l) 
 
0.164 -0.024 0.352 
Triglycerides (mmol/l) 
 
0.018 -0.107 0.142 
HDL Cholesterol (mmol/l) 
 
0.090* 0.005 0.175 
Systolic blood pressure (mmHg) 
 
1.239 -2.607 5.086 
Diastolic blood pressure (mmHg) 
 
1.652 -0.491 3.795 
 
 
Summary: 
 
 
 Simple maternal demographic and clinical characteristics obtained at the first 
antenatal visit provide a good prediction of GDM. 
 
 Low HDL and high t-PA are independent predictors of GDM but also enhance 
prediction beyond the simple model of maternal demographic and clinical 
characteristics. 
 
 First trimester maternal serum 25(OH)D levels are not associated with the 
development of GDM. 
 
 First trimester maternal serum 25 (OH)D levels are negatively correlated with 2-hour 
glucose levels and positively associated with HDL cholesterol. 
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6. Discussion  
 
6. 1 There is a differential effect of maternal racial origin on the association between 
advancing maternal age and BMI on the prevalence of GDM 
 
This retrospective study of prospectively collected data has demonstrated strong interactions 
between traditional risk factors such as advancing maternal age, increasing BMI and racial 
group on the development of GDM. As the average maternal age at first pregnancy in the 
UK population has been increasing markedly over the last three decades 296 there is an 
increasing need to study the link between advancing maternal age and pregnancy 
outcomes. Traditionally, women having their first pregnancy over the age of 30 were 
categorized as ‗elderly primigravidae‘. However, most of the risks associated with advancing 
age rise only slowly from age 30 to 35, but accelerate after the age of 35 (e.g. the risk of 
fetal chromosomal abnormalities, hypertension etc). Therefore, currently, advanced maternal 
age is usually considered as those aged 35 or more. However, sociological developments 
and advances in reproductive techniques have encouraged women to have their first babies 
even at the age of 40 years or more – ‘40 is the new 30‘. 
 
Many studies have found an association between advancing maternal age and rates of 
GDM.58-60, 297-9 Some of these studies suggest a threshold for maternal age associated with 
greater risk, however these thresholds vary between studies from >25 to >35 years of age. 
Hoseini et al297 conducted a retrospective case control study examining the impact of pre-
gravid maternal risk factors and risk of GDM. They found an increased risk of GDM beyond 
26 years of age, noting a 2-fold increase in GDM (OR=2.1, p=0.028). This was supported by 
Nilofer et al,298 who explored the prediction of GDM and found that by using a threshold for 
maternal age of over 25, sensitivities and specificities of 98% and 69% respectively were 
produced.  
Carolan et al299 conducted a population-based cross-sectional study that investigated the 
effect of maternal age and country/region of birth on GDM incidence demonstrated that the 
overall incidence of GDM within their study population was 4.8%, which is considerably 
higher than that of the UK. There was a strong trend of rates of GDM to increase with 
advancing maternal age, and higher rates of GDM were found particularly in women over the 
age of 35. Women over the age of 35 had six times the rates of GDM in comparison to 
women less than 20 years of age. This particular study also found a strong influence of 
maternal origin of birth, with higher rates of GDM in those women whose origin of birth was 
Asian. In comparison to Australian born women, Asian women had rates of GDM that were 
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almost three times higher, particularly in the older age group (>30 years of age). 
Our study found an increased rate of GDM with maternal age over 25 years of age, 
increasing steadily as age increased. The association between advancing maternal age and 
risk of GDM was maintained even after adjusting for confounding factors such as race and 
BMI. This is thought to be subsequent to declining -cell function and insulin sensitivity with 
advancing age, where the development of GDM is influenced by an individuals‘ reduced 
ability to secrete insulin. Importantly, advancing maternal age was much more important in 
women of South Asian and Black African origin than in White Europeans. A non-white 
pregnant woman of 25-29 years of age has a similar risk of developing GDM as a White 
European woman of 40 years of age; at least 3-4 times higher than a young (20-24 years 
old) White European. Advancing maternal age is also important in Black Caribbeans but we 
can only be confident about our results between 24-34 years old, because the number of 
subjects in the older age groups was small.  
 
Large population studies have observed a variation in the prevalence of GDM between racial 
groups, with a higher prevalence of GDM in non-white racial groups.67-75 However, the effect 
of obesity within racial groups does not seem to parallel the distribution of rates of GDM. 
Non-white racial groups, especially Asian women, develop GDM at a lower BMI. Racial 
differences may be due to a combination of factors.  
 Differences in body composition between Asian and White populations 
 Thrifty gene hypothesis vs thrifty phenotype hypothesis 
 Migration, urbanization and changes in lifestyle and diet within Asian populations  
 
6.1.1 Body composition in Asians 
The differential association between increasing BMI and development of GDM within racial 
groups, particularly within the South Asian group, was not surprising. There is a growing 
body of evidence showing differences in percentage body fat and body fat distribution 
between racial groups, particularly with South Asian groups in comparison to their non-white 
counterparts.300- 312The Asian population is unique in that they present with a ‗thin-fat‘ body 
composition. 
Asians have a higher proportion of body fat at lower BMIs in comparison to European and 
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Black African groups. Higher levels of central obesity (waist circumference, waist hip ratio, 
visceral fat and skin fold thickness) 305-12 have been reported in Asian groups in comparison 
to other racial groups. A higher proportion of Asians display a dyslipidaemic profile with high 
levels of triglycerides and cholesterol and low levels of HDL cholesterol.307-12 Increased body 
fat correlates positively with insulin resistance, resulting in a greater risk of diabetes and 
other associated metabolic disorders within this group, and the likelihood of type 2 DM is 
commonly underestimated in the South Asian population. Body composition and an 
increased propensity for insulin resistance may account for how a modest increase in weight 
gain within Asian populations increases the risk of diabetes substantially more than 
comparable increases in White populations. 
Increased insulin resistance in Asian women has further been conveyed by the suggestion 
that Asian women are more likely to have an abnormal post pregnancy glucose challenge in 
relation to diagnosing Type 2 DM later on in life.313-16 McClean et al conducted a 
retrospective study over a 10 year period. They examined glucose tolerance test 6 weeks 
postpartum in a multiethnic population who had developed GDM during pregnancy.  Non-
European women, particularly South Asian Women, were found to have high higher rates of 
persistent abnormalities than European women (31.9% vs 15%, p<0.001).317 
These differences have led to controversy surrounding the current WHO classification of 
BMI. 78 The WHO has a global classification for BMI with overweight being classified as a 
BMI ≥ 25. BMI classifications are supposed to be a reflection of risk for type 2 DM and 
cardiovascular disease. However, in view of larger proportions of Asians at greater risk of 
Type 2 DM and cardiovascular disease occurring at lower BMIs different cut-offs have been 
proposed for Asian groups. Nevertheless, the WHO recommends continuing the current 
global classification of BMI, as absolute prevalence and incidence of type 2 DM varies 
greatly within Asian sub-groups318- a higher prevalence being noted in Indian Asian and 
Fillipino subgroups.319 
6.1.2 Asian population and the thrifty hypotheses 
A suggested explanation for Asian populations displaying higher rates of GDM is the thrifty 
gene hypothesis. This hypothesis suggests that fetal programming plays an important role in 
the origin of diabetes, metabolic syndrome and cardiovascular disease. The exposure to 
periods of famine has resulted in selection in favour of the thrifty genotype which enhanced 
survival by minimising energy loss and facilitating energy storage in form of fat in ‗feast‘ so 
as to improve survival in ‗famine‘.320 Therefore, it suggests that these individuals have a 
genetic tendency to rapidly deposit fat in times of plenty as this would be advantageous to 
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the survival of some populations and considers the likelihood to develop diabetes an 
adaptive trait that evolved into a pathological trait due to changes in diet and lifestyle.  
This compares to the thrifty phenotype hypothesis, which suggests that rather than factors 
placing an individual at increased risk of DM and associated morbidities being genetic, they 
are programmed within the intra-uterine environment.  The intra-uterine environment plays a 
major role in the structure and development of the fetus and is heavily influenced by 
maternal metabolic and nutritional status.321-32 Therefore an adverse intra-uterine 
environment potentially determines the origin of diabetes, metabolic syndrome and 
cardiovascular disease. It has also been suggested that maybe the two hypotheses are not 
exclusive of each other but perhaps interlinked and the explanation involves a combination 
of factors.322 
The hypotheses have not been rigorously tested and others suggest an underlying genetic 
predisposition to obesity resulting in a propensity to increased insulin resistance and 
associated disorders.323 
6.1.3 Asians,  migration and urbanisation 
Although initially individuals who migrate tend to be healthier than those that do not 
(migration requiring the fitness, energy and enthusiasm to take on an often demanding 
challenge), it is also known that subsequent generations from migrant groups generally tend 
to suffer from worse health and display disadvantageous risk factor profiles.323 The migration 
of ethnic minority groups to higher income countries and urban areas may account for the 
increased risk of metabolic syndrome in these groups. 324 
Urbanisation caused by the geographical growth of cities, and population migration into 
cities to seek work, is associated with an increased supply of foods rich in calories, sugar, fat 
and refined carbohydrates as well as a change in lifestyle to one that is less physically 
active.325 Also dietary acculturation, the process by which a minority group adapts to the 
food and eating patterns of the host country, leads a the change in traditional diets to include 
more energy-rich components.326 This change in diet compounds  an unhealthier lifestyle 
and increases the risk of obesity, diabetes and cardiovascular disease. The adverse effects 
of the change in diet are more likely to be revealed in those individuals prone to insulin 
resistance.  
Bodansky et al showed that the incidence of Type 1 DM increased in immigrants to the UK 
from 3.1/100000 per year to 11.7/100000 per year over a period of 10 years.327 This 
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highlights the influence of environmental factors such as diet and acculturation within a 
population with an already increased genetic background risk of diabetes.  
 
6.1.4 Black populations and diabetes  
The largest migration of individuals of Black African descent from West Africa and the 
Caribbean into the UK was post-second world war. The increased risk of diabetes within 
these populations is well documented.328-31 However, the suggested explanations for this 
racial disparity are less clear than those accounting for the risk of diabetes in South Asian 
populations. Factors involved in the risk may involve both genetic and environmental 
components. 
Black Afro-Caribbean populations tend to have an unusual risk factor for diabetes. They are 
known to be more insulin resistant than their white counterparts, displaying raised levels of 
glucose, glycosylated haemoglobin and insulin.332-339 However, the lipid profile is not 
consistent with the insulin resistant state, where typically Afro-Caribbean populations have 
lower triglyceride and higher HDL- cholesterol levels.335 This more favourable lipid profile 
may account for the low levels of coronary heart disease mortality that Black populations 
demonstrate despite the increased risk of diabetes.340 
A difference in anthropometric measurements has also been noted, with Black populations 
generally having higher BMIs, but unlike South Asian populations, measurement of visceral 
fat, which is consistent with insulin resistance, is lower in comparison to white populations. It 
has been suggested that it is the increased subcutaneous fat that may contribute to the 
diabetes risk.341 
Population studies that have explored trends in diabetes and pregnancy outcomes within 
racial groups have tended to investigate Afro-Caribbean or African American groups. 
However, this dismisses the possible genetic admixture within these racial groups and 
assumes these women behave similarly metabolically. In our study, we have separated the 
two groups and have shown that not all subgroups within the black population are the same. 
One study that has explored health outcomes within Black African and Black Caribbean 
populations has found that Black Africans tend to have worse self-reported health outcomes 
than Black Caribbeans. The two groups also differ in terms of educational, economic and 
social dimensions, which may further influence this disparity.342 
If studies involving Asian subgroups have highlighted that not all Asians are alike, then 
perhaps the same should be considered for Black populations, where in this Thesis, Black 
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Caribbeans tend to behave similarly to White Europeans with regards to the interaction of 
maternal age and BMI on rates on GDM. Modern humans originated from Africa and black 
Africans are known to have the highest levels of genetic variation of any geographical 
human population.343 As Black Africans in Western countries have genetic origins in different 
parts of Africa, this genetic variation may account for the differences within Black 
populations. This is reflected in the variation in prevalence of type 2 DM within African 
regions, with the highest prevalence within sub-saharan African regions.344  
Most studies assess the interaction between traditional risk factors as part of a mathematical 
model created to predict the development of GDM. Our study explicitly investigated the 
interrelationships of the aforementioned risk factors.  There are few previous studies that 
explored the interrelationship between risk factors for GDM. Ramos et al345 conducted a 
large retrospective cohort study evaluating the interrelationship between ethnicity and 
obesity on obstetric outcomes such as caesarean section and pre-eclampsia rates as well 
as GDM. They found that the prevalence of GDM and other pregnancy outcomes increased 
with increasing BMI category. The prevalence of GDM was highest in obese (BMI>29) Latino 
and Asian groups. The prevalence of GDM associated with obesity was lowest in White and 
African American groups, with the lowest prevalence in the latter group. Rodrigues et al346, 
found pre-gravid weight is an independent predictor for GDM in Cree Women and non-
Native women (mostly whites). However, an increase in weight increased the risk of GDM in 
Cree women, demonstrating an interaction between race and BMI on GDM development.  
Studies, published after our study, have further examined the interrelationship between race, 
BMI and GDM. Similarly to our findings, Heddersen et al347, conducted a large population 
study (n=123,040) exploring the relationship between risk factors for GDM and found a 
significant variation in prevalence of GDM, within BMI categories for different racial groups. 
Asian women showed an increased risk of GDM at lower BMI cut-offs points (BMI 19.0- 
24.9) in comparison to Non-Hispanic Whites and African Americans. However, African 
Americans had a generally lower prevalence of GDM at higher BMI, which contrasts with our 
study, which showed a high prevalence of GDM, within the Black African group with 
increasing BMI. Inconsistencies between studies may be due to differing diagnostic criteria 
for GDM, differences in geographical origin within Africa or the small numbers of Black 
subgroups. 
There are different opinions regarding BMI cut offs for Asian racial groups when screening 
for GDM should be considered. In the UK, NICE22 recommends screening for GDM on the 
basis of risk factors related to maternal race, BMI >30 and previous obstetric and family 
history. These risk factors are assumed to be independent from one another and therefore 
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do not accurately reflect the interaction between race, maternal age, and BMI.  
The importance of BMI and the effect on pregnancy outcome within different racial groups is 
also highlighted. Racial disparities have been suggested to continue post pregnancy 
surveillance regarding the subsequent development of diabetes following a pregnancy 
affected by GDM, particularly in relation to non-white women. 348 
Special attention and additional health resources should be directed towards non-white 
racial groups, where education regarding changes in lifestyle and diet to prevent increasing 
obesity and subsequent adverse health and pregnancy outcomes within these groups would 
be particularly relevant. 
6.2 There is an influence of advancing maternal age, BMI, racial group and diabetic 
status (GDM or not) on birth weight 
 
Birthweight is an important predictor of infant morbidity and mortality as well as a factor that 
influences the future risk of obesity, diabetes and cardiovascular disease. Birthweight is 
influenced by both constitutional and environmental factors but the magnitude of the impact 
of these factors remains unclear. 
 
This retrospective study of prospectively collected data has demonstrated racial variation in 
birthweight in non-GDM and GDM populations even after adjusting for maternal BMI and 
age.  Previous studies have shown racial differences in birthweight at term with a shift 
towards lower birthweight in non-white racial groups.349-354 The causes of the racial variation 
in birthweight remain unclear. 
 
Previous studies have attempted to determine whether non-modifiable factors contribute 
more to determining birthweight than environmental factors or modifiable factors such as 
BMI.355- 367 Maternal constitutional factors such as height have been shown in several studies 
to be important contributing factors to the racial differences and this suggests an underlying 
genetic influence.358-63 Studies have predominantly focused on the relationship between race 
and low birthweight. However, macrosomia is also associated with adverse pregnancy and 
long term outcomes364-371 and is a well established complication of pregnancies affected by 
GDM. Macrosomia predisposes babies to electrolyte and metabolic disturbances such as 
hypoglycaemia, hyperbilirubinaemia, hypomagnesia369, as well as increased risk of birth 
trauma and operative delivery. In the long term there is an increased risk of obesity in 
childhood/ early adulthood370 and an increased risk of cardiovascular and metabolic 
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disturbances.373-86 This occurs in the absence of a maternal history of pre-existing diabetes 
or GDM.376 
 
Large cohort studies have documented variable rates of macrosomia, ranging between 5-
20%. This may be due to different definitions of macrosomia such as birthweight over 4000g, 
over 4500g or birthweight over the 90th percentile. 376-381 In this study we chose to use the 
definition of birthweight over the 90th percentile, taking into consideration the gestational age 
and gender of the baby to calculate birthweight z-scores. The rates of macrosomia in this 
study are consistent with other studies. 
 
Predisposing factors such as advancing maternal age, parity, BMI, gestational age and 
weight gain during pregnancy are recognised as being positively associated with fetal 
macrosomia.382-393 However, there is substantial variation in the literature regarding the 
magnitude of the effect of these factors on macrosomia. The influence of maternal body 
composition on birthweight in non-diabetic pregnancies has previously been investigated.382-
386  and a significant positive association between pre-pregnancy BMI and birthweight has 
been observed. 386Jensen et al387, found that independent of maternal glucose levels, there 
was an association of between obesity in women (WHO classification of BMI) and adverse 
pregnancy outcomes such as large-for-gestational age infants and neonates weighing over 
4000g.  
 
There is a wealth of literature confirming a variation in birthweight by racial origin 388-402 in 
pregnancies not complicated by GDM. The majority of studies have recognised racial 
disparities predominantly between White and Black populations.403-15 Studies in the US have 
persistently found lower birthweight in Black in comparison to white populations as well as 
an increased prevalence of adverse perinatal outcomes such as pre-term delivery 396 and 
fetal growth restriction. Similar findings of racial variation persist in studies conducted in the 
UK with South Asian offspring being consistently lighter in comparison to White populations‘ 
offspring even when correcting for maternal height and weight.397 The underlying 
mechanisms for these effects probably involve maternal and fetal dysregulation of glucose, 
insulin, lipid and amino acid metabolism. Further studies have explored racial disparities in 
rates of macrosomia. Stotland et al377, examined the epidemiology of macrosomia, where 
rates of macrosomia remained lower within non-white groups in comparison to white groups, 
regardless of the definition of macrosomia (>4kg or>4.5kg). Rates of macrosomia were 
greater in White than Black populations. However, this study did not take into consideration 
other influencing maternal characteristics such as maternal BMI. Similarly, Ramos et al,345 
showed that rates of macrosomia rise with increasing maternal BMI. They did not quantify 
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the racial differences in rates of macrosomia within increasing BMI categories but have 
shown a reduced risk of macrosomia in Black obese populations compared to obese White 
populations. 
 
Our study confirmed the above findings. Furthermore, in women who developed GDM, there 
was an accelerated growth pattern within non-white groups, with a higher rate of 
macrosomia in Black populations. 
 
Studies that have also examined the influence of GDM on birthweight have recognised 
higher rates of macrosomia 396-400 in pregnancies complicated by GDM compared to those 
that remained normoglycaemic. However, there have been fewer studies that have 
examined the influence of GDM on birthweight within different racial groups. Those that have 
been published have yielded inconsistent results. Saldana et al400 found that there was no 
significant effect of GDM on birthweight within either white or black racial groups. Only in 
black women with pregnancies complicated by impaired glucose tolerance, a degree of 
glucose intolerance less severe than GDM, were there significantly increased rates of 
macrosomia and higher birthweights in comparison to Black women who had normal 
glucose tolerance. This difference was not seen in the White racial group. This would 
suggest genetic background as an important predictor of birthweight as well as 
environmental factors, such as pre-existing diabetes or GDM. 
 
Esakoff et al401 also examined the effect of racial variation on perinatal outcomes in 
pregnancies in women with GDM where Latina women with GDM had the highest ORs of 
macrosomia (delivering neonates over 4kg and 4.5kg) in comparison to African American 
and Asian racial groups. African American women had a lower prevalence of delivering a 
macrosomic neonate in comparison to the white group, suggesting that the effect of GDM 
within this group was less dramatic. 
 
Keiffer et al402 demonstrated a racial disparity in the impact of diabetes on birthweight where 
the differences in the birthweights of infants of diabetic compared with non-diabetic mothers 
were much more dramatic for black infants. They found a larger difference in mean 
birthweight in infants of black mothers (211.67g) in comparison to infants of white mothers 
(115.75g). This study also found that pre-pregnancy BMI and diabetic status were both 
independently associated with birthweight. In our study, the influence of increasing BMI on 
birthweight is more marked in pregnancies complicated by GDM, particularly within Black 
populations. Although the findings are similar to those in our study, Keiffer et al did not make 
6. Discussion 
The Epidemiology and Prediction of Gestational Diabetes Mellitus   125 
a distinction between pregnancies complicated with GDM and those who had pre-existing 
DM.  
 
Recent studies have recognized the importance of insulin like growth factor as an important 
growth factor and its role in modifying placental transfer of nutrients such as glucose and 
amino acids.403 In non diabetic pregnancies it is positively associated with birthweight.400 
Racial variation may still persist and influence fetal growth. Lower levels of insulin like 
growth factor have been suggested as explanations for a lower birthweight in non-white 
racial groups, particularly Black/African racial groups, in comparison to white racial 
groups.403-8 
 
Differences in the baby‘s body composition have also been suggested as an explanation for 
lower birthweight in Black populations in comparison to white populations with lean body 
mass being significantly less in Black vs white babies.408 However, there are no studies 
exploring racial variation in neonatal body composition in pregnancies complicated by GDM.  
 
In multiple regression, maternal age was not significantly associated with birthweight in 
pregnancies complicated with GDM within all racial groups, suggesting that BMI, racial origin 
and diabetic status mediate/ modulate the influence of maternal age on birthweight.  
 
The limitations of both of the above studies (hypothesis 1 & 2) are that they were 
retrospective (although the data were collected prospectively) including 15 different 
maternity units in North West Thames and consequently there would have been some 
inconsistency in the screening methods and diagnosis of GDM. This may have led to an 
underreporting of GDM cases in some units and consequently the inclusion of some women 
with occult diabetes in the non-GDM group. However, such misclassification would have 
expected to reduce the differences between groups, and so the associations reported in the 
current manuscript are likely, if anything, to be an underestimate of the true differences. 
The use of self-reporting of racial group is also a limitation as this may not match with  the 
individual‘s genes and predisposition to genetic conditions.  
 
 
Other insulin resistant states and the influence of risk factors such as maternal age, 
Body mass index and race on outcomes.  
 
Polycystic ovary syndrome (PCOS) is a common, heritable endocrine disorder that affects 
women throughout their lives. PCOS is characterized by oligo- an- ovulation, clinical and/or 
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biochemical signs of hyperadrogenism and polycystic ovaries. PCOS represents another 
insulin resistant state where the presence of insulin resistance and hyperinsulinaemia is 
common and ranges from 50-70%.409 Insulin resistance occurs independent of obesity, 
however individuals with PCOS are believed to have an underlying genetic predisposition, 
where insulin resistance is further exacerbated by factors such as obesity. Women with 
PCOS also display an increased risk of type 2 DM and cardiovascular disease.409 
 
Infertility and delayed first pregnancy affects approximately 40%410 of women with PCOS 
resulting from an-ovulatory infertility. Irrespective of PCOS, pregnancy achievement and 
maintenance is adversely affected by obesity. Obese women have a lower chance of 
pregnant resulting in delayed first pregnancy.  The first line management in women with 
PCOS and increased BMI is weight loss. A loss of 5-10% has been shown to increase 
ovulation and pregnancy rates.411 The influence of BMI on fertility in PCOS is further 
emphasised by response to fertility treatments. There is the suggestion that women who are 
obese and have PCOS are less likely to respond to assisted reproductive techniques. 
Weight reduction in these women can increase their chance of conception spontaneously 
and with ovulation induction..412 
 
Advancing maternal age is known to be associated with a decline in fertility. In PCOS there 
is a decline in hyperadrongenism and menstrual cycles become more regular with advancing 
age.413 Younger age has been found to be predictive of successful pregnancy and live birth; 
more advanced maternal age was predictive only of ovulation. Although, older women are 
more likely to ovulate, the reduction in quality of the oocyte influences the ability to maintain 
a pregnancy and further affects a delay in first pregnancy.414 
 
Less is known regarding the influence of race on PCOS, particularly the influence of race on 
metabolic consequences and fertility rates. Ladson et al, performed a case control study 
aiming to explore the metabolic and reproductive differences between white and Black 
women with PCOS. There was no difference between reproductive hormone levels between 
racial groups, determined through measurement of luteinising hormone (LH), follicle-
stimulating hormone (FSH), dehydroepiandrosterone (DHEAS) and sex hormone binding 
globulin (SHBG). 415 
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6.3 First trimester maternal biomarkers can improve early prediction of GDM 
 
 
This study was a multi ethnic population study and supports the importance of maternal 
characteristics in the prediction of GDM in early pregnancy but also encourages the potential 
use of novel biomarkers in conjunction with traditional risk factors as a means of enhancing 
prediction. 
 
Despite the vast documentation and number of studies surrounding GDM, including the 
pathology, complications, risk factors, and benefits of diagnosing and treating it, there 
remains no general consensus regarding screening. There is a continuing debate regarding 
the relative value of universal vs selective screening, where currently in the UK universal 
screening on the basis of risk factors for GDM is recommended. However, changing the way 
in which women are screened could improve detection rate and be more cost effective.  
 
Previous studies have attempted to further improve the prediction of GDM in early 
pregnancy by creating ‗prediction tools‘ based on clinical risk factors for GDM, with variable 
results. Naylor et al416, pre HAPO, looked into the possible benefits of screening women for 
GDM with the use of a clinical scoring system. This was a model based on risk factors that 
were judged to be independent predictors of GDM such as maternal age, BMI and race Data 
was collected from approximately 3000 women. They then randomly selected data from half 
of the women and categorized them into three groups (low, intermediate and high risk) 
based on a clinical scoring system using weighted risk factors such as age, pre-pregnancy 
BMI and race. The remainder of women were screened with a 50-g oral glucose challenge 
test, with the threshold for a positive result based on their risk score. Naylor et al, found that 
this selective screening approach resulted in a 34.6% reduction in the number of screening 
tests performed, without a decrease in the detection rate of GDM. 
 
Caliskan et al417 also found high detection rates on the basis of selective screening, 
however, the number of incident cases of GDM in the study was low (n=14). The study also 
ignored racial origin as a risk factor for GDM, and all clinical risk factors were weighted 
equally. 
 
The development of Type 2 DM risk models that could be used in pregnancy has yielded 
AUC-ROC values ranging between 0.74-0.85.101 Van Leeuwen et al418 aimed to create 
models to estimate the probability of GDM from maternal characteristics and achieved AUC-
ROC 0.77 (95% CI 0.69-0.85) which is a similar value to the current study. However, the 
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number of incident GDM cases in the study by Van Leeuwen et al was considerably lower 
(n=22) than in the current study. Teede et el419, generated a similar AUC-ROC value with a 
larger number of GDM cases (n=2880) and also took into consideration, when establishing 
clinical risk scores, different weighting within particular Asian subgroups.  
 
Several studies have examined the association between novel biomarkers and the risk of 
Type 2 DM and transferred this association into the context of GDM, in an attempt to predict 
it and reduce the prevalence of its associated complications. Many of the studies have also 
examined the use of biomarkers in combination and not in isolation. These markers are 
known to share similar metabolic pathways, which may influence the findings.  
 
Maternal hypo-adiponectinaemia during the first trimester has been previously found to be 
associated with increased risk of developing GDM. This association persisted even after 
adjustment for the confounding factor of BMI and is consistent with the current study. A lipid 
profile characterized by low HDL and raised triglycerides, LDL and total cholesterol levels 
are also consistent with previous studies examining lipid profiles in those individuals who 
later develop GDM and Type 2 DM. The current study highlighted the dyslipidaemic profile 
(raised triglycerides and LDL with low HDL) in women who subsequently developed GDM. 
This compares to the studies by Enqubahrie et al172 and Montelongo et al420 who found no 
association between the risk of GDM and other lipids such as total cholesterol, HDL and 
LDL.  However, differences may be due to numbers of cases, study populations, where 
racial groups have been shown to exhibit different lipid profiles in pregnancies with and 
without GDM. 
 
Evidence of increased inflammation in women who subsequently develop GDM was 
demonstrated with significantly raised CRP levels in comparison to controls and is consistent 
with previous studies.211, 193 However, although the association between these traditional and 
novel factors is noted, many of these biomarkers were not independent predictors of GDM. 
Only t-PA and HDL were found to be first trimester independent predictors of GDM. This 
may be due to the fact that a lot of biomarkers examined have overlapping metabolic 
functions and therefore are not completely independent.101 
 
Hyperglycaemia is a key prognostic factor in the development of vascular diseases in those 
patients with DM and good glycaemic control has been shown to reduce the associated 
vascular complications.421Tissue plasminogen activator (t-PA) is not only a marker of 
endothelial dysfunction and an independent predictor of cardiovascular disease but is also 
associated with inflammation and insulin resistance, which is higher in diabetics. 421-5 
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Endothelial dysfunction during pregnancy is not well understood. The current study found 
that t-PA is significantly increased in early pregnancy in those who develop GDM in 
comparison to those who remain normoglycaemic during pregnancy. Other studies have 
found that this difference remains post partum, where women with a previous history of 
GDM have found to have raised t-PA levels and other markers of endothelial dysfunction, 
suggesting an underlying endothelial dysfunction in these women that predisposes them to 
GDM and diabetes in later life.204 
 
The predictive ability of biomarkers in the first trimester is limited. Previous studies have 
either focused on one or two biomarkers in isolation and the association with GDM but have 
not further examined the predictive ability of these biomarkers. This is further hindered by 
previous studies conducted during the first trimester have yielded inconsistent results 
regarding the association with development of GDM, which encourages the need for larger 
studies.  
 
At present, there is little clinical utility for the use of biomarkers in the prediction of GDM. 
However, this thesis conveys the potential of particular biomarkers and possibly provokes a 
need for further larger studies to explore their clinical use.  
  
Vitamin D deficiency during pregnancy and its associated complications is an important 
public health problem. However, previous studies examining the association between 
25(OH)D concentrations and pregnancy complications, particularly GDM have given 
inconsistent results.264-8 The majority of studies that have been conducted concentrated on 
levels of 25(OH)D in the second and third trimesters of pregnancy. Some studies found that 
although levels of 25(OH)D were inversely correlated with fasting glucose and insulin but 
there was no significant increased risk of GDM with lower levels of 25(OH)D.269 
  
Our study conducted within a multiethnic population found no difference in 25(OH)D levels 
measured in the first trimester in women who either developed GDM or remained 
normoglycaemic during pregnancy. Baker et al264, have since conducted a nested case 
control study and measured 25(OH) D levels at 13 weeks gestation. There was no difference 
in 25(OH)D levels in those pregnancies that developed GDM and those who did not. Low 
vitamin D levels were not associated with an increased risk of GDM. Zhang et al265, 
measured levels of 25(OH) D at 16 weeks gestation within a Chinese population and found 
significantly lower 25(OH)D levels in those who developed GDM in comparison to those who 
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remained normoglycaemic . This significance remained after adjustment for BMI. Further 
larger population studies are needed to explore this further.  
 
Differences in results may be attributed to procedures used to measure 25(OH) D levels. 
Methods used include immunoassays, high performance liquid chromatography (HPLC) and 
liquid chromatography tandem-mass spectrometry (LC-MS/MS). Immunoassays are the 
most popular method predominantly due to their convenience and speed of results. 
Immunoassays have been found to generate results that vary strongly, due to different 
standards and artificial calibrators being used by the suppliers.426 This then makes it difficult 
to compare the results generated with other studies. HPLC and LC-MS/MS has a higher 
sensitivity and selectivity and LC-MS/MS is currently regarded as the gold standard, as it 
can separate and accurately quantify both 25(OH)D2 and 25(OH)D3. 
427-32 
 
Currently in the UK, it is advised that women receive information regarding their health and 
nutrition during pregnancy.263 All pregnant women are advised to take daily supplementation 
of vitamin D (10mcg/day). It is advised that high-risk groups receive particular attention as to 
whether they are taking this supplement. However, the clinical significance and improvement 
in pregnancy outcomes with Vitamin D supplementation is yet to be determined. 
 
The reference ranges for 25 (OH)D in pregnancy are variable and a consensus about 
normal ranges has not yet been reached. Yu et al 262 aimed to examine the normal range of 
values of 25 (OH)D within a large population with uncomplicated pregnancies. They found 
that first trimester maternal levels of vitamin D were influenced by maternal characteristics 
and the season during which the vitamin D measurements were taken; vitamin D levels were 
higher with advancing maternal age and during the summer months but lower with 
increasing BMI. The 5th percentile for 25(OH)D was recorded as 10.8 ng/ml in this study. 
This is much lower than the suggested cut-off of 30ng/ml to suggest a diagnosis of vitamin D 
deficiency.  
 
Although vitamin D has been found to be associated with adverse pregnancy outcomes as 
mentioned previously, there is a lack of evidence to support supplementation during 
pregnancy. Lawlor et al433 found no association between maternal vitamin D during 
pregnancy and bone mineral content in children, on average 10 years of age. The optimum 
concentration of vitamin D in pregnancy and the dose required to achieve it have not been 
determined. Single oral doses of vitamin D or daily oral doses during pregnancy have 
previously been explored. Although oral daily supplementation was thought to be a better 
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method of achieving this, only a third of women achieved vitamin D sufficiency.434  Further 
research is needed here.
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7. Conclusions 
 
There is a significant interaction between maternal race, age and BMI on the development of 
GDM. Advancing maternal age and BMI are more important risk factors for GDM in South 
Asian and Black African women than in White European or Black Caribbean women. This is 
more pronounced in South Asians who develop GDM at younger ages and at lower BMI.  
 
Maternal BMI and diabetic status are important determinants of birthweight. The influence of 
BMI on birthweight is more pronounced at higher BMI‘s and in pregnancies complicated by 
GDM. This is particularly so for Black women.  
 
Several studies have examined the association between novel biomarkers and the risk of 
Type 2 DM and transferred this association within the context of GDM in an attempt to 
predict it before the onset of the disease and its associated complications. Many of the 
studies have also examined the use of biomarkers within groups and not in isolation. These 
markers are known to share similar metabolic pathways, which may influence the findings. 
Further research is needed to understand the role of these biomarkers in isolation to allow 
us to further explore their potential role in prediction of GDM as early as the first trimester. 
However, based on our study, it appears that HDL and t-PA can improve first trimester 
prediction of GDM above the traditional risk factors. 
 
The prevalence of diabetes is continuing to increase worldwide. It is already one of the 
biggest health challenges in the UK and indeed worldwide at the present. This is due to the 
huge health and socio-economic consequences associated with the disease. The 
development of diabetes in pregnancy highlights a group of women at increased risk of 
diabetes and associated complications, in the future. It also highlights a group of children at 
increased risk of obesity and diabetes. Early detection will enable these groups to be 
targeted and also increase these individuals‘ chances of adopting sustainable lifestyle 
choices.  
 
This study highlights the strong influence of race and genetic predisposition on an individual 
during pregnancy and how this affects pregnancy outcome. Further research into the 
interaction between risk factors is needed as this may enable us to develop more specific 
screening criteria in the future.  
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Fig 5.10 The prevalence of GDM (95%CI) in the different maternal BMI groups according to race 
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Table 12 Summary of studies assessing maternal SHBG levels in GDM 
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Table 28 Univariate analysis of the influence maternal age, BMI and racial group on development of GDM 
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Table 40 Multivariate analysis investigating possible determinants of birthweight z-score for Non GDM within Black women 
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Abbreviation 
 
Meaning  
DM Diabetes Mellitus 
 
GDM Gestational Diabetes Mellitus 
 
GIGT Gestational Impaired Glucose tolerance 
 
NGT Normal glucose tolerance 
 
SPSS Statistical Package for Social Sciences 
 
SMMIS St Mary‘s Maternity Information System 
 
LDL Low Density Lipoprotein 
 
CRP C-reactive protein 
 
HDL High Density Lipoprotein 
 
-GT Gamma-glutamyl transferase 
 
TG Triglyceride 
 
ALT Alanine transaminase 
 
25(OH)D 25 hydroxylase vitamin D  
 
t-PA Tissue plasminogen activator 
 
BMI Body Mass Index 
 
OR Odds Ratio 
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aOR Adjusted odds ratio 
 
RR Relative risk  
 
aRR Adjusted relative risk 
 
CI Confidence interval 
 
aOR Adjusted odds ratio 
 
GLUT Glucose transport proteins 
 
HAPO Hyperglycaemia and Adverse Pregnancy 
Outcome 
 
ACHOIS Australian Carbohydrate Intolerance 
Study in Pregnant Women  
 
vs versus 
 
NICE National Institute of Clinical Excellence 
 
GTT Glucose tolerance test 
 
OGTT Oral glucose tolerance test 
 
N Number in over study/ population 
 
NPV Negative predictive value 
 
PPV Positive predictive value 
 
r Correlation coefficient 
 
Prev Previous 
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wks Weeks 
 
MoM Multiples of the median 
 
trim Trimester 
 
ROC Receiver operator curve 
 
SHBG Sex hormone binding globulin 
 
TNF- Tumour necrosis factor alpha 
 
VDR Vitamin D receptor 
 
Hba1c Glycosylated haemoglobin 
 
GAfREC Governance arrangements for Research 
and ethics committee 
 
REC Research and ethics committee 
 
NICU Neonatal intensive care unit 
 
TOP Termination of pregnancy 
 
Kg Kilograms 
 
m Metres 
 
g Grams  
 
gm Centimetres 
 
GA Gestational age 
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yrs Years 
 
Min Minimum 
 
Max Maximum 
 
SD Standard deviation 
 
SPE Solid phase extraction 
 
Std error Standard error  
 
r2 Coefficient of determination 
 
AUC-ROC Area under the curve – receiver operator 
curve 
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